Novel nucleic acid and amino acid sequences and novel variants of alternative splicing

ABSTRACT

The present invention concerns nucleic acid sequences and amino acid sequences. The sequences include sequences coding for variants obtained by alternative splicing, for homologs of the known thrombopoietins and sequences that encode for novel homologs of transporter proteins

FIELD OF THE INVENTION

[0001] The present invention concerns novel nucleic acid sequences, vectors and host cells containing them, amino acid sequences encoded by said sequences, and antibodies reactive with said amino acid sequences, as well as pharmaceutical compositions comprising any of the above. The present invention further concerns methods for screening for candidate activators or deactivators utilizing said amino acid sequences.

BACKGROUND OF THE INVENTION

[0002] Alternative splicing (AS) is an important regulatory mechanism in higher eukaryotes (P. A. Sharp, Cell 77, 805-8152 (1994). It is thought to be one of the most important mechanisms for differential expression related to tissue or development stage specificity. It is known to play a major role in numerous biological systems, including human antibody responses, and sex determination in Drosophila, (S. Stamm, M. Q. Zhang, T. G. Marr and D. M. Helfinan, Nucleic Acids Research 22, 1515-1526 (1994); B. Chabot, Trends Genet. 12, 472-478 (1996); R. E. Breitbart, A. Andreadis, B. Nadal-Ginard, Annual Rev. Biochem., 56, 467-495 (1987); C. W. Smith, J. G. Patton, B. Nadal-Ginard, Annu. Rev. Genet., 27, 527-577 (1989)).

[0003] Until recently it was commonly believed that alternative splicing existed in only a small fraction of genes (about 5%). A recent observation based on literature survey of known genes revises this conservative estimate to as high as an estimate that at least 30% of human genes are alternatively spliced (M. S. Gelfand, I. Dubchak, I. Draluk and M. Zorn, Nucleic Acids Research 27, 301-302 (1999). The importance of the actual frequency of this phenomenon lies not only in the direct impact on the number of proteins created (100,000 human genes, for example, would be translated to a much higher number of proteins), but also in the diversity of functionality derived from the process.

[0004] Several mechanisms at different stages may be held responsible for the complexity of higher eukalyote which include: alternative splicing at the transcription level, RNA editing at the post-transcriptional level, and post-translational modifications are the ones characterized to date.

[0005] Thrombopoietin (TPO) is a central regulator of the megakaryocytopoiesis. This molecule is lineage-specific cytokine affecting the proliferation and maturation of megakaiyocytes from their committed progenitor cells and acts at a late stage of megakaryocyte development. It may be the major physiological regulator of circulating platelets. Two forms of TPO have been entered at clinical trials, the full length recombinant version (THTOP) and a truncated form. The administration of both forms cause a dose-dependent increase in platelet count with no affect on white cell count or hematacrit. The platelets induced by these two forms are morphologically and functionally normal. When administered following myello suppressive chemotherapy the two forms of TPO significantly enhance platelet recovery. TPO progenator cells of multiple hematopoietic lineage may enhance the effect of filgrastim on peripheral blood progenator cell levels after chemotherapy.

[0006] The regulated exocytotic release of neurotransmitters in response to neural activity requires storage within intracellular vesicles. In the nervous system, these vesicles are the synaptic vesicles that are derived from the endosomal compartment, whereas in endocrine cells larger secretory granules, such as the chromaffin granules of adrenal medulla, are derived from the trans golgi networks. For classical transmitters, that are synthesized in the cytoplasm or appear there after removal from the synapses by plasma membrane reuptake, storage depends upon the active transport into the vesicles. Several distinct transport activities have been identified for monoamines, acetylcholine, glutamate, GABA and glycine. Vesicular monoamine transporters (VMATs) catalyze transport and storage of monoamines, serotonin, dopamine, norepinephrine, epinephrine, and histamine. The driving force utilized by the VMAT is the H+ electrochemical gradient generated by the vacuolar ATP-dependent H+ pump (V-ATPase) located on vesicular plasma membrane. VMAT is inhibited by a wide variety of compounds including reserpine and tetrabenazine. In contrast to the plasma membrane transporters for dopamine, norepinephrine, and 5-HT which show relative substrate specificity, the monoamine transporter recognizes various monoamine with similar affinity.

[0007] All characterized monoaminegenic cells utilize the monoamine transporters for the vesicular accumulation of monoaminees prior to their release. This system operates in neuronal (catecholaminergic, serotoninergic or histaminergic) as well as in endocrine or neuroendocrine cells including endocrine cells of the gastric epithelium which secrete biologically active peptides and small messenger molecules such as histamine, serotonin, and gamma-aminobutyric acid.

[0008] The monoaminees, serotonin, dopamine, norepinephrine, epinephrine and histamine, play a crucial role in the function of the hypothalamic-pituitary-adrenal axis and in the integration of information in sensory, limbic, and motor systems. The monoaminee transporters are the most important determinants of extracellular levels of monoaminees, which act by packaging monoaminees into synaptic and secretory vesicles by exchange of protons.

[0009] An essential property of synaptic transmission is the rapid termination of action following neurotransmitter release. For many neurotransmitters, including catecholamine, serotonin, and certain amino acids (e.g., gamma-aminobutylic acid (GABA), glutamate and glycine), rapid termination of synaptic action is achieved by the uptake of the neurotransmitter into the presynaptic terminal and surrounding glial cells. This rapid re-accumulation of a neurotransmitter is the result of re-uptake by the presynaptic terminals. At presynaptic terminals, the various molecular structures for re-uptake are highly specific for such neurotransmitters as choline and the biogenic amines (low molecular weight neurotransmitter substances such as dopamine, norepinephrine, epinephrine, serotonin and histamine). These molecular structures are termed “transporters”. The transporters move neurotransmitter substances from the synaptic cleft back across the cell membrane of the presynaptic neuron and into the cytoplasm of the presynaptic terminus thus terminating the function of these substances. Inhibition or stimulation of neurotransmitter uptake provides a means for modulating the effects of the endogenous neurotransmitters.

[0010] Transporters of sugars are responsible for change in sugar concentrations according to membranes. For example the glucose transporter enables half of the glucose present inside the cell to leave within four seconds at normal body temperature. The glucose transporter operates through conformational change that the transporter undergoes while moving glucose across the membranes. Alternating between two conformations it moves its glucose-binding site from one side of the membrane to another. By “flipping” between its two conformational states the transporter facilitates the diffusion of glucose, i.e. it enables the glucose to avoid the barrier of the plasmid membrane while moving spontaneously down its concentration gradient so that when concentration reaches equilibrium net movement of glucose ceases.

[0011] The beta-galactosides are transported into cells by the lactose-protein symport which utilized the potential energy present in the protein gradiant transmitting simultaneously also a protein. Other transporters are known such as the multidrug Efflux Transporter 2.

GLOSSARY

[0012] In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows:

[0013] “Variant nucleic acid sequence”—the sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 28, sequences having at least 90% identity (see below) to said sequence and fragments (see below) of the above sequences of least 20 b.p. long. These sequences are sequences coding for a novel, naturally occurring, alternative splice variants of native and known genes. It should be emphasized that the novel variants of the present invention are naturally occurring sequences resulting from alternative splicing of genes and not merely truncated, mutated or fragmented forms of known sequences which are artificially produced.

[0014] “Thrombopoietin-like sequence (TL)”—the sequence shown in any one of SEQ ID NO: 29 or 30, sequences having at least 70% identity to said sequences and fragments of the above sequence being 20 b.p. long. The two sequences are sequences coding for homologs of the known thrombopoietins and are both splice variants. It should be noted that the term “TL” does not necessarily signify that the TL protein coded by the above sequences has the same, or even similar physiological effect as the known Thrombopoietin, merely that it shows sequence homology with the known thrombopoietin.

[0015] “Transporter protein homolog (TH)”—the sequence shown in any one of SEQ ID NOs: 31 to 41, sequences having at least 70% identity to said sequence, and fragments of the above sequences being 20 b.p. long. These sequences have homology to various vesicular neurotransmitter transporters, such as to the monoamine transporters and features homology to sugar and other transporters of C. Elegance. SEQ ID NO: 38 and SEQ ID NO: 39 are in fact splice variants of one another, and SEQ ID NO: 40 and SEQ ID NO: 41 are updates of SEQ ID Nos 38 and 39.

[0016] The term TH does not necessarily signify that the protein coded by the above sequences has the same or even similar physiological activities to known transporters, especially of monoamines or amines or sugars and merely indicates that it shows sequence homology with these transporters.

[0017] “Variant product—also referred at times as the “variant protein” or “variant polypeptide”—is an amino acid sequence encoded by the variant nucleic acid sequence of SEQ ID NOS: 1 to 28 which is a naturally occurring mRNA sequence obtained as a result of alternative splicing. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having chemically modified amino acids (see below) such as a glycopeptide or glycoprotein. One example of products are shown in any one of SEQ ID NO: 42 to SEQ ID NO: 69. The term also includes homologues (see below) of said sequences in which one or more amino acids has been added, deleted, substituted (see below) or chemically modified (see below) as well as fragments (see below) of this sequence having at least 10 amino acids.

[0018] “TL product”—is an amino acid sequence coded by any one of SEQ ID NO: 29 or 30. An example of this sequence is a sequence of SEQ ID NO: 70 which is a common sequence coded by both SEQ ID NO: 29 and SEQ ID NO: 30. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having “chemically modified” (see below) amino acids such as glycopeptide or glycoprotein.

[0019] “TH product”—is am amino acid sequence coded by SEQ ID NO: 31 to SEQ ID NO: 41. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having chemically modified amino acids (see below) such as glycopeptides or glycoproteins. Examples of such MTPH-products are shown in SEQ ID NO: 71 to SEQ ID NO: 81. This term also includes analogs of said sequence in which one or more amino acids has been added, deleted, substituted (see below) or chemically modified (see below) as well as fragments of this sequence having at least ten amino acids.

[0020] “Nucleic acid sequence”—a sequence composed of DNA nucleotides, RNA nucleotides or a combination of both types and may includes natural nucleotides, chemically modified nucleotides and synthetic nucleotides.

[0021] “Amino acid sequence”—a sequence composed of any one of the 20 naturally appearing amino acids, amino acids which have been chemically modified (see below), or composed of synthetic amino acids.

[0022] “Fragment of variant nucleic acid sequence”—novel short stretch of nucleic acid sequences of at least 20 b.p., which does not appear as a continuous stretch in the original nucleic acid sequence of the variant (see below). The fragment may be a sequence which was previously undescribed in the context of the published RNA and which affects the amino acid sequence encoded by the known gene. For example, where the variant nucleic includes a sequence which was not included in the original sequence (for example, a sequence which was an intron in the original sequence) the fragment may contain said additional sequence. The fragment may also be a region which is not an intron, which was not present in the original sequence. For example where the variant lacks a non-terminal region, which was present in the original sequence. The two stretches of nucleotides spanning this region (upstream and downstream) are brought together by splicing in the variant, but are spaced from each by the spliced out region in the original sequence and are thus not continuous in the original sequence. A continuous stretch of nucleic acids comprising said two sparing stretches of nucleotides is not present in the original sequence and thus falls under the definition of fragment.

[0023] “Fragment of TL sequence/Fragment of TH sequence”—a continuous portion, preferably of about 20 nucleic acid sequences of the TL or TH sequences, respectively.

[0024] “Fragments of variant products”—novel amino acid sequences coded by the “fragment of valiant nucleic acid sequence” defined above.

[0025] “Fragments of TL/TH product”—a polypeptide which has an amino acid sequence which is the same as pair of but not all of the amino acid sequences of the TL/TH products, respectively.

[0026] “Homologues of variants”—amino acid sequences of variants in which one or more amino acids has been added, deleted or replaced. The addition, deletion or replacement should be in the regions or adjacent to regions where the variant differs from the original sequence (see below).

[0027] “Homologues of TL/TH”—an amino acid sequence of the TL/TH, respectively, in which one or more amino acids has been added, deleted or replaced.

[0028] “Conservative substitution”—refers to the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. [Six general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, Gln, or Glu, is a conservative substitution.

[0029] “Non-conservative substitution”—refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

[0030] “Chemically modified”—when referring to the product of the invention, means a product (protein) where at least one of its amino acid resides is modified either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the numerous known modifications typical, but not exclusive examples include: acetylation, acylation, amidation, ADP-ribosylation, glycosylation, GPI anchor formation, covalent attachment of a lipid or lipid derivative, methylation, myristlyation, pegylation, prenylation, phosphorylation, ubiqutination, or any similar process.

[0031] “Biologically active”—refers to the variant product having some sort of biological activity, for example, some physiologically measurable effect on target cells, molecules or tissues. In addition, this term refers to TL or TH product having sort of physiological activity, although the activity may be different than the original thrombopoietin or the original transport protein, to which these proteins show alignment.

[0032] “Immunologically active” defines the capability of a natural, recombinant or synthetic varient product, TL product or TH product or any fragment thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. Thus, for example, an immunologically active fragment of valiant product denotes a fragment which retains some or all of the immunological properties of the variant product, e.g can bind specific anti-variant product antibodies or which can elicit an immune response which will generate such antibodies or cause proliferation of specific immune cells which produce valiant.

[0033] “Optimal alignment”—is defined as an alignment giving the highest percent identity score. Such alignment can be performed using a variety of commercially available sequence analysis programs, such as the local alignment program LALIGN using a ktup of 1, default parameters and the default PAM. A preferred alignment is the one performed using the CLUSTAL-W program from MacVector (TM), operated with an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM similarity matrix. If a gap needs to be inserted into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired with a corresponding amino acid residue (i.e., the calculation does not consider residues in the second sequences that are in the “gap” of the first sequence). In case of alignments of known gene sequences with that of the new variant, the optimal alignment invariably included aligning the identical pails of both sequences together, then keeping apart and unaligned the sections of the sequences that differ one from the other.

[0034] “Having at least % identity”—with respect to two amino acid or nucleic acid sequence sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 90% amino acid sequence identity means that 90% of the amino acids in two or more optimally aligned polypeptide sequences are identical, 70% identity 70% homology, etc. However this definition, where relating to variants of alternative splicing, explicitly excludes sequences which are 100% identical with the original sequence from which the variant of the invention was varied.

[0035] “Isolated nucleic acid molecule having a variant/TL/TH nucleic acid sequence”—is a nucleic acid molecule that includes the nucleic acid sequence for any of the above. Said isolated nucleic acid molecule may include any of the above nucleic acid sequence as an independent insert; may include any of the above nucleic acid sequence fused to an additional coding sequences, encoding together a fusion protein in which any of the above coding sequence is the dominant coding sequence (for example, the additional coding sequence may code for a signal peptide); or any of the above nucleic acid sequence may be in combination with non-coding sequences, e.g., introns or control elements, such as promoter and terminator elements or 5′ and/or 3′ untranslated regions, effective for expression of the coding sequence in a suitable host; or may be a vector in which any of the above coding sequences is a heterologous.

[0036] “Expression vector”—refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaiyotic expression vectors are known and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art.

[0037] “Deletion”—is a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

[0038] “Insertion” or “addition”—is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring sequence.

[0039] “Substitution”—replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As regards amino acid sequences the substitution may be conservative or non-conservative.

[0040] “Antibody”—refers to IgG, IgM, IgD, IgA, or IgG antibody. The definition includes polyclonal antibodies or monoclonal antibodies. This term refers to whole antibodies or fragments of the antibodies comprising the antigen-binding domain of the anti-variant product antibodies, e.g. antibodies without the Fc portion, single chain antibodies, fragments consisting of essentially only the variable, antigen-binding domain of the antibody, etc.

[0041] “Distinguishing antibody”—an antibody capable of binding to the variant product and not the original amino acid sequence from which it has been varied, or an antibody capable of binding to the original nucleic acid sequence and not to the variant production.

[0042] “Activator”—as used herein, refers to a molecule which mimics the effect of the natural variant product, the TL product or the TH products, or at times even increases or prolongs the duration of the biological activity of said products, as compared to that induced by the product without the activation. The mechanism may be by any mechanism known to prolonging activities of biological molecules such as binding to receptors; prolonging the lifetime of the molecules; increasing the activity of the molecules on its target; increasing the affinity of molecules to its receptor; inhibiting degradation or proteolysis of the molecules, or mimicking the biological activity of the variants on their targets, etc. Activators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which can bind to and activate the valiant product.

[0043] “Deactivator” or (“Inhibitor”)—refers to a molecule which modulates the activity of the valiant product, the TL product or the TH product in an opposite manner to that of the activator, by decreasing or shortening the duration of the biological activity of any of these products. This may be done by any mechanism known to deactivate or inhibit biological molecules such as block of the receptor, block of active site, competition on binding site in target, enhancement of degradation, etc. Deactivators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which bind to and modulate the activity of said product.

[0044] “Treating a disease”—refers to administering a therapeutic substance effective to ameliorate symptoms associated with a disease, to lessen the severity or cure the disease, or to prevent the disease from occurring.

[0045] “Detection”—refers to a method of detection of a disease, disorder, pathological or normal condition. This term may refer to detection of a predisposition to a disease as well as for establishing the prognosis of the patient by determining the severity of the disease.

[0046] “Probe”—the valiant nucleic acid sequence, a TL nucleic acid sequence or a TH nucleic acid sequence or a sequence complementary therewith, when used to detect presence of other similar sequences in a sample. The detection is carried out by identification of hybridization complexes between the probe and the assayed sequence. The probe may be attached to a solid support or to a detectable label.

[0047] “Original sequence”—in the context of the variant sequence, refers to the sequence from which the variants of the invention have been varied as a result of alternative slicing. This term referring to the amino acid sequence will also be denoted as “original peptide”.

SUMMARY OF THE INVENTION

[0048] By one aspect the present invention is based on the finding of several novel, naturally occuitmg splice variants, which are naturally occurring sequences obtained by alternative splicing of known genes. The novel splice variants of the invention are not merely truncated forms, fragments or mutations of known genes, but rather novel sequences which naturally occur within the body of individuals.

[0049] The term “alternative splicing” in the context of the present invention and claims refers to: intron inclusion, exon exclusion, addition or deletion of terminal sequences in the variant as compared to the original sequences, as well as to the possibility of “intron retention”. Intron retention is an intermediate stage in the processing of RNA transcripts, where prior to production of fully processed mRNA the intron (naturally spliced in the original sequence) is retained in the variant. These intermediately processed RNAs may have physiological significance and are also within the scope of the invention.

[0050] The novel valiant products of the invention may have the same physiological activity as the original peptides from which they have been varied (although perhaps at a different level); may have an opposite physiological activity from the activity featured by the original peptides from which they are varied; may have a completely different, unrelated activity to the activity of the original from which they are varied; or alternatively may have no activity at all and this may lead to various diseases or pathological conditions. The variants may differ from the original sequences by property or properties not connected to physiological activities such as: clearance rate, turn-over time, resistance to degradation, affinity of interactions with co-factor, tissue distribution, expression patterns, etc.

[0051] The novel variants may also serve for detection purposes, i.e. their presence or level may be indicative of a disease, disorder, pathological or normal condition or alternatively the ratio between the level variants and the level original sequence from which they were varied (either at the mRNA level or the amino acid sequence level), or the ratio to other variants may be indicative to a disease, disorder, pathological or normal condition.

[0052] For example, for detectional purposes, it is possible to establish differential expression of various variants in various tissues. A certain variant may be expressed mainly in one tissue, while the original sequence from which it has been varied, or another variant may, be expressed mainly in another tissue. Understanding of the distribution of the variants in various tissues may be helpful in basic research, for understanding the physiological function of the genes as well as may help in targeting pharmaceuticals or developing pharmaceuticals.

[0053] The study of the variants may also be helpful to distinguish various stages in the life cycles of the same type of cells which may also be helpful for development of pharmaceuticals for various pathological conditions in which cell cycles is non-normal, notably cancer.

[0054] Thus the detection may by determination of the presence or the level of expression of the valiant within a specific cell population, comprising said presence or level between various cell types in a tissue, between different tissues and between individuals.

[0055] By a second aspect, the present invention is based on the surprising finding that there exists in humans two novel homologs (each a result of alternative splicing of a new gene) of the Thrombopoietin (herein after: TL) having a significant homology to this protein. The novel TL is homolog to the known thrombopoietin in the erythropoietin-like N-terminal domain.

[0056] By a third aspect, the present invention is based on the surprising finding of novel molecules which feature homology to several transporter molecules including the vesicular transporter molecules of biogenic amines, for example the momoamine transporters, vesicular acetylcholine transporters and other neurotransmitter transporters, as well as to several transporters of sugars.

[0057] Thus the present invention provides by its first aspect (variant sequences), a novel isolated nucleic acid molecule comprising or consisting of any one of the coding sequence SEQ ID NO: 1 to SEQ ID NO: 28, fragments of said coding sequence having at least 20 nucleic acids (provided that said fragments are continuous stretches of nucleotides not present in the original sequence from which the variant was varied), or a molecule comprising a sequence having at least 90%, identity to SEQ ID NO: 1 to SEQ ID NO: 28, provided that the molecule is not completely identical to the original sequence from which the variant was varied.

[0058] The present invention further provides a protein or polypeptide comprising or consisting of an amino acid sequence encoded by any of the above nucleic acid sequences, termed herein “variant product”, for example, an amino acid sequence having the sequence as depicted in any one of SEQ ID NO: 42 to SEQ ID NO: 69, fragments of the above amino acid sequence having a length of at least 10 amino acids coded by the above fragments of the nucleic acid sequences, as well as homologues of the above amino acid sequences in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitution) added, deleted, or chemically modified.

[0059] The deletions, insertions and modifications should be in regions, or adjacent to regions, wherein the variant differs from the original sequence.

[0060] For example, where the valiant is different from the original sequence by addition of a short stretch of 10 amino acids, in the terminal or non-terminal portion of the peptide, the invention also concerns homologues of that valiant where the additional short stretch is altered for example, it includes only 8 additional amino acids, includes 13 additional amino acids, or it includes 10 additional amino acids, however some of them being conservative or non-conservative substitutes of the original additional 10 amino acids of the novel variants. In all cases the changes in the homolog, as compared to the original sequence, are in the same regions where the valiant differs from the original sequence, or in regions adjacent to said region.

[0061] Another example is where the variant lacks a non-terminal region (for example of 20 amino acids) which is present in the original sequence (due for example to exon exclusion). The homologues may lack in the same region only 17 amino acids or 23 amino acids. Again the deletion is in the same region where the variant lacks a sequence as compared to the original sequence, or in a region adjacent thereto.

[0062] It should be appreciated that once a man versed in the art's attention is directed to the importance of a specific region, due to the fact that this region differs in the variant as compared to the original sequence, there is no problem in derivating said specific region by addition to it, deleting from it, or substituting some amino acids in it. Thus homologues of variants which are derivated from the variant by changes (deletion, addition, substitution) only in said region as well as in regions adjacent to it are also a part of the present invention. Generally, if the variant is distinguished from the original sequence by some sort of physiological activity, then the homolog is distinguished from the original sequence in essentially the same manner.

[0063] The present invention provides by the second of its aspects, a novel isolated nucleic acid molecule comprising of or consisting of the nucleic acid sequence of any one of SEQ ID NO: 29 or SEQ ID NO: 30, fragment of the sequence having at least 20 nucleic acids, or a molecule comprising a sequence having at least 70%, preferably 80%, and most preferably 90% identity to any one of SEQ ID NO: 29 or 30. The present invention further provides a protein or a polypeptide comprising or consisting of an amino acid sequence encoded by any one of the above nucleic acid sequences, termed herein as “TL product”. For example, the amino acid sequence depicted in SEQ ID NO: 70 (since both SEQ ID NO: 29 and 30 code for the same amino acid sequence) fragments of the above amino acid sequence having a length of at least 10 amino acids as well as homolog of the amino acid sequence of SEQ ID NO: 70 in which one or more amino acid residues have been substituted, by conservative or non conservative substitution, added, deleted or chemically modified.

[0064] The present invention further provides by its third aspect a novel isolated nucleic acid molecule comprising or consisting of any of the nucleic acid sequence of SEQ ID NO: 31 to 41, fragments of said sequence having at least 20 nucleic acids, or a molecule comprising a sequence having at least 70%, preferably 80%, and most preferably 90% identity to any of SEQ ID NO: 31 to 41. The present invention further provides a protein or polypeptide comprising or consisting of an amino acid sequence encoded by any of the above nucleic acid sequences, termed hereinafter: “TH product”. For example, an amino acid sequence having a sequence as depicted in any one of SEQ ID NO: 71 to 81, fragments of the above amino acid sequence having a length of at least 10 amino acids, as well as homologs of the amino acid sequences SEQ ID NO: 71 to SEQ ID NO: 81 in which one or more of the amino acid residues have been substituted (by conservative or non conservative substitution) added, deleted, or chemically modified.

[0065] The present invention further provides nucleic acid molecule comprising or consisting of a sequence which encodes the above valiant, TL and TH amino acid sequences, (including the fragments and homologues of the amino acid sequences). Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid sequences, beyond those depicted in any one of SEQ ID NO: 42 to SEQ ID NO: 81, can code for any of the amino acid sequence of the invention (variants, TL and TH). Those alternative nucleic acid sequences which code for the same amino acid sequences codes by the sequence SEQ ID NO: 1 to SEQ ID NO: 41 are also an aspect of the of the present invention.

[0066] The present invention further provides expression vectors and cloning vectors comprising any of the above nucleic acid sequences, as well as host cells transected by said vectors.

[0067] The present invention still further provides pharmaceutical compositions comprising, as an active ingredient, said nucleic acid molecules, said expression vectors, or said protein or polypeptide.

[0068] These pharmaceutical compositions are suitable for the treatment of diseases and pathological conditions, which can be ameliorated or cured by raising the level of any one of the valiant products of the invention, by raising the level of the TL product or by raising the level of TH products of the invention. The diseases in connection with the variants of the invention are as explained below in Example I.

[0069] The diseases in connection with the TL aspect are, for example, thrombocytopenia, a reduction in clot-inducing platelets, which occur in cancer patients treated with chemotherapy or a condition of delayed platelet recovery after hematopoietic stem cell transplantation.

[0070] The diseases in connection with the TH are those which can be ameliorated, cured or prevented by raising the level of the TH product. Typically these are diseases which are manifested by non-normal levels of transport of various ligands and/or by non-normal levels of secretion of various ligands. Alternatively, the diseases may be due to conditions in which the level of the transport is normal, but a therapeutically beneficial effect may be achieved by raising the level of the transport protein or by regulating its activity. For example, diseases where it is desired to modulate the release or uptake of secreted substances such as neurotransmitters and sugar.

[0071] For example, where the ligand is neurotransmitters (neurotransmitters as choline) and the biogenic amines (low molecular weight neurotransmitter substances such as dopamine, norepinephrine, epinephrine, serotonin and histamine) the diseases may be such in which a beneficial effect may be achieved by regulation of the secretion of neurotransmitters (which can be non-normal levels of secretion or normal levels of secretion), and this may include pathological conditions involved with substance abuse (such as cocaine or other drug abuse), diseases which involve spasmic movement due to unregulated neuronal firing; schizophrenia, dementia and other neuro degenerative diseases; depression and epilepsy as well as diseases involved in non-normal transport of sugars through membranes, such as various types of diabetes.

[0072] The TH product of the present invention may also be used in conjunction with imaging substances for detection and imaging purposes and may be used either as a target to which imaging substances bind and this binds to the membranes (for example neurotransmitter vesicles' membranes, or sugar transporting membranes) or alternatively the products themselves may be used to transport imaging substances, which mimick the natural ligands (neurotransmitters as choline and the biogenic amines low molecular weight neurotransmitter substances such as dopamine, norepinephrine, epinepluine, serotonin and histamine or sugars) in their binding to the product and thus are transferred by the product of the invention across membranes for imaging purposes.

[0073] By another embodiment, the present invention provides a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO: 1 to SEQ ID NO: 28, or complementary to a sequence having at least 90% identity to said sequence (with the proviso added above) or a fragment of said two sequences (according to the above definition of fragment).

[0074] By this second embodiment, the present invention provides a nucleic acid molecule comprising or consisting of a non coding sequence which is complementary to that of any one of SEQ ID NO: 29 or 30, or complementary to a sequence having at least 70% identity to said sequence or fragment of said two sequences.

[0075] In addition, according to the third aspect, the present invention provides a nucleic acid molecule comprising or consisting of a non coding sequence which is complementary to any of the sequences of SEQ ID NO: 31 to SEQ ID NO: 41, or complementary to a sequence having at least 70% identity with said sequence, or fragment of said two sequences.

[0076] The complementary sequence may be a DNA sequence which hybridizes with any one of SEQ of ID NO: 1 to SEQ ID NO: 41 or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence. The complementary sequence may be a DNA sequence which can be transcribed into an mRNA being an antisense to the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 41 or into an mRNA which is an antisense to a fragment of the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 41 which has a length sufficient to hybridize with the mRNA transcribed from SEQ ID NO: 1 to SEQ ID NO: 41, so as to inhibit its translation. The complementary sequence may also be the mRNA or the fragment of the mRNA itself.

[0077] The complementary nucleic acids according to the first, second and third aspects of the invention may be used for therapeutic or diagnostic applications for example as probes used for the detection of the variants, TL or TH sequences of the invention. The presence of the variant transcript, TL or TH or the level of the variant transcript, TL or TH transcripts may be indicative of a multitude of diseases, disorders and various pathological as well as normal conditions. In addition or alternatively, the ratio of the level of the transcripts of the variants of the invention may also be compared to that of the transcripts of the original sequences from which have been varied, or to the ratio of the level of transcript of other variants, and said ratio may be indicative to a multitude of diseases, disorders and various pathological and normal conditions.

[0078] As regards the TL transcript, the level of each of the alternative splice variants depicted in SEQ ID NO: 29 or 30, to each other may also be indicative to a plurality of diseases.

[0079] As regards the TH transcripts, the level or ratio of each of the alternative splice variants of SEQ ID NO: 31 to 41 or the ratio to each other; may also be indicative to a multitude of diseases, disorders and various pathological and normal conditions.

[0080] The present invention also provides expression vectors comprising any one of the above defined complementary nucleic acid sequences and host cells transfected with said nucleic acid sequences or vectors, being complementary to those specified in the first aspect of the invention.

[0081] The invention also provides anti-valiant product antibodies, anti-TL product antibodies and anti-TH product antibodies, namely antibodies directed against the variant product which specifically bind to said variant product. Said antibodies are useful both for diagnostic and therapeutic purposes. For example said antibodies may be as an active ingredient in a pharmaceutical composition as will be explained below.

[0082] The present invention also provides pharmaceutical compositions comprising, as an active ingredient, the nucleic acid molecules which comprise or consist of said complementary sequences, or of a vector comprising said complementary sequences. The pharmaceutical composition thus provides pharmaceutical compositions comprising, as an active ingredient, said anti-variant product antibodies, said anti-TL product antibodies or said anti-MTPH product antibodies.

[0083] The pharmaceutical compositions comprising said anti-variant product antibodies, anti-TL product antibodies or anti-TH antibodies or the nucleic acid molecule comprising said complementary sequence, are suitable for the treatment of diseases and pathological conditions where a therapeutically beneficial effect may be achieved by neutralizing the variant, TL or TH (either at the transcript or product level) or decreasing the amount of the variant product, TL or TH product or blocking its binding to its target, for example, by the neutralizing effect of the antibodies, or by the effect of the antisense mRNA in decreasing the expression level of the variant TL or TH sequences).

[0084] According to another embodiment of the invention the present invention provides methods for detecting the level of the transcript (mRNA) of said variant product, TL product or TH in a body fluid sample, or in a specific tissue sample, for example by use of probes comprising or consisting of said coding sequences (and determing level of hybridization of the proteins) or by using any amplification method utility suitable primers; as well as methods for detecting levels of expression of said product in tissue, e.g. by the use of antibodies capable of specifically reacting with the variant products of the invention. Detection of the level of the expression of the valiant of the invention in particular as compared to that of the original sequence from which it was varied or compared to other valiant sequences all varied from the same original sequence may be indicative of a plurality of physiological or pathological conditions.

[0085] The method, according to this latter aspect, for detection of a nucleic acid sequence which encodes the valiant product, the TL product or the TH in a biological sample, comprises the steps of:

[0086] (a) providing a probe comprising at least one of the nucleic acid sequences defined above (SEQ ID NO: 1 to SEQ ID NO: 41);

[0087] (b) contacting the biological sample with said probe under conditions allowing hybridization of nucleic acid sequences thereby enabling formation of hybridization complexes;

[0088] (c) detecting hybridization complexes, wherein the presence of the complexes indicates the presence of nucleic acid sequence encoding the valiant product, the TL product or the TH in the biological sample.

[0089] The method as described above is qualitative, i.e. indicates whether the transcript is present in or absent from the sample. The method can also be quantitative, by determining the level of hybridization complexes and then calibrating said levels to determining levels of transcripts of the desired variant, TL or TH in the sample.

[0090] Both qualitative and quantitative determination methods can be used for diagnostic, prognostic and therapy planning purposes.

[0091] By a preferred embodiment the probe is part of a nucleic acid chip used for detection purposes, i.e. the probe is a part of an array of probes each present in a known location on a solid support.

[0092] The method, according to the same latter aspect, for detection of a nucleic acid sequence which encodes the valiant product, the TL product or the TH in a biological sample, comprises the steps of:

[0093] (I) contacting the sample with primers for amplification of any one of SEQ ID NO: 1 to SEQ ID NO: 41;

[0094] (II) proving reagents for amplification;

[0095] (III) detecting the presence of amplified products,

[0096] Said products indicating the presence of the nucleic acid in the sample.

[0097] The nucleic acid sequence used in the above method may be a DNA sequence an RNA sequence, etc; it may be a coding or a sequence or a sequence complementary thereto (for respective detection of RNA transcripts or coding-DNA sequences). By quantization of the level of hybridization complexes and calibrating the quantified results it is possible also to detect the level of the transcript in the sample.

[0098] Methods for detecting mutations in the region coding for the valiant, TL or TH product are also provided, which may be methods carried out in a binary fashion, namely merely detecting whether there is any mismatches between the normal variant, TL or TH nucleic acid sequence of the invention and the one present in the sample, or carried out by specifically detecting the nature and location of the mutation.

[0099] The present invention also concerns a method for detecting variant product, a TL product or TH product in a biological sample, comprising the steps of:

[0100] (a) contacting with said biological sample any of the antibodies of the invention, thereby forming an antibody-antigen complex; and

[0101] (b) detecting said antibody-antigen complexes

[0102] wherein the presence of said antibody-antigen complex correlates with the presence of variant product, TL product or TH product, respectively in said biological sample.

[0103] Many diseases are diagnosed by detecting the presence of antibodies against a protein characterizing the disease in the blood, serum or any other body fluid of the patient. The present invention also concerns a method for detecting anti-variant antibody in a biological sample, comprising:

[0104] (a) contacting said sample with the valiant product, TL product or a MTPH product of the invention, thereby forming an antibody-antigen complex; and

[0105] (b) detecting said antibody-antigen complex

[0106] wherein the presence of said antibody-antigen complex correlates with the presence of anti-valiant, anti-TL or anti-TH antibodies in the sample.

[0107] As indicated above, both methods (for detection of any one of the products and for detection of any one of the antibodies against the product) can be quantitized to determine the level or the amount of the variant or antibody in the sample, alone or in comparison to the level of the original amino acid sequence from which it was varied or compared to the level of antibodies against the original amino acid sequence, and qualitative and quantitative results may be used for diagnostic, prognostic and therapy planning purposes.

[0108] The invention also concerns distinguishing antibodies, i.e. antibodies capable of binding either to the variant product or to the original sequence from which the valiant has been varied, while not binding to the original sequence or the variant product respectively. These distinguishing antibodies may be used for detection purposes.

[0109] By yet another aspect the invention also provides a method for identifying candidate compounds capable of binding to the variant product, the TL product or the TH product and modulating their activity (being either activators or deactivators). The method includes:

[0110] (i) providing a protein or polypeptide comprising an amino acid sequence substantially as depicted in any one of SEQ ID NO: 42 to 81, or a fragment of such a sequence;

[0111] (ii) contacting a candidate compound with said amino acid sequence;

[0112] (iii) measuring the physiological effect of said candidate compound on the activity of the amino acid sequences and selecting those compounds which show a significant effect on said physiological activity.

[0113] The present invention also concerns compounds identified by the methods described above, which compound may either be an activator of the variant product, the TL product or the TH, or a deactivator thereof.

[0114] The detection may be for the same diseases which the pharmaceutical composition of the invention are referred as capable of treating.

BRIEF DESCRIPTION OF THE DRAWINGS

[0115] In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

[0116] FIGS. 1 to 28 show the alignment of any one of SEQ ID NO: 1 to SEQ ID NO: 28, respectively, to the original sequence from which they were varied.

[0117]FIG. 29 is the alignment of SEQ ID NO: 38 and SEQ ID NO: 39, i.e. of the two splice variants.

[0118]FIG. 30 is an alignment between SEQ ID NO: 78 and SEQ ID NO: 79, i.e. of the two splice variants.

[0119]FIG. 31 is an alignment between SEQ ID NO: 40 and SEQ ID NO: 41, i.e. of the two splice variants.

[0120]FIG. 32 is an alignment between SEQ ID NO: 80 and SEQ ID NO: 81, i.e. of the two splice variants.

[0121]FIG. 33 is an alignment between SEQ ID NO: 40 and TH sequence.

[0122]FIG. 34 is an alignment between SEQ ID NO: 41 and TH sequence.

[0123]FIG. 35 is an alignment between SEQ ID NO: 40 and a known protein (acession no. gi4887697).

[0124]FIG. 36 is an alignment between between SEQ ID NO: 40 and a known protein (acession no. gi4506987).

[0125]FIG. 37 is an alignment between SEQ ID NO: 41 and a known protein (acession no. gi4887697)

[0126] FIG. 38 is an alignment between SEQ ID NO: 41 and a known protein (acession no. gi4506987)FIG. 39 (A-H) shows a prediction of transmembrane domains of SEQ ID NO:80

[0127]FIG. 40 (A-H) shows a prediction of transmembrane domains of SEQ ID NO:81

[0128]FIG. 41 is a Northern Blot analysis of mRNA obtained from (A.) various brain regions or (B.) various human tissues, and tested with TH specific nucleotide probe.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS EXAMPLE I Differences Between Variants and Original Sequences

[0129] The following is a table that compares the sequences of the variants of the invention to the original sequences from which they were varied and indicates here the variant differs from the original sequence. The terminology NV-1 to NV-28 corresponds to SEQ ID NO: 1 to SEQ ID NO: 28. TABLE New Protein Variant Name # Description of the new variant NEURO- NV_1 Insertion of an alternative exon of 15 amino MODULIN acids after amino acid 171 of the original protein NEURO- NV_2 Alternative exon at 5′ end; alternative 39 MODULIN amino acids instead of first 11 amino acids in the original protein. EDF-1 NV_3 Alternative exon at 3′ end of 7 amino acids instead of 25 amino acids EDF-1 NV_4 Alternative exon at 3′ end of 25 amino acids instead of 76 amino acids EDF-1 NV_5 Alternative exon at 3′ end of 13 amino acids instead of 20 amino acids Glucose NV_6 Alternative exon at 3′ end of 4 amino acids transporter instead of 25 amino acids. Missing end of glycoprotein CYTOPLASMIC domain Glucose NV_7 Alternative exon at 3′ end of 22 amino acids transporter instead of 13 amino acids in the end of glycoprotein CYTOPLASMIC domain. Glucose NV_8 Alternative exon at 3′ end of 23 amino acids transporter instead of 44 amino acids in the end of glycoprotein CYTOPLASMIC domain. Glucose NV_9 Alternative exon at 3′ end of 7 amino acids transporter instead of 44 amino acids in the end of glycoprotein CYTOPLASMIC domain Glucose NV_10 Alternative exon at 3′ end of 22 amino acids transporter instead of 73 ammo acids in the end of glycoprotein CYTOPLASMIC domain. Missing last transmembrane domain. B- NV_11 The variant has an alternative 5′ exon; 3 LYMPHOCYTE amino acids instead of 191 amino acids. The ANTIGEN CD20 variant is lacking 3 transmembrane domains, out of possible 4 transmembrane domains. The variant is also lacking 1 out 2 cytoplasmic domains and all 3 disulfide chains. G1/S-SPECIFIC NV_12 Alternative exon at 3′ end; alternative 64 CYCLIN D2 amino acids instead of 99 amino acids. MELANOMA NV_13 Alternative exon at 3′ end of 1 amino acids ANTIGEN instead of 21 amino acids RECOGNIZED BY T-CELLS 1 MELANOMA NV_14 Alternative exon at 3′ end of 36 amino acids ANTIGEN instead of 60 amino acids. RECOGNIZED In the alternative exon is a predicted BY T-CELLS 1 transmembrane domain TYROSINE- NV_15 Alternative exon at 3′ end of 9 amino acids PROTEIN instead of 348 ammo acids. The new variant KINASE is missing a large portion of the cytoplasmic RECEPTOR domain. The variant is also missing the UFO entire PROTEIN KINASE domain, resulting in a probable loss of its activity. TUMOR NV_16 Deletion of 36 amino acids between NECROSIS positions 173-210 FACTOR, ALPHA- INDUCED PROTEIN 2 (B94 PROTEIN) COMPLEMENT NV_17 Alternative exon at 3′ end of 32 amino acids C5 instead of 457 amino acids. The new variant is lacking the C5B (ALPHA′) domain, and is missing the last potential glycosylation site. COMPLEMENT NV_18 Alternative exon at 3′ end of 13 amino acids C5 instead of 74 amino acids. The new variant is lacking the end of the C5B (ALPHA′) domain, and is missing the last potential glycosylation site T-CELL NV_19 Deletion of 55 amino acids between 241-296 SURFACE GLYCO- PROTEIN CD1B TENASCIN NV_20 Deletion of 35 amino acids between 1879- 1914. Missing small part of FIBRONECTIN TYPE-III 15 TNFR2- TRAF NV_21 Alternative exon at 3′ end of 6 amino acids SIGNALING instead of 319 amino acids. The new variant COMPLEX is lacking Zinc Finger and half of the third PROTEIN 2 BIR repeat. Also, the new variant has two SNIP in amino acid 235 and 241 cytokine- NV_22 Alternative exon at 3′ end of 46 amino acids inducible SH2 instead of 267 amino acids. protein 6 NEURONAL NV_23 Alternative exon at 5′ end of 35 amino acids MEMBRANE instead of 22 amino acids GLYCO- PROTEIN M6-B FIBROBLAST NV_24 Alternative exon at 5′ end of 31 amino acids GROWTH instead of 67 amino acids. The new variant is FACTOR missing the two BIPARTITE NUCLEAR HOMOLOGOUS LOCALIZATION SIGNAL FACTOR 1 FIBRONECTIN NV_25 Deletion of 102 amino acids between 542- RECEPTOR 644. The deletion is in the BETA SUBUNIT EXTRACELLULAR domain; in the INTEGRIN CYSTEINE-RICH REPEATS domain. The BETA-1 new variant is lacking 1 (out of 12) potential glycosylation sites FIBRONECTIN NV_26 Deletion of 255 amino acids between 171- RECEPTOR 427. The deletion is in the BETA SUBUNIT EXTRACELLULAR domain. The new INTEGRIN variant is lacking 5 (out of 12) potential BETA-1 glycosylation sites ENDOTHELIN B NV_27 Alternative exon at 3′ end of 13 amino acids RECEPTOR instead of 268 amino acids The new variant is missing 5 (out of 7) transmembrane domains; missing 2 (out of 4) extracellular domains; missing 3 (out of 4) cytoplasmic domains; missing 1 (out of 1) disulfide bonds; missing 3 (out of 3) PALMITATE sites.

EXAMPLE II Designation of the Original Sequences, Therapeutical and Diagnostic Utilization of the Variant Sequences

[0130] Each novel variant of the invention is varied from an original sequence which has a known designation. The designation of the RNA sequences of the original sequences from which it was varied and the Accession Number of the original sequence are given below. First, information concerning the original sequence is given and then designation of the novel variants of the invention is given as NV-1 to NV-28 corresponding to SEQ ID NO: 1 to SEQ ID NO: 28.

[0131] The variants of SEQ ID NO: 1 to SEQ ID NO: 28 may be used to detect and treat a plurality of diseases or disorders stemming from malfunction of the original sequence.

Neuromodulin

[0132] AXONAL MEMBRANE PROTEIN GAP-43

[0133] FUNCTION: THIS PROTEIN IS ASSOCIATED WITH NERVE GROWTH. IT IS A MAJOR COMPONENT OF THE MOTILE “GROWTH CONES” THAT FORM THE TIPS OF ELONGATING AXONS.

[0134] SUBCELLULAR LOCATION: CYTOPLASMIC SURFACE OF GROWTH CONE AND SYNAPTIC PLASMA MEMBRANES.

[0135] PTM: PHOSPHORYLATION OF THIS PROTEIN BY A PROTEIN KINASE C IS SPECIFICALLY CORRELATED WITH CERTAIN FORMS OF SYNAPTIC PLASTICITY.

[0136] MISCELLANEOUS: BINDS CALMODULIN WITH A GREATER AFFINITY IN THE ABSENCE OF CA++ THAN IN ITS PRESENCE

NV_(—)1

[0137] Insertion of an alternative exon of 15 amino acids after amino acid 171.

[0138] This new exon is predicted as transmembrane domain. The new variant maintains all the necessary functional domains; phosphorylation sites, palmitate regions, and the domain important for membrane binding.

[0139] SEQ ID NO: 1 and sequences coded thereby may be used to detect or treat diseases relating to the central nervous system

NV_(—)2

[0140] Alternative exon at 5′ end; alternative 39 amino acids instead of first 11 amino acids.

[0141] Missing 4 amino acids IMPORTANT FOR MEMBRANE BINDING, missing 2 lipid PALMITATE

[0142] SEQ ID NO. 2 and sequences coded thereby may be used to detect or treat diseases relating to the central nervous system.

EDF-1 protein

[0143] A novel gene product down-regulated in human endothelial cell differentiation EDF-1 encodes a basic intracellular protein of 148 amino acids that is homologous to MBF1 (multiprotein-bridging factor 1) of the silkworm Bombyx mori and to H7, which is implicated in the early developmental events of Dictyostelium discoideum.

NV_(—)3

[0144] Alternative exon at 3′ end of 7 amino acids instead of 25 amino acids.

NV_(—)4

[0145] Alternative exon at 3′ end of 25 amino acids instead of 76 amino acids

NV_(—)5

[0146] Alternative exon at 3′ end of 13 amino acids instead of 20 amino acids

[0147] All the above SEQ ID NOS: 3, 4, 5 and proteins coded thereby may be used to detect diseases concerning non-normal endothelial cells differentiation.

Glucose Transporter Glycoprotein

[0148] FUNCTION: FACILITATIVE GLUCOSE TRANSPORTER. THIS ISOFORM MAY BE RESPONSIBLE FOR CONSTITUTIVE OR BASAL GLUCOSE UPTAKE. HAS A VERY BROAD SUBSTRATE SPECIFICITY; CAN TRANSPORT A WIDE RANGE OF ALDOSES INCLUDING BOTH PENTOSES AND HEXOSES.

[0149] SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. TISSUE SPECIFICITY: EXPRESSED AT VARIABLE LEVELS IN MANY HUMAN TISSUES.

NV_(—)6

[0150] Alternative exon at 3′ end of 4 amino acids instead of 25 amino acids. Missing end of CYTOPLASMIC domain

NV_(—)7

[0151] Alternative exon at 3′ end of 22 amino acids instead of 13 amino acids in the end of CYTOPLASMIC domain.

NV_(—)8

[0152] Alternative exon at 3′ end of 23 amino acids instead of 44 amino acids in the end of CYTOPLASMIC domain.

NV_(—)9

[0153] Alternative exon at 3′ end of 7 amino acids instead of 44 amino acids in the end of CYTOPLASMIC domain.

NV_(—)10

[0154] Alternative exon at 3′ end of 22 amino acids instead of 73 amino acids in the endof CYTOPLASMIC domain. Missing last transmembrane domain. All the above SEQ ID NOS. 6-10 and proteins coded thereby may be used to detect and treat diseases and disorders caused by non-normal glucose transport.

B-LYMPHOCYTE ANTIGEN CD20

[0155] FUNCTION: THIS PROTEIN MAY BE INVOLVED IN THE REGULATION OF B-CELL ACTIVATION AND PROLIFERATION.

[0156] SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.

[0157] PTM: PHOSPHORYLATED. MIGHT BE FUNCTIONALLY REGULATED BY PROTEIN KINASE(S).

NV_(—)11

[0158] The variant has an alternative 5′ exon; 3 amino acids instead of 191 amino acids. The valiant is lacking 3 transmembrane domains, out of possible 4 transmembrane domains. The variant is also lacking 1 out 2 cytoplasmic domains and all 3 disulfide chains.

[0159] SEQ ID NO. 11 and proteins coded thereby may be used to treat and detect diseases involved in regulation of B-cell activation and proliferation, such as diseases involving the immune system.

G1/S-SPECIFIC CYCLIN D2

[0160] FUNCTION: ESSENTIAL FOR THE CONTROL OF THE CELL CYCLE AT THE G1/S (START) TRANSITION. INTERACTS WITH THE CDC2 PROTEIN KINASE TO FORM MPF.

[0161] SIMILARITY: BELONGS TO THE CYCLIN FAMILY. CYCLIN D SUBFAMILY.

NV_(—)12

[0162] Alternative exon at 3′ end; alternative 64 amino acids instead of 99 amino acids.

[0163] SEQ ID NO. 12 and proteins coded thereby can be used to treat or detect diseases involved in non-normal cell cycles, notably cancer diseases or degenerative diseases.

MELANOMA ANTIGEN RECOGNIZED BY T-CELLS 1

[0164] TISSUE SPECIFICITY: EXPRESSION IS RESTRICTED TO MELANOMA AND MELANOCYTE CELL LINES AND RETINA

NV_(—)13

[0165] Alternative exon at 3′ end of 1 amino acids instead of 21 amino acids.

NV_(—)14

[0166] Alternative exon at 3′ end of 36 amino acids instead of 60 amino acids. In the alternative exon is a predicted transmembrane domain.

[0167] SEQ ID NO: 13 and SEQ ID NO: 14 and proteins coded thereby can be used to treat and detect melanoma, as well as to detect melanocyte cell lines.

TYROSINE-PROTEIN KINASE RECEPTOR UFO (AXL ONCOGENE)

[0168] FUNCTION: MAY FUNCTION AS A SIGNAL TRANSDUCER BETWEEN SPECIFIC CELL TYPES OF MESODERMAL ORIGIN.

[0169] SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.

[0170] DISEASE: HAS TRANSFORMING POTENTIAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDER OR CHRONIC MYELOCYTIC LEUKEMIA.

[0171] SIMILARITY: TO OTHER PROTEIN-TYROSINE KINASES IN THE CATALYTIC DOMAIN.

[0172] SIMILARITY: CONTAINS 2 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAINS.

[0173] SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.

NV_(—)15

[0174] Alternative exon at 3′ end of 9 amino acids instead of 348 amino acids. The new variant is missing a large portion of the cytoplasmic domain. The variant is also missing the entire PROTEIN KINASE domain, resulting in a probable loss of its activity.

[0175] SEQ ID NO: 15 and proteins coded thereby may be used to treat and detect diseases involving non-normal signal transduction especially in mesodermal cells.

TUMOR NECROSIS FACTORS ALPHA-INDUCED PROTEIN 2 (B94 PROTEIN)

[0176] FUNCTION: MAY PLAY A ROLE AS A MEDIATOR OF INFLAMMATION AND ANGIOGENESIS.

[0177] DEVELOPMENTAL STAGE: DIFFERENTIALLY EXPRESSED IN DEVELOPMENT AND CAPILLARY TUBE-LIKE FORMATION IN VITRO.

[0178] INDUCTION: BY TNF AND OTHER PROINFLAMMATORY FACTORS.

NV_(—)16

[0179] Deletion of 36 amino acids between positions 173-210.

[0180] SEQ ID NO. 10 and sequences coded thereby may be used to treat and detect diseases involving the immune system, such as inflammatory diseases, autoimmune diseases and cancer.

COMPLEMENT C5

[0181] FUNCTION: ACTIVATION OF C5 BY A C5 CONVERTASE INITIATES THE SPONTANEOUS ASSEMBLY OF THE LATE COMPLEMENT COMPONENTS, C5-C9, INTO THE MEMBRANE ATTACK COMPLEX. C5B HAS A TRANSIENT BINDING SITE FOR C6. THE C5B-C6 COMPLEX IS THE FOUNDATION UPON WHICH THE LYTIC COMPLEX IS ASSEMBLED.

[0182] FUNCTION: DERIVED FROM PROTEOLYTIC DEGRADATION OF COMPLEMENT C5, C5 ANAPHYLATOXIN IS A MEDIATOR OF LOCAL INFLAMMATORY PROCESS. IT INDUCES THE CONTRACTION OF SMOOTH MUSCLE, INCREASES VASCULAR PERMEABILITY AND CAUSES HISTAMINE RELEASE FROM MAST CELLS AND BASOPHILIC LEUKOCYTES. C5A ALSO STIMULATES THE LOCOMOTION OF POLYMORPHONUCLEAR LEUKOCYTES (CHEMOKINESIS) AND DIRECT THEIR MIGRATION TOWARD SITES OF INFLAMMATION (CHEMOTAXIS).

[0183] SUBUNIT: C5 PRECURSOR IS FIRST PROCESSED BY THE REMOVAL OF 4 BASIC RESIDUES, FORMING TWO CHAINS, BETA & ALPHA, LINKED BY A DISULFIDE BOND. C5 CONVERTASE ACTIVATES C5 BY CLEAVING THE ALPHA CHAIN, RELEASING C5A ANAPHYLATOXIN & GENERATING C5B (BETA CHAIN+ALPHA′ CHAIN).

[0184] SIMILARITY: TO C3, C4 AND ALPHA-2-MACROGLOBULIN.

[0185] SIMILARITY: CONTAINS 1 ANAPHYLATOXIN-LIKE DOMAIN.

NV_(—)17

[0186] Alternative exon at 3′ end of 32 amino acids instead of 457 amino acids. The new variant is lacking the C5B (ALPHA′) domain, and is missing the last potential glycosylation site.

[0187] SEQ ID NO. 17 and SEQ ID NO. 18 and sequences coded thereby may be used to detect and treat diseases involved in non-normal complement activity.

NV_(—)18

[0188] Alternative exon at 3′ end of 13 amino acids instead of 74 amino acids. The new variant is lacking the end of the C5B (ALPHA′) domain, and is missing the last potential glycosylation site.

T-CELL SURFACE GLYCOPROTEIN CD1B

[0189] FUNCTION: NOT KNOWN.

[0190] SUBUNIT: ASSOCIATES NON-COVALENTLY WITH BETA-2- MICRO-GLOBULIN.

[0191] SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.

[0192] TISSUE SPECIFICITY: EXPRESSED ON CORTICAL THYMOCYTES, ON CERTAIN T-CELL LEUKEMIAS, AND IN VARIOUS OTHER TISSUES.

[0193] SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.

NV_(—)19

[0194] Deletion of 55 amino acids between 241-296.

[0195] SEQ ID NO. 19 and proteins coded thereby may be used to treat and detect diseases concerning globulines, in particular immune-related diseases.

TENASCIN

[0196] FUNCTION: SAM (SUBSTRATE-ADHESION MOLECULE) THAT APPEARS TO INHIBIT CELL MIGRATION. MAY PLAY A ROLE IN SUPPORTING THE GROWTH OF EPITHELIAL TUMORS.

[0197] SUBUNIT: HEXAMERIC. A HOMOTRIMER MAY BE FORMED IN THE TRIPLE COILED-COIL REGION AND MAY BE STABILIZED BY DISULFIDE RINGS AT BOTH ENDS. TWO OF SUCH HALF-HEXABRACHIONS MAY BE DISULFIDE LINKED WITHIN THE CENTRAL GLOBULE.

[0198] SUBCELLULAR LOCATION: EXTRACELLULAR MATRIX.

[0199] ALTERNATIVE PRODUCTS: FOUR VARIANTS ARE PRODUCED FROM A SINGLE GENE IN A TISSUE- AND TIME-SPECIFIC MANNER DURING DEVELOPMENT.

[0200] INDUCTION: BY TGF-BETA.

[0201] SIMILARITY: CONTAINS 15 EGF-LIKE DOMAINS.

[0202] SIMILARITY: CONTAINS 15 FIBRONECTIN TYPE III-LIKE DOMAINS.

[0203] SIMILARITY: CONTAINS 1 FIBRINOGEN-LIKE DOMAIN.

NV_(—)20

[0204] Deletion of 35 amino acids between 1879-1914. Missing small part of FIBRONECTIN TYPE-III 15

[0205] SEQ ID NO. 20 and sequences encoded thereby may be used to treat epithelial tumors.

TNFR2-TRAF SIGNALING COMPLEX PROTEIN 2

[0206] FUNCTION: APOPTOTIC SUPPRESSOR. THE BIR MOTIFS REGION INTERACTS WITH TNF RECEPTOR ASSOCIATED FACTORS 1 AND 2 (TRAF1 AND TRAF2) TO FORM AN HETEROMERIC COMPLEX, WHICH IS THEN RECRUITED TO THE TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2).

[0207] SUBCELLULAR LOCATION: CYTOPLASMIC (POTENTIAL).

[0208] TISSUE SPECIFICITY: PRESENT IN MANY FETAL AND ADULT TISSUES. MAINLY EXPRESSED IN ADULT SKELETAL MUSCLE, THYMUS, TESTIS, OVARY, AND PANCREAS, LOW OR ABSENT IN BRAIN AND PERIPHERAL BLOOD LEUKOCYTES.

[0209] SIMILARITY: BELONGS TO THE IAP FAMILY.

[0210] SIMILARITY: CONTAINS 3 BIR DOMAINS (BACULOVIRAL INHIBITION OF APOPTOSIS PROTEIN REPEAT).

[0211] SIMILARITY: CONTAINS A C3HC4-CLASS ZINC FINGER.

NV_(—)21

[0212] Alternative exon at 3′ end of 6 amino acids instead of 319 amino acids. The new variant is lacking Zinc Finger and half of the third BIR repeat. Also, the new variant has two SNIP in amino acid 235 and 241.

[0213] SEQ ID NO. 21 may be used to suppress apoptosis for example in neurodegenerative diseases. Antibodies and complementary sequences may be used in case apoptosis is to be encouraged, such as in cancer.

CYTOKINE-INDUCIBLE SH2 PROTEIN 6 NV_(—)22

[0214] Alternative exon at 3′ end of 46 amino acids instead of 267 amino acids.

NEURONAL MEMBRANE GLYCOPROTEIN M6-B

[0215] FUNCTION: MAY BE INVOLVED IN NEURAL DEVELOPMENT.

[0216] SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN (BY SIMILARITY).

[0217] TISSUE SPECIFICITY: NEURONS AND GLIA; CEREBELLAR BERGMANN GLIA, IN GLIA WITHIN WHITE MATTER TRACTS OF THE CEREBELLUM AND CEREBRUM, AND IN EMBRYONIC DORSAL ROOT GANGLIA.

[0218] SIMILARITY: BELONGS TO THE MYELIN PROTEOLIPID PROTEIN FAMILY.

NV_(—)23

[0219] Alternative exon at 5′ end of 35 amino acids instead of 22 amino acids. SEQ ID NO. 23 and proteins encoded thereby may be used to detect and treat neurodegenerative diseases.

FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTOR 1

[0220] FUNCTION: PROBABLY INVOLVED IN NERVOUS SYSTEM DEVELOPMENT AND FUNCTION.

[0221] SUBCELLULAR LOCATION: NUCLEAR (PROBABLE).

[0222] TISSUE SPECIFICITY: BRAIN, EYE AND TESTIS; HIGHLY EXPRESSED IN EMBRYONIC RETINA, OLFACTORY EPITHELIUM, OLFACTORY BULB, AND IN A SEGMENTAL PATTERN OF THE BODY WALL; IN ADULT OLFACTORY BULB, LESS IN CEREBELLUM, DEEP CEREBELLAR NUCLEI, CORTEX, AND MULTIPLE MIDBRAIN STRUCTURES.

[0223] SIMILARITY: BELONGS TO THE HEPARIN-BINDING GROWTH FACTORS FAMILY.

NV_(—)24

[0224] Alternative exon at 5′ end of 31 amino acids instead of 67 amino acids. The new variant is missing the two BIPARTITE NUCLEAR LOCALIZATION SIGNAL. SEQ ID NO. 24 and sequences encoded thereby may be used to detect and treat neurodegenerative diseases.

FIBRONECTIN RECEPTOR BETA SUBUNIT INTEGRIN BETA-1

[0225] FUNCTION: ASSOCIATES WITH ALPHA-1 OR ALPHA-6 TO FORM A LAMININ RECEPTOR, WITH ALPHA-2 TO FORM A COLLAGEN RECEPTOR, WITH ALPHA-4 TO INTERACT WITH VCAM-1, WITH ALPHA-5 TO FORM A FIBRONECTIN RECEPTOR AND WITH ALPHA-8. INTEGRINS RECOGNIZE THE SEQUENCE R-G-D IN THEIR LIGAND.

[0226] SUBUNIT: DIMER OF AN ALPHA AND BETA SUBUNIT. THE BETA-1 CHAIN IS KNOWN TO ASSOCIATE WITH ALPHA-1, -2, -3, -4, -5, -6, -7, -8, -9, AND -V.

[0227] SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.

[0228] PTM: THE CYSTEINE RESIDUES ARE INVOLVED IN INTRACHAIN DISULFIDE BONDS.

[0229] SIMILARITY: BELONGS TO THE INTEGRIN BETA CHAIN FAMILY.

NV_(—)25

[0230] Deletion of 102 amino acids between 542-644. The deletion is in the EXTRACELLULAR domain; in the CYSTEINE-RICH REPEATS domain. The new variant is lacking 1 (out of 12) potential glycosylation sites.

NV_(—)26

[0231] Deletion of 255 amino acids between 171-427. The deletion is in the EXTRACELLULAR domain. The new valiant is lacking 5 (out of 12) potential glycosylation sites.

[0232] SEQ ID NO. 25 and SEQ ID NO. 26 encoded thereby may be used to treat and detect conditions involving collagen disorders, and various forms of fibrosis.

ENDOTHELIN B RECEPTOR

[0233] FUNCTION: NON-SPECIFIC RECEPTOR FOR ENDOTHELIN 1, 2, AND 3. MEDIATES ITS ACTION BY ASSOCIATION WITH G PROTEINS THAT ACTIVATE A PHOSPHATIDYLINOSITOL-CALCIUM SECOND MESSENGER SYSTEM.

[0234] SUBCELLULAR LOCATION: INTEGRAL, MEMBRANE PROTEIN.

[0235] DISEASE: DEFECTS IN EDNRB ARE A CAUSE OF TYPE IV (WS4 OR SHAH- WAARDENBURG SYNDROME) (WS/HSCR) WHICH IS CHARACTERIZED BY THE ASSOCIATION OF WS AND HIRSCHSPRUNG DISEASE (HSCR).

[0236] DISEASE: DEFECTS IN EDNRB ARE THE CAUSE OF TYPE 2 HIRSCHSPRUNG DISEASE (HSCR2) (OR AGANGLIONIC MEGACOLON), A CONGENITAL DISORDER CHARACTERIZED BY ABSENCE OF ENTERIC GANGLIA ALONG A VARIABLE LENGTH OF THE INTESTINE. HSCR IS THE MOST COMMON CAUSE OF CONGENITAL INTESTINAL OBSTRUCTION EARLY SYMPTOMS RANGE FROM COMPLETE ACUTE NEONATAL OBSTRUCTION, CHARACTERIZED BY VOMITING, ABDOMINAL DISTENTION AND FAILURE TO PASS STOOL, TO CHRONIC CONSTIPATION IN THE OLDER CHILD.

NV_(—)27

[0237] Alternative exon at 3′ end of 13 amino acids instead of 268 amino acids. The new variant is missing 5 (out of 7) transmembrane domains; missing 2 (out of 4) extracellular domains; missing 3 (out of 4) cytoplasmic domains; missing 1 (out of 1) disulfide bonds; missing 3 (out of 3) PALMITATE sites.

[0238] SEQ ID NO. 27 and sequences encoded thereby may be used to treat and detect Type IV (WS4 or Shahwaaardenburg syndrome and Hirschsprung disease.

RAS-LIKE PROTEIN NV_(—)28

[0239] Deletion of 86 amino acids between 75-161.

[0240] SEQ ID. NO. 28 and sequences encoded thereby may be used to detect and treat cancer.

EXAMPLE III Variant, TL and TH Nucleic Acid Sequence

[0241] The nucleic acid sequences of the invention include nucleic acid sequences which encode variant product and fragments and analogs thereof as well as nucleic acid sequences which code for the TL or the TH products. The nucleic acid sequences may alternatively be sequences complementary to the above coding sequences, or to regions of said coding sequence. The length of the complementary sequence is sufficient to avoid the expression of the coding sequence. The nucleic acid sequences may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and genomic DNA. The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand. The nucleic acid sequences may also both include dNTPs, rNTPs as well as non naturally occurring sequences. The sequence may also be a pail of a hybrid between an amino acid sequence and a nucleic acid sequence.

[0242] In a general embodiment, the nucleic acid sequence has at least 90%, identity with any one of the sequence identified as SEQ ID NO: 1 to SEQ ID NO: 41 provided that this sequence is not completely identical with that of the original sequence. In another general embodiment the nucleic acid sequence has at least 70% identity, preferably 80% identity, most preferably 90% identity with any of the sequences of SEQ ID NO: 1 to SEQ ID NO: 41.

[0243] The nucleic acid sequences may include the coding sequence by itself. By another alternative the coding region may be in combination with additional coding sequences, such as those coding for fusion protein or signal peptides, in combination with non-coding sequences, such as introns and control elements, promoter and terminator elements or 5′ and/or 3 untranslated regions, effective for expression of the coding sequence in a suitable host, and/or in a vector or host environment in which any of the above nucleic acid sequence is introduced as a heterologous sequence.

[0244] The nucleic acid sequences of the present invention may also have the product coding sequence fused in-frame to a marker sequence which allows for purification of the variant product. The marker sequence may be, for example, a hexahistidine tag to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al. Cell 37:767 (1984)).

[0245] Also included in the scope of the invention are fragments as defined above also referred to herein as oligonucleotides, typically having at least 20 bases, preferably 20-30 bases corresponding to a region of the coding-sequence nucleic acid sequence. The fragments may be used as probes, primers, and when complementary also as antisense agents, and the like, according to known methods.

[0246] As indicated above, the nucleic acid sequence may be substantially a depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 41 or fragments thereof or sequences having at least 90% identity to the above sequence as explained above, or sequences having at least 70%, preferably 80%, most preferably 90% identity to the above sequences. Alternatively, due to the degenerative nature of the genetic code, the sequence may be a sequence coding for any one of the amino acid sequence of SEQ ID NO: 42 to SEQ ID NO: 81, or fragments or analogs of said amino acid sequence.

[0247] A. Preparation of Nucleic Acid Sequences

[0248] The nucleic acid sequences may be obtained by screening cDNA libraries using oligonucleotide probes which can hybridize to or PCR-amplify nucleic acid sequences which encode any one of the products disclosed above. cDNA libraries prepared from a variety of tissues are commercially available and procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd Edition), Cold Spring Harbor Press, Plainview, N.Y and Ausubel F M et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y.

[0249] The nucleic acid sequences may be extended to obtain upstream and downstream sequences such as promoters, regulatory elements, and 5′ and 3′ untranslated regions (UTRs). Extension of the available transcript sequence may be performed by numerous methods known to those of skill in the art such as PCR or primer extension (Sambrook et al., supra), or by the RACE method using, for example, the Marathon RACE kit (Clontech, Cat. #K1802-1).

[0250] Alternatively, the technique of “restriction-site” PCR (Gobinda et al. PCR Methods Applic. 2:318-22, (1993)), which uses universal primers to retrieve flanking sequence adjacent a known locus, may be employed. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

[0251] Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al., Nucleic Acids Res. 16:8186, (1988)). The primers may be designed using OLIGO(R) 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth, Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

[0252] Capture PCR (Lagerstrom, M. et al., PCR Methods Applic. 1:111-19, (1991)) is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into a flanking part of the DNA molecule before PCR.

[0253] Another method which may be used to retrieve flanking sequences is that of Parker, J. D., et al., Nucleic Acids Res., 19:3055-60, (1991)). Additionally, one can use PCR, nested primers and PromoterFinder™ libraries to “walk in” genomic DNA (PromoterFinder™; Clontech, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5′ and upstream regions of genes.

[0254] A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5′ nontranslated regulatory region.

[0255] The nucleic acid sequences and oligonucleotides of the invention can is also be prepared by solid-phase methods, according to known synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined to form continuous sequences up to several hundred bases.

[0256] B. Use of Nucleic Acid Sequence for the Production of Products

[0257] In accordance with the present invention, nucleic acid sequences specified above may be used as recombinant DNA molecules that direct the expression of any of the products of the invention (i.e. the variant products, the TL products or the TH products).

[0258] As will be understood by those of skill in the art, it may be advantageous to produce product-encoding nucleotide sequences possessing codons other than those which appear in any one of SEQ ID NO: 1 to SEQ ID NO: 41 which are those which naturally occur in the human genome. Codons preferred by a particular prokaryotic or eukaryotic host (Murray, E. et al. Nuc Acids Res., 17:477-508, (1989)) can be selected, for example, to increase the rate of product expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequences.

[0259] The nucleic acid sequences of the present invention can be engineered in order to alter the product coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the product. For example, alterations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, etc.

[0260] The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are also described in Sambrook, et al., (supra).

[0261] The present invention also relates to host cells which are genetically engineered with vectors of the invention, and the production of the product of the invention by recombinant techniques. Host cells are genetically engineered (i.e., transduced, transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the expression of the valiant nucleic acid sequence. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art.

[0262] The nucleic acid sequences of the present invention may be included in any one of a variety of expression vectors for expressing a product. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However; any other vector may be used as long as it is replicable and viable in the host. The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and related sub-cloning procedures are deemed to be within the scope of those skilled in the art.

[0263] The DNA sequence in the expression vector is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis. Examples of such promoters include: LTR or SV40 promoter, the E. coli lac or trp promoter, the phage lambda PL promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation, and a transcription terminator The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

[0264] The vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. Examples of appropriate expression hosts include: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila and Spodoptera Sf9; animal cells such as CHO, COS, HEK 293 or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. The invention is not limited by the host cells employed.

[0265] In bacterial systems, a number of expression vectors may be selected depending upon the use intended for any of the products of the invention. For example, when large quantities of product are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional E.coli cloning and expression vectors such as Bluescript(R) (Stratagene), in which the polypeptide coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster J Biol Chem. 264:5503-5509, (1989)); pET vectors (Novagen, Madison Wis.); and the like.

[0266] In the yeast Saccharomyces cerevisiae a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al., (Methods in Enzymology 153:516-544, (1987)).

[0267] In cases where plant expression vectors are used, the expression of a sequence encoding any of the products of the invention may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV(Bnisson et al., Nature 310:511-514.(1984)) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu et al., EMBO J., 6:307-311, (1987)). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al., EMBO J 3:1671-1680, (1984); Broglie et al., Science 224:838-843, (1984)); or heat shock promoters (Winter J and Sinibaldi R. M., Results Probl. Cell Differ., 17:85-105, (1991)) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S. or Murry L. E. (1992) in McGraw Hill Yearbook of Science and Technology, McGraw Hill, New York, N.Y., pp 191-196; or Weissbach and Weissbach (1988) Methods for Plant Molecular Biology, Academic Press, New York, N.Y., pp 421-463.

[0268] The products of the invention may also be expressed in an insect system. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The product coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect S. frugiperda cells or Trichoplusia larvae in which valiant protein is expressed (Smith et al., J. Virol. 46:584, (1983); Engelhard, E. K. et al., Proc. Nat. Acad. Sci. 91:3224-7, (1994)).

[0269] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a product coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing any one of the products of the invention in infected host cells (Logan and Shenk, Proc. Natl. Acad. Sci. 81:3655-59, (1984). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

[0270] Specific initiation signals may also be required for efficient translation of products coding sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where the product coding sequence, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf, D. et al., (1994) Results Probl. Cell Differ., 20:125-62, (1994); Bittner et al., Methods in Enzymol 153:516-544, (1987)).

[0271] In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., and Battey, I. (1986) Basic Methods in Molecular Biology). Cell-free translation systems can also be employed to produce polypeptides using RNAs derived from the DNA constructs of the present invention.

[0272] A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a “pre-pro” form of the protein may also be important for collect insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

[0273] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express variant product may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

[0274] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M., et al., Cell 11:223-32, (1977)) and adenine phosphoribosyltransferase (Lowy I., et al., Cell 22:817-23, (1980)) genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler M., et al., Proc. Natl Acad. Sci. 77:3567-70, 1(1980)); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al., J Mol. Biol., 150:1-14, (1981)) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Munry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman S. C. and R. C. Mulligan, Proc. Natl. Acad Sci. 85:8047-51, (1988)). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrates, luciferin and ATP, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et. al., Methods Mol. Biol., 55:121-131, (1995)).

[0275] Host cells transformed with a nucleotide sequence encoding any one of the products of the invention may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The product produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing nucleic acid sequences encoding any one of the products of the invention can be designed with signal sequences which direct secretion of the product through a prokaryotic or eukaryotic cell membrane.

[0276] The product of the invention may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, Wash.). The inclusion of a protease-cleavable polypeptide linker sequence between the purification domain and the product is useful to facilitate purification. One such expression vector provides for expression of a fusion protein compromising a product of the invention fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, as described in Porath, et al., Protein Expression and Purification, 3:263-281, (1992)) while the enterokinase cleavage site provides a means for isolating products of the invention from the fusion protein. pGEX vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

[0277] Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well know to those skilled in the art.

[0278] The products of the invention can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

[0279] C. Diagnostic Applications Utilizing Nucleic Acid Sequences

[0280] The nucleic acid sequences of the present invention may be used for a variety of diagnostic purposes. The nucleic acid sequences may be used to detect and quantitate expression of the sequences of the invention in patient's cells, e.g. biopsied tissues, by detecting the presence of mRNA coding for any one of the products of the invention. Alternatively, the assay may be used to detect soluble products of the invention in the serum or blood. This assay typically involves obtaining total mRNA from the tissue, blood or serum and contacting the mRNA with a nucleic acid probe. The probe is a nucleic acid molecule of at least 20 nucleotides, preferably 20-30 nucleotides, capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding any one of the products of the invention under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of any one of the nucleic acid sequences of the invention. This assay can be used to distinguish between absence, presence, and excess expression of the product and to monitor levels of expression of any one of the nucleic acid sequences during therapeutic intervention. In addition, the assay may be used to compare the levels of any one of the variants of the invention to the levels of any one of the corresponding original sequences from which it has been varied, or to compare the level of variants varied from one original sequence to levels of other variants varied from the same original which comparison may have some physiological meaning, for example for the indication of a physiological condition.

[0281] The invention also contemplates the use of the nucleic acid sequences as a diagnostic for diseases resulting from inherited defective sequences (of variants, TL or TH sequences), or diseases in which the ratio of the amount of the original sequence from which the variant was varied to the novel variants of the invention is altered. These sequences can be detected by comparing the sequences of the defective (i.e., mutant) coding region with that of a normal coding region. Association of the sequence coding for mutant product with abnormal valiant product activity may be verified. In addition, sequences encoding mutant products can be inserted into a suitable vector for expression in a functional assay system (e.g., colorimetric assay, complementation experiments in a variant protein deficient strain of HEK293 cells) as yet another means to verify or identify mutations. Once mutant genes have been identified, one can then screen populations of interest for carriers of the mutant gene.

[0282] Individuals carrying mutations in any one of the nucleic acid sequence of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including but not limited to such as from blood, urine, saliva, placenta, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki, et al., Nature 324:163-166, (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype.

[0283] Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such RNase and S1 protection or the chemical cleavage method (e.g. Cotton, et al., Proc. Natl. Acad. Sci. USA, 85:4397-4401, (1985)), or by differences in melting temperatures. “Molecular beacons” (Kosttikis L. G. et al., Science 279:1228-1229, (1998)), hair-pin-shaped, single-stranded synthetic oligo- nucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used to detect point mutations or other sequence changes as well as monitor expression levels of the product. Such diagnostics would be particularly useful for prenatal testing.

[0284] Another method for detecting mutations uses two DNA probes which are designed to hybridize to adjacent regions of a target, with abutting bases, where the region of known or suspected mutation(s) is at or near the abutting bases. The two probes may be joined at the abutting bases, e.g., in the presence of a ligase enzyme, but only if both probes are correctly base paired in the region of probe junction. The presence or absence of mutations is then detectable by the presence or absence of ligated probe.

[0285] Also suitable for detecting mutations in the product coding sequence are oligonucleotide array methods based on sequencing by hybridization (SBH), as described, for example, in U.S. Pat. No. 5,547,83 9. In a typical method, the DNA target analyte is hybridized with an array of oligonucleotides formed on a microchip. The sequence of the target can then be “read” from the pattern of target binding to the array.

[0286] D. Gene Mapping Utilizing Nucleic Acid Sequences

[0287] The nucleic acid sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

[0288] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 20-30 bp) from the cDNA. Computer analysis of the 3′ untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, which would complicate the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

[0289] PCR mapping of somatic cell hybrids or using instead radiation hybrids are rapid procedures for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

[0290] Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma et al., Human Chromosomes: a Manual of Basic Techniques, (1988) Pergamon Press, New York.

[0291] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in the OMIM database (Center for Medical Genetics, Johns Hopkins University, Baltimore, Md. and National Center for Biotechnology Information, National Library of Medicine, Bethesda, Md.). The OMIM gene map presents the cytogenetic map location of disease genes and other expressed genes. The OMIM database provides information on diseases associated with the chromosomal location. Such associations include the results of linkage analysis mapped to this interval, and the correlation of translocations and other chromosomal aberrations in this area.

[0292] E. Therapeutic Applications of Nucleic Acid Sequences

[0293] Nucleic acid sequences of the invention may also be used for therapeutic purposes. Turning first to the second embodiment of each aspect of the invention, inhibition of expression of any one of the products of the invention, expression of any one of the products may be modulated through antisense technology, which controls gene expression through hybridization of complementary nucleic acid sequences, i.e. antisense DNA or RNA, to the control, 5′ or regulatory regions of the gene encoding the product. For example, the 5′ coding portion of the nucleic acid sequence sequence which codes for the product of the present invention is used to design an antisense oligonucleotide of from about 10 to 40 base pairs in length. Oligonucleotides derived from the transcription start site, e.g. between positions −10 and +10 from the start site, are preferred. An antisense DNA oligonucleotide is designed to be complementary to a region of the nucleic acid sequence involved in transcription (Lee et al., Nucl. Acids, Res., 6:3073, (1979); Cooncy et al., Science 241:456, (1988); and Dervan et al., Science 251:1360, (1991)), thereby preventing transcription and the production of the variant products. An antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the products (Okano J Neurochem. 56:560, (1991)). The antisense constructs can be delivered to cells by procedures known in the art such that the antisense RNA or DNA may be expressed in vivo. The antisense may be antisense mRNA or DNA sequence capable of coding such antisense mRNA. The antisense mRNA or the DNA coding thereof can be complementary to the full sequence of nucleic acid sequences coding for any one of the products of the invention or to a fragment of such a sequence which is sufficient to inhibit production of the product.

[0294] Turning now to the expression of any one of the products of the invention may be increased by providing coding sequences for coding for said product under the control of suitable control elements ending its expression in the desired host.

[0295] The nucleic acid sequences of the invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

[0296] The products of the invention as well as any activators and deactivators compounds (see below) which are polypeptides, may also be employed in accordance with the present invention by expression of such polypeptides in vivo, which is often referred to as “gene therapy.” Cells from a patient may be engineered with a nucleic acid sequence (DNA or RNA) encoding a polypeptide ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

[0297] Similarly, cells may be engineered in vivo for expression of a polypeptide in vivo by procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells in vivo and expression of the polypeptide in vivo. These and other methods for administering a product of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells in vivo after combination with a suitable delivery vehicle.

[0298] Retroviruses from which the retroviral plasmid vectors mentioned above may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

[0299] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, psi-2, psi-AM, PA12, T19-14X, VT-19-17-H2, psi-CRE, psi-CRIP, GP+E-86, GP+envAn12, and DAN cell lines as described in Miller (Human Gene Therapy, Vol. 1, pg. 5-14, (1990)). The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0300] The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

[0301] The genes introduced into cells may be placed under the control of inducible promoters, such as the radiation-inducible Egr-1 promoter, (Maceri, H. J., et al, Cancer Res., 56(19): 4311 (1996)), to stimulate production of products of the invention or antisense inhibition in response to radiation, eg., radiation therapy for treating tumors.

EXAMPLE IV Products

[0302] The substantially purified product of the invention has been defined above as the product coded from the nucleic acid sequence of the invention. By its first embodiment the amino acid sequence is an amino acid sequence having at least 90% identity to any one of the sequences identified as SEQ ID NO: 42 to SEQ ID NO: 69 provided that the amino acid sequence is not identical to that of the original sequence from which it has been varied. The protein or polypeptide may be in mature and/or modified form, also as defined above. Also contemplated are protein fragments having at least 10 contiguous amino acid residues, preferably at least 10-20 residues, derived from the variant product, as well as homologues as explained above.

[0303] The sequence variations are preferably those that are considered conserved substitutions, as defined above. Thus, for example, a protein with a sequence having at least 90% sequence identity with any of the products identified as SEQ ID NO: 42 to SEQ ID NO: 69, preferably by utilizing conserved substitutions as defined above is also part of the invention, and provided that it is not identical to the original peptide from which it has been varied.

[0304] By a second aspect of the present invention, the amino acid sequence is an amino acid having at least 70% identity, preferably 80% identity, most preferably 90% identity to the sequences of SEQ ID NO: 70 (for TL) or 71 to 81 (for TH). The protein or polypeptide may be in a mature and/or modified form as defined above, and also contemplated are protein fragments having at least 10 amino acid residues, preferably 10-20 residues as well as homologs as defined above.

[0305] The sequence variations are preferably those that are considered conserved substitutions as defined above.

[0306] In a more specific embodiment, the protein has or contains any one of the sequence identified as SEQ ID NO: 42 to SEQ ID NO: 81. The variant product may be (i) one in which one or more of the amino acid residues in a sequence listed above are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue), or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the variant product is fused with another compound, such as a compound to increase the half-life of the protein (for example, polyethylene glycol (PEG)), or a moiety which serves as targeting means to direct the protein to its target tissue or target cell population (such as an antibody), or (iv) one in which additional amino acids are fused to the variant product. Such fragments, variants and derivatives are deemed to be within the scope of those skilled in the art from the teachings herein.

[0307] A. Preparation of Products

[0308] Recombinant methods for producing and isolating the product of the invention, and fragments of the protein are described above.

[0309] In addition to recombinant production, fragments and portions of any one of the products may be produced by direct peptide synthesis using solid-phase techniques (cf. Stewart et al., (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco; Merrifield J., J. Am. Chem. Soc., 85:2149-2154, (1963)). In vitro peptide synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with the instructions provided by the manufacturer. Fragments of the product may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

[0310] II. Therapeutic Uses and Compositions Utilizing the Product

[0311] The product of the invention is generally useful in treating diseases and disorders which are characterized by a lower than normal level of the product of the invention expression, and or diseases which can be cured or ameliorated by raising the level of the product of the invention, even if the level is normal.

[0312] Products or fragments may be administered by any of a number of routes and methods designed to provide a consistent and predictable concentration of compound at the target organ or tissue. The product-containing compositions may be administered alone or in combination with other agents, such as stabilizing compounds, and/or in combination with other pharmaceutical agents such as drugs or hormones.

[0313] Product-containing compositions may be administered by a number of routes including, but not limited to oral, intravenous, intramuscular transdermal, subcutaneous, topical, sublingual, or rectal means as well as by nasal application. Product-containing compositions may also be administered via liposomes. Such administration routes and appropriate formulations are generally known to those of skill in the art.

[0314] The product can be given via intravenous or intraperitoneal injection. Similarly, the product may be injected to other localized regions of the body. The product may also be administered via nasal insufflation. Enteral administration is also possible. For such administration, the product should be formulated into an appropriate capsule or elixir for oral administration, or into a suppository for rectal administration.

[0315] The foregoing exemplary administration modes will likely require that the product be formulated into an appropriate carrier; including ointments, gels, suppositories. Appropriate formulations are well known to persons skilled in the art.

[0316] Dosage of the product will vary, depending upon the potency and therapeutic index of the particular polypeptide selected.

[0317] A therapeutic composition for use in the treatment method can include the product in a sterile injectable solution, the polypeptide in an oral delivery vehicle, the product in an aerosol suitable for nasal administration, or the product in a nebulized form, all prepared according to well known methods. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.

EXAMPLE V Screening Methods for Activators and Deactivators (Inhibitors)

[0318] The present invention also includes an assay for identifying molecules, such as synthetic drugs, antibodies, peptides, or other molecules, which have a modulating effect on the activity of the product of the invention, e.g. activators or deactivators of the product of the present invention. Such an assay comprises the steps of providing a product encoded by the nucleic acid sequences of the present invention, contacting the product with one or more candidate molecules to determine the candidate molecules modulating effect on the activity of the product, and selecting from the molecules a candidate's molecule capable of modulating product physiological activity.

[0319] The variant product, the TL product or the TH product, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be tree in solution, affixed to a solid support, borne on a cell membrane or located intracellularly. The formation of binding complexes, between the product and the agent being tested, may be measured. Alternatively, the activator or deactivator may work by serving as agonist or antagonist, respectively, of the receptor of any one of the products, binding entity or target site, and their effect may be determined in connection with any of the above.

[0320] Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the variant product is described in detail by Geysen in PCT Application WO 84/03564, published on Sep. 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with the full valiant product or with fragments of the product and washed. Bound product is then detected by methods well known in the art. Substantially purified product can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0321] Antibodies to the product, as described in Example VI below, may also be used in screening assays according to methods well known in the art. For example, a “sandwich” assay may be performed, in which an anti-product antibody is affixed to a solid surface such as a microtiter plate and the product is added. Such an assay can be used to capture compounds which bind to the product. Alternatively, such an assay may be used to measure the ability of compounds to influence with the binding of the product of the invention to the receptor, and then select those compounds which effect the binding.

EXAMPLE VI Anti-product-Antibodies

[0322] A. Synthesis

[0323] In still another aspect of the invention, the purified product of the invention is used to produce anti-product antibodies which have diagnostic and therapeutic uses related to the activity, distribution, and expression of the product.

[0324] Antibodies to the product may be generated by methods well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library. Antibodies, i.e., those which inhibit dimer formation, are especially preferred for therapeutic use.

[0325] A fragment of the product of the invention for antibody induction does not require biological activity but have to feature immunological activity; however, the protein fragment or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids of the sequences specified in any one of SEQ ID NO: 42 to SEQ ID NO: 81. Preferably they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of product amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to valiant product.

[0326] For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with the product or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and Coiynebacterium parvum are potentially useful human adjuvants.

[0327] Monoclonal antibodies to the product may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (Nature 256:495-497, (1975)), the human B-cell hybridoma technique (Kosbor et al., Immunol. Today 4:72, (1983); Cote et al., Proc. Natl. Acad. Sci. 80:2026-2030, (1983)) and the EBV-hybridoma technique (Cole, et al, Mol. Cell Biol. 62:109-120, (1984)).

[0328] Techniques developed for the production of “chimeric antibodies”, the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can also be used (Morrison et al., Proc. Natl. Acad. Sci. 81:6851-6855, (1984); Neuberger et al., Nature 312:604-608, (1984); Takeda et al., Nature 314:452-454, (1985)). Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single-chain antibodies specific for the product of the invention

[0329] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al. (Proc. Natl. Acad. Sci. 86:3833-3837, 1989)), and Winter G and Milstein C., (Nature 349:293-299, (1991)).

[0330] Antibody fragments which contain specific binding sites for product protein may also be generated. For example, such fragments include, but are not limited to, the F(ab′)₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse W. D. et al., Science 256:1275-1281, (1989)).

[0331] B. Diagnostic Applications of Antibodies

[0332] A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between the product and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific product is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox D. E., et al., (J Exp. Med. 158:1211, (1983)).

[0333] Antibodies which specifically bind the product are useful for the diagnosis of conditions or diseases characterized by expression of any one of the products of the invention (where normally it is not expressed) by over or under expression of any one of the products of the invention as well as for detection of diseases in which the proportion between the amount of the variants of the invention and the original sequence from which it varied is altered. Alternatively, such antibodies may be used in assays to monitor patients being treated with any one of the products, its activators, or its deactivators. Diagnostic assays for products include methods utilizing the antibody and a label to detect the product in human body fluids or extracts of cells or tissues. The products and antibodies of the present invention may be used with or without modification. Frequently, the proteins and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known in the art.

[0334] A variety of protocols for measuring the product of the invention, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescent activated cell sorting (FACS). As noted above, a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the product is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, et al. (supra). Such protocols provide a basis for diagnosing altered or abnormal levels of product expression. Normal or standard values for product expression are established by combining body fluids or cell extracts taken from normal subjects, preferably human, with antibody to the product under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by various methods, preferably by photometric methods. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of disease state.

[0335] The antibody assays are useful to determine the level of the product present in a body fluid sample, in order to determine whether it is being expressed at all, whether it is being overexpressed or underexpressed in the tissue, or as an indication of how levels of various products are responding to drug treatment.

[0336] By another aspect the invention concerns methods for determining the presence or level of various anti-product antibodies in a biological sample obtained from patients, such as blood or serum sample using as an antigen the valiant product. Determination of said antibodies may be indicative to a plurality of pathological conditions or diseases.

[0337] C. Therapeutic Uses of Antibodies

[0338] In addition to their diagnostic use the antibodies may have a therapeutical utility in blocking or decreasing the activity of any one of the products in pathological conditions where beneficial effect can be achieved by such a decrease.

[0339] The antibody employed is preferably a humanized monoclonal antibody, or a human Mab produced by known globulin-gene library methods. The antibody is administered typically as a sterile solution by IV injection, although other parenteral routes may be suitable. Typically, the antibody is administered in an amount between about 1-15 mg/kg body weight of the subject. Treatment is continued, e.g., with dosing every 1-7 days, until a therapeutic improvement is seen.

[0340] Although the invention has been described with reference to specific methods and embodiments, it is appreciated that various modifications and changes may be made without departing from the invention.

1 81 1 1827 DNA Homo sapiens misc_feature (1)..(1827) n = a,c,g,t any unknown or other 1 taggtganng tngaaataan ntggtaaaaa aaaaggctgg taccggtccg gaattcccgg 60 gatctggggg aagtgattak tcactgaagg ctagasaaca attccgagaa agagacggag 120 agagagggaa gaaaaagaca gatagatatt ggggggaagg agaaramwgg agaagagagg 180 gaagagagga cagcggagag agagcaccag agagagaggg agagagagag agagcgctag 240 agagagggag cgagcatgtg cgatgagcaa tagctgtgga ccttacagtt gctgctaact 300 gccctggtgt gtgtgaggga gagagaggga gggagrgaga gagagcgcgc twcgcgagag 360 agcgagtgag caagcgagca gaaaagaggt ggagaggggg ggaataagaa agagagagaa 420 ggaaaggaga gaaggcagga agaaggcaag ggacgagaca accatgctgt gctgtatgag 480 aagaaccaaa caggttgaaa aaaatgatga cgaccaaaag attgaacaag atggtatcaa 540 accagaagat aaagctcata aggccgcaac caaaattcag gctagcttcc gtggacacat 600 aacaaggaaa aagctcaaag gagagaagaa ggatgatgtc caagctgctg aggctgaagc 660 taataagaag gatgaagccc ctgttgccga tggggtggag aagaagggag aaggcaccac 720 tactgccgaa gcagccccag ccactggctc caagcctgat gagcccggca aagcaggaga 780 aactccttcc gaggagaaga agggggaggg tgatgctgcc acagagcagg cagcccccca 840 ggctcctgca tcctcagagg agaaggccgg ctcagctgag acagaaagtg ccactaaagc 900 ttccactgat aactcgccgt cctccaaggc tgaagatgcc ccagccaagg aggagcctaa 960 acaagccgat gtgcctgctc ctttggggtt tttcccaacc ccttgggggc ccttttgctt 1020 gctgctgtca ctgctgctgc tgccaccacc cctgccgcag aggatgctgc tgccaaggca 1080 acagcccagc ctccaacgga gactggggag agcagccaag ctgaagagaa catagaagct 1140 gtagatgaaa ccaaacctaa ggaaagtgcc cggcaggacg agggtaaaga agaggaacct 1200 gaggctgacc aagaacatgc ctgaactcta agaaatggct ttccacatcc ccaccctccc 1260 ctctcctgag cctgtctctc cctaccctct tctcagctcc actctgaagt cccttcctgt 1320 cctgctcacg tctgtgagtc tgtcctttcc cacccactag ccctctttct ctctgtgtgg 1380 caaacattta aaaaaaaaaa aaaaaagcag gaaagatccc aagtcaaaca gtgtggctta 1440 aacatttttt gtttcttggt gttgttatgg caagtttttg gtaatgatga ttcaatcatt 1500 ttgggaaatt cttgcactgt atccaagtta tttgatctgg tgcgtgtggc cctgtgggag 1560 tccactttcc tctctctctc tctctctgtt ccaagtgtgt gtgcaatgtt ccgttcatct 1620 gaggagtcca aaatatcgag tgaattcaaa atcatttttg ttttcctcct tttcaatgtg 1680 atggaatgaa caaaaaggaa aaaattcaaa aaacccagtt tgttttaaaa ataaataaat 1740 aaagcaaatg tgccaattag cgtaaacttg cggctctaag gctccttttt caacccgaat 1800 attaataaat catgagagta atcaagg 1827 2 2182 DNA Homo sapiens misc_feature (1)..(2182) n = a,c,g,t any unknown or other 2 taggtganng tngaaataan ntggtaaaaa aaaaggctgg taccggtccg gaattcccgg 60 gatctggggg aagtgattak tcactgaagg ctagasaaca attccgagaa agagacggag 120 agagagggaa gaaaaagaca gatagatatt ggggggaagg agaaramwgg agaagagagg 180 gaagagagga cagcggagag agagcaccag agagagaggg agagagagag agagcgctag 240 agagagggag cgagcatgtg cgatgagcaa tagctgtgga ccttacagtt gctgctaact 300 gccctggtgt gtgtgaggga gagagaggga gggagrgaga gagagcgcgc twcgcgagag 360 agcgagtgag caagcgagca gaaaagaggt ggagaggggg ggaataagaa agagagagaa 420 ggaaaggaga gaaggcagga agaaggcaag ggacgagaca accatgctgt gctgtatgag 480 aagaaccaaa cagaattaaa agggaacctg gtctctgggt tgttttcaac atctcaagtg 540 tgaattttcc ctgtcaaaat cttcacaagg aaaatgagtc acagcatcac ctgggtgacg 600 aggtcataac acctcagccc gttgcttaaa aaattttatt tctacttttc tattgtaaag 660 agatctcaaa acaggaagat aaaattggac tgacagctct acagcctagt cttttagaca 720 gtgaactagg ccagcattgn cagacactgg cgatgacaaa gtcctgctct gaattatgcc 780 accccgcact ccacttttta cctttgcctg ggaggctttg aggaaaaatc ttcagagagc 840 agttcgacct agtccttatt cacttggctt cttgactttc tggattcaag gggttgaaaa 900 aaatgatgac gaccaaaaga ttgaacaaga tggtatcaaa ccagaagata aagctcataa 960 ggccgcaacc aaaattcagg ctagcttccg tggacacata acaaggaaaa agctcaaagg 1020 agagaagaag gatgatgtcc aagctgctga ggctgaagct aataagaagg atgaagcccc 1080 tgttgccgat ggggtggaga agaagggaga aggcaccact actgccgaag cagccccagc 1140 cactggctcc aagcctgatg agcccggcaa agcaggagaa actccttccg aggagaagaa 1200 gggggagggt gatgctgcca cagagcaggc agccccccag gctcctgcat cctcagagga 1260 gaaggccggc tcagctgaga cagaaagtgc cactaaagct tccactgata actcgccgtc 1320 ctccaaggct gaagatgccc cagccaagga ggagcctaaa caagccgatg tgcctgctgc 1380 tgtcactgct gctgctgcca ccacccctgc cgcagaggat gctgctgcca aggcaacagc 1440 ccagcctcca acggagactg gggagagcag ccaagctgaa gagaacatag aagctgtaga 1500 tgaaaccaaa cctaaggaaa gtgcccggca ggacgagggt aaagaagagg aacctgaggc 1560 tgaccaagaa catgcctgaa ctctaagaaa tggctttcca catccccacc ctcccctctc 1620 ctgagcctgt ctctccctac cctcttctca gctccactct gaagtccctt cctgtcctgc 1680 tcacgtctgt gagtctgtcc tttcccaccc actagccctc tttctctctg tgtggcaaac 1740 atttaaaaaa aaaaaaaaaa agcaggaaag atcccaagtc aaacagtgtg gcttaaacat 1800 tttttgtttc ttggtgttgt tatggcaagt ttttggtaat gatgattcaa tcattttggg 1860 aaattcttgc actgtatcca agttatttga tctggtgcgt gtggccctgt gggagtccac 1920 tttcctctct ctctctctct ctgttccaag tgtgtgtgca atgttccgtt catctgagga 1980 gtccaaaata tcgagtgaat tcaaaatcat ttttgttttc ctccttttca atgtgatgga 2040 atgaacaaaa aggaaaaaat tcaaaaaacc cagtttgttt taaaaataaa taaataaagc 2100 aaatgtgcca attagcgtaa acttgcggct ctaaggctcc tttttcaacc cgaatattaa 2160 taaatcatga gagtaatcaa gg 2182 3 438 DNA Homo sapiens misc_feature (1)..(438 ) n = a,c,g,t any unknown or other 3 gcgtcgcgcg ccagggtctc tagcagctgc cgctgagccg ccggacggac gctcgtcttc 60 gcccgccatg gccgagagcg actgggacac ggtgacggtg ctgcgcaaga agggccctac 120 ggccgcccag gccaaatcca agcaggctat cttagcggca cagagacgag gagaagatgt 180 ggagacttcc aagaaatggg ctgctggcca gaacaaacaa cattctatta ccaagaacac 240 ggccaagctg gaccgggaga cagaggagct gcaccatgac agggtgaccc tggaggtggg 300 caaggtgatc cagcaaggtc ggcagagcaa ggggcttacg cagaaggacc tggccacgaa 360 aatcaatgag aagccacagg tgatcgcgga ctatgagagc ggacgggcca tacccaagca 420 cctggttatt ggtcgacc 438 4 362 DNA Homo sapiens misc_feature (1)..(362 ) n = a,c,g,t any unknown or other 4 gcgtcgcgcg ccagggtctc tagcagctgc cgctgagccg ccggacggac gctcgtcttc 60 gcccgccatg gccgagagcg actgggacac ggtgacggtg ctgcgcaaga agggccctac 120 ggccgcccag gccaaatcca agcaggctat cttagcggca cagagacgag gagaagatgt 180 ggagacttcc aagaaatggg ctgctggcca gaacaaacaa cattctatta ccaagaacac 240 ggccaagctg gaccgggaga cagaggagct gcaccatgac aggtacctga gtggcagtga 300 tcacagtcgc agacagggct acgagaggac tgcacgaaat ataagcaaag tatcgctata 360 ac 362 5 816 DNA Homo sapiens misc_feature (1)..(816 ) n = a,c,g,t any unknown or other 5 gcgtcgcgcg ccagggtctc tagcagctgc cgctgagccg ccggacggac gctcgtcttc 60 gcccgccatg gccgagagcg actgggacac ggtgacggtg ctgcgcaaga agggccctac 120 ggccgcccag gccaaatcca agcaggctat cttagcggca cagagacgag gagaagatgt 180 ggagacttcc aagaaatggg ctgctggcca gaacaaacaa cattctatta ccaagaacac 240 ggccaagctg gaccgggaga cagaggagct gcaccatgac agggtgaccc tggaggtggg 300 caaggtgatc cagcaaggtc ggcagagcaa ggggcttacg cagaaggacc tggccacgaa 360 aatcaatgag aagccacagg tgatcgcgga ctatgagagc ggacgggcca tacccaataa 420 ccaggtgctt ggcaaaatcg agcgggccat tgatgtggga accaggagtg ctcgtgtgct 480 gagagcccag tgaggcacgg gagcggcgtg gcttctcatt gattttcgtg gccaggtcct 540 tctgcgtaag cccttgctct gccgaccttg ctggatcacc ttgcccacct ccagggtcac 600 cctgtcatgg tgcagctcct ctgtctcccg gtccagcttg gccgtgttct tggtaataga 660 atgttgcttg ttctggccag cagcccattt cttggaagtc tccacatctt ctcctcgtct 720 ctgtgccgct aagatagcct gccttggatt tggcctggcg ggcgtaggcc tatcttgcgc 780 agcncgtcac cgtgtcgtcg acgcggcggg aattag 816 6 2683 DNA Homo sapiens misc_feature (1)..(2683) n = a,c,g,t any unknown or other 6 ggcaagaggc aagaggtagc aacagcgagc gtgccggtcg ctagtcgcgg gtccccgagt 60 gagcacgcca gggagcagga gaccaaacga cgggggtcgg agtcagagtc gcagtgggag 120 tccccggacc ggagcacgag cctgagcggg agagcgccgc tcgcacgccc gtcgccaccc 180 gcgtacccgg cgcagcagag ccaccagcgc agcttgccat ggagcccagc agcaagaagc 240 tgacgggtcg cctcatgctg gccgtgggag gagcagtgct tggctccctg cagtttggct 300 acaacactgg agtcatcaat gccccccaga aggtgatcga ggagttctac aaccagacat 360 gggtccaccg ctatggggag agcatcctgc ccaccacgct caccacgctc tggtccctct 420 cagtggccat cttttctgtt gggggcatga ttggctcctt ctctgtgggc cttttcgtta 480 accgctttgg ccggcggaat tcaatgctga tgatgaacct gctggccttc gtgtccgccg 540 tgctcatggg cttctcgaaa ctgggcaagt cctttgagat gctgatcctg ggccgcttca 600 tcatcggtgt gtactgcggc ctgaccacag gcttcgtgcc catgtatgtg ggtgaagtgt 660 cacccacagc ccttcgtggg gccctgggca ccctgcacca gctgggcatc gtcgtcggca 720 tcctcatcgc ccaggtgttc ggcctggact ccatcatggg caacaaggac ctgtggcccc 780 tgctgctgag catcatcttc atcccggccc tgctgcagtg catcgtgctg cccttctgcc 840 ccgagagtcc ccgcttcctg ctcatcaacc gcaacgagga gaaccgggcc aagagtgtgc 900 taaagaagct gcgcgggaca gctgacgtga cccatgacct gcaggagatg aaggaagaga 960 gtcggcagat gatgcgggag aagaaggtca ccatcctgga gctgttccgc tcccccgcct 1020 accgccagcc catcctcatc gctgtggtgc tgcagctgtc ccagcagctg tctggcatca 1080 acgctgtctt ctattactcc acgagcatct tcgagaaggc gggggtgcag cagcctgtgt 1140 atgccaccat tggctccggt atcgtcaaca cggccttcac tgtcgtgtcg ctgtttgtgg 1200 tggagcgagc aggccggcgg accctgcacc tcataggcct cgctggcatg gcgggttgtg 1260 ccatactcat gaccatcgcg ctacactgct ggagcagcta ccctggatgt cctatctgag 1320 catcgtggcc atctttggct ttgtggcctt ctttgaagtg ggtcctggcc ccatcccatg 1380 gttcatcgtg gctgaactct tcagccaggg tccacgtcca gctgccattg ccgttgcagg 1440 cttctccaac tggacctcaa atttcattgt gggcatgtgc ttccagtatg tggagcaact 1500 gtgtggtccc tacgtcttca tcatcttcac tgtgctcctg gttctgttct tcatcttcac 1560 ctacttcaaa gttcctgaga ctaaaggccg gaccttcgat gagatcgctt ccggcttcgc 1620 tgccgggttc tagtctcctt tgcactgagg gccacactat taccatgaga agagggcctg 1680 tgggagcctg caaactcact gctcaagaag acatggagac tcctgccctg ttgtgtatag 1740 atgcaagata tttatatata tttttggttg tcaatattaa atacagacac taagttatag 1800 tatatctgga caagccaact tgtaaataca ccacctcact cctgttactt acctaaacag 1860 atataaatgg ctggttttta gaaacatggt tttgaaatgc ttgtggattg agggtaggag 1920 gtttggatgg gagtgagaca gaagtaagtg gggttgcaac cactgcaacg gcttagactt 1980 cgactcagga tccagtccct tacacgtacc tctcatcagt gtcctcttgc tcaaaaatct 2040 gtttgatccc tgttacccag agaatatata cattctttat cttgacattc aaggcatttc 2100 tatcacatat ttgatagttg gtgttcaaaa aaacactagt tttgtgccag ccgtgatgct 2160 caggcttgaa atgcattatt ttgaatgtga agtaaatact gtacctttat ttgacaggct 2220 caaagaggtt atgtgcctga agtcgcacag tgaataagct aaaacacctg cttttaacaa 2280 tggtaccata caaccactac tccattaact ccacccacct cctgcacccc tccccacaca 2340 cacaaaatga accacgttct ttgtatgggc ccaatgagct gtcaagctgc cctgtgttca 2400 tttcatttgg aattgccccc tctggttcct ctgtatacta ctgcttcatc tctaaagaca 2460 gctcatcctc ctccttcacc cctgaatttc cagagcactt catctgctcc ttcatcacaa 2520 gtccagtttt ctgccactag tctgaatttc atgagaagat gccgatttgg ttcctgtggg 2580 tcctcagcac tattcagtac agtgcttgat gcacagcagg cactcagaaa atactggagg 2640 aaataaaaca ccaaagatat ttgtctctag aggctatgct gac 2683 7 2613 DNA Homo sapiens misc_feature (1)..(2613) n = a,c,g,t any unknown or other 7 ggcaagaggc aagaggtagc aacagcgagc gtgccggtcg ctagtcgcgg gtccccgagt 60 gagcacgcca gggagcagga gaccaaacga cgggggtcgg agtcagagtc gcagtgggag 120 tccccggacc ggagcacgag cctgagcggg agagcgccgc tcgcacgccc gtcgccaccc 180 gcgtacccgg cgcagcagag ccaccagcgc agcttgccat ggagcccagc agcaagaagc 240 tgacgggtcg cctcatgctg gccgtgggag gagcagtgct tggctccctg cagtttggct 300 acaacactgg agtcatcaat gccccccaga aggtgatcga ggagttctac aaccagacat 360 gggtccaccg ctatggggag agcatcctgc ccaccacgct caccacgctc tggtccctct 420 cagtggccat cttttctgtt gggggcatga ttggctcctt ctctgtgggc cttttcgtta 480 accgctttgg ccggcggaat tcaatgctga tgatgaacct gctggccttc gtgtccgccg 540 tgctcatggg cttctcgaaa ctgggcaagt cctttgagat gctgatcctg ggccgcttca 600 tcatcggtgt gtactgcggc ctgaccacag gcttcgtgcc catgtatgtg ggtgaagtgt 660 cacccacagc ccttcgtggg gccctgggca ccctgcacca gctgggcatc gtcgtcggca 720 tcctcatcgc ccaggtgttc ggcctggact ccatcatggg caacaaggac ctgtggcccc 780 tgctgctgag catcatcttc atcccggccc tgctgcagtg catcgtgctg cccttctgcc 840 ccgagagtcc ccgcttcctg ctcatcaacc gcaacgagga gaaccgggcc aagagtgtgc 900 taaagaagct gcgcgggaca gctgacgtga cccatgacct gcaggagatg aaggaagaga 960 gtcggcagat gatgcgggag aagaaggtca ccatcctgga gctgttccgc tcccccgcct 1020 accgccagcc catcctcatc gctgtggtgc tgcagctgtc ccagcagctg tctggcatca 1080 acgctgtctt ctattactcc acgagcatct tcgagaaggc gggggtgcag cagcctgtgt 1140 atgccaccat tggctccggt atcgtcaaca cggccttcac tgtcgtgtcg ctgtttgtgg 1200 tggagcgagc aggccggcgg accctgcacc tcataggcct cgctggcatg gcgggttgtg 1260 ccatactcat gaccatcgcg ctacactgct ggagcagcta ccctggatgt cctatctgag 1320 catcgtggcc atctttggct ttgtggcctt ctttgaagtg ggtcctggcc ccatcccatg 1380 gttcatcgtg gctgaactct tcagccaggg tccacgtcca gctgccattg ccgttgcagg 1440 cttctccaac tggacctcaa atttcattgt gggcatgtgc ttccagtatg tggagcaact 1500 gtgtggtccc tacgtcttca tcatcttcac tgtgctcctg gttctgttct tcatcttcac 1560 ctacttcaaa gttcctgaga ctaaaggccg gaccttcgat gagatcgctt ccggcttccg 1620 gcagggggga gccagccaaa gtgacaagac tcctgccctg ttgtgtatag atgcaagata 1680 tttatatata tttttggttg tcaatattaa atacagacac taagttatag tatatctgga 1740 caagccaact tgtaaataca ccacctcact cctgttactt acctaaacag atataaatgg 1800 ctggttttta gaaacatggt tttgaaatgc ttgtggattg agggtaggag gtttggatgg 1860 gagtgagaca gaagtaagtg gggttgcaac cactgcaacg gcttagactt cgactcagga 1920 tccagtccct tacacgtacc tctcatcagt gtcctcttgc tcaaaaatct gtttgatccc 1980 tgttacccag agaatatata cattctttat cttgacattc aaggcatttc tatcacatat 2040 ttgatagttg gtgttcaaaa aaacactagt tttgtgccag ccgtgatgct caggcttgaa 2100 atgcattatt ttgaatgtga agtaaatact gtacctttat ttgacaggct caaagaggtt 2160 atgtgcctga agtcgcacag tgaataagct aaaacacctg cttttaacaa tggtaccata 2220 caaccactac tccattaact ccacccacct cctgcacccc tccccacaca cacaaaatga 2280 accacgttct ttgtatgggc ccaatgagct gtcaagctgc cctgtgttca tttcatttgg 2340 aattgccccc tctggttcct ctgtatacta ctgcttcatc tctaaagaca gctcatcctc 2400 ctccttcacc cctgaatttc cagagcactt catctgctcc ttcatcacaa gtccagtttt 2460 ctgccactag tctgaatttc atgagaagat gccgatttgg ttcctgtggg tcctcagcac 2520 tattcagtac agtgcttgat gcacagcagg cactcagaaa atactggagg aaataaaaca 2580 ccaaagatat ttgtctctag aggctatgct gac 2613 8 2919 DNA Homo sapiens misc_feature (1)..(2919) n = a,c,g,t any unknown or other 8 ggcaagaggc aagaggtagc aacagcgagc gtgccggtcg ctagtcgcgg gtccccgagt 60 gagcacgcca gggagcagga gaccaaacga cgggggtcgg agtcagagtc gcagtgggag 120 tccccggacc ggagcacgag cctgagcggg agagcgccgc tcgcacgccc gtcgccaccc 180 gcgtacccgg cgcagcagag ccaccagcgc agcttgccat ggagcccagc agcaagaagc 240 tgacgggtcg cctcatgctg gccgtgggag gagcagtgct tggctccctg cagtttggct 300 acaacactgg agtcatcaat gccccccaga aggtgatcga ggagttctac aaccagacat 360 gggtccaccg ctatggggag agcatcctgc ccaccacgct caccacgctc tggtccctct 420 cagtggccat cttttctgtt gggggcatga ttggctcctt ctctgtgggc cttttcgtta 480 accgctttgg ccggcggaat tcaatgctga tgatgaacct gctggccttc gtgtccgccg 540 tgctcatggg cttctcgaaa ctgggcaagt cctttgagat gctgatcctg ggccgcttca 600 tcatcggtgt gtactgcggc ctgaccacag gcttcgtgcc catgtatgtg ggtgaagtgt 660 cacccacagc ccttcgtggg gccctgggca ccctgcacca gctgggcatc gtcgtcggca 720 tcctcatcgc ccaggtgttc ggcctggact ccatcatggg caacaaggac ctgtggcccc 780 tgctgctgag catcatcttc atcccggccc tgctgcagtg catcgtgctg cccttctgcc 840 ccgagagtcc ccgcttcctg ctcatcaacc gcaacgagga gaaccgggcc aagagtgtgc 900 taaagaagct gcgcgggaca gctgacgtga cccatgacct gcaggagatg aaggaagaga 960 gtcggcagat gatgcgggag aagaaggtca ccatcctgga gctgttccgc tcccccgcct 1020 accgccagcc catcctcatc gctgtggtgc tgcagctgtc ccagcagctg tctggcatca 1080 acgctgtctt ctattactcc acgagcatct tcgagaaggc gggggtgcag cagcctgtgt 1140 atgccaccat tggctccggt atcgtcaaca cggccttcac tgtcgtgtcg ctgtttgtgg 1200 tggagcgagc aggccggcgg accctgcacc tcataggcct cgctggcatg gcgggttgtg 1260 ccatactcat gaccatcgcg ctacactgct ggagcagcta ccctggatgt cctatctgag 1320 catcgtggcc atctttggct ttgtggcctt ctttgaagtg ggtcctggcc ccatcccatg 1380 gttcatcgtg gctgaactct tcagccaggg tccacgtcca gctgccattg ccgttgcagg 1440 cttctccaac tggacctcaa atttcattgt gggcatgtgc ttccagtatg tggagcaact 1500 gtgtggtccc tacgtcttca tcatcttcac tgtgctcctg gttctgttct tcatcttcac 1560 ctggagacta agccctgtcg agacacttgc cttcttcacc cagctaatct gtagggctgg 1620 acctatgtcc taaggacaca ctaatcgaac tatgaactac aaagcttcta tcccaggagg 1680 tggctatggc cacccgttct gctggcctgg atctccccac tctaggggtc aggctccatt 1740 aggatttgcc cccttcccat ctcttcctac ccaaccactc aaattaatct ttctttacct 1800 gagaccagtt gggagcactg gagtgcaggg aggagagggg aagggccagt ctgggctgcc 1860 gggttctagt ctcctttgca ctgagggcca cactattacc atgagaagag ggcctgtggg 1920 agcctgcaaa ctcactgctc aagaagacat ggagactcct gccctgttgt gtatagatgc 1980 aagatattta tatatatttt tggttgtcaa tattaaatac agacactaag ttatagtata 2040 tctggacaag ccaacttgta aatacaccac ctcactcctg ttacttacct aaacagatat 2100 aaatggctgg tttttagaaa catggttttg aaatgcttgt ggattgaggg taggaggttt 2160 ggatgggagt gagacagaag taagtggggt tgcaaccact gcaacggctt agacttcgac 2220 tcaggatcca gtcccttaca cgtacctctc atcagtgtcc tcttgctcaa aaatctgttt 2280 gatccctgtt acccagagaa tatatacatt ctttatcttg acattcaagg catttctatc 2340 acatatttga tagttggtgt tcaaaaaaac actagttttg tgccagccgt gatgctcagg 2400 cttgaaatgc attattttga atgtgaagta aatactgtac ctttatttga caggctcaaa 2460 gaggttatgt gcctgaagtc gcacagtgaa taagctaaaa cacctgcttt taacaatggt 2520 accatacaac cactactcca ttaactccac ccacctcctg cacccctccc cacacacaca 2580 aaatgaacca cgttctttgt atgggcccaa tgagctgtca agctgccctg tgttcatttc 2640 atttggaatt gccccctctg gttcctctgt atactactgc ttcatctcta aagacagctc 2700 atcctcctcc ttcacccctg aatttccaga gcacttcatc tgctccttca tcacaagtcc 2760 agttttctgc cactagtctg aatttcatga gaagatgccg atttggttcc tgtgggtcct 2820 cagcactatt cagtacagtg cttgatgcac agcaggcact cagaaaatac tggaggaaat 2880 aaaacaccaa agatatttgt ctctagaggc tatgctgac 2919 9 2860 DNA Homo sapiens misc_feature (1)..(2860) n = a,c,g,t any unknown or other 9 ggcaagaggc aagaggtagc aacagcgagc gtgccggtcg ctagtcgcgg gtccccgagt 60 gagcacgcca gggagcagga gaccaaacga cgggggtcgg agtcagagtc gcagtgggag 120 tccccggacc ggagcacgag cctgagcggg agagcgccgc tcgcacgccc gtcgccaccc 180 gcgtacccgg cgcagcagag ccaccagcgc agcttgccat ggagcccagc agcaagaagc 240 tgacgggtcg cctcatgctg gccgtgggag gagcagtgct tggctccctg cagtttggct 300 acaacactgg agtcatcaat gccccccaga aggtgatcga ggagttctac aaccagacat 360 gggtccaccg ctatggggag agcatcctgc ccaccacgct caccacgctc tggtccctct 420 cagtggccat cttttctgtt gggggcatga ttggctcctt ctctgtgggc cttttcgtta 480 accgctttgg ccggcggaat tcaatgctga tgatgaacct gctggccttc gtgtccgccg 540 tgctcatggg cttctcgaaa ctgggcaagt cctttgagat gctgatcctg ggccgcttca 600 tcatcggtgt gtactgcggc ctgaccacag gcttcgtgcc catgtatgtg ggtgaagtgt 660 cacccacagc ccttcgtggg gccctgggca ccctgcacca gctgggcatc gtcgtcggca 720 tcctcatcgc ccaggtgttc ggcctggact ccatcatggg caacaaggac ctgtggcccc 780 tgctgctgag catcatcttc atcccggccc tgctgcagtg catcgtgctg cccttctgcc 840 ccgagagtcc ccgcttcctg ctcatcaacc gcaacgagga gaaccgggcc aagagtgtgc 900 taaagaagct gcgcgggaca gctgacgtga cccatgacct gcaggagatg aaggaagaga 960 gtcggcagat gatgcgggag aagaaggtca ccatcctgga gctgttccgc tcccccgcct 1020 accgccagcc catcctcatc gctgtggtgc tgcagctgtc ccagcagctg tctggcatca 1080 acgctgtctt ctattactcc acgagcatct tcgagaaggc gggggtgcag cagcctgtgt 1140 atgccaccat tggctccggt atcgtcaaca cggccttcac tgtcgtgtcg ctgtttgtgg 1200 tggagcgagc aggccggcgg accctgcacc tcataggcct cgctggcatg gcgggttgtg 1260 ccatactcat gaccatcgcg ctacactgct ggagcagcta ccctggatgt cctatctgag 1320 catcgtggcc atctttggct ttgtggcctt ctttgaagtg ggtcctggcc ccatcccatg 1380 gttcatcgtg gctgaactct tcagccaggg tccacgtcca gctgccattg ccgttgcagg 1440 cttctccaac tggacctcaa atttcattgt gggcatgtgc ttccagtatg tggagcaact 1500 gtgtggtccc tacgtcttca tcatcttcac tgtgctcctg gttctgttct tcatcttcac 1560 cacctatgtc ctaaggacac actaatcgaa ctatgaacta caaagcttct atcccaggag 1620 gtggctatgg ccacccgttc tgctggcctg gatctcccca ctctaggggt caggctccat 1680 taggatttgc ccccttccca tctcttccta cccaaccact caaattaatc tttctttacc 1740 tgagaccagt tgggagcact ggagtgcagg gaggagaggg gaagggccag tctgggctgc 1800 cgggttctag tctcctttgc actgagggcc acactattac catgagaaga gggcctgtgg 1860 gagcctgcaa actcactgct caagaagaca tggagactcc tgccctgttg tgtatagatg 1920 caagatattt atatatattt ttggttgtca atattaaata cagacactaa gttatagtat 1980 atctggacaa gccaacttgt aaatacacca cctcactcct gttacttacc taaacagata 2040 taaatggctg gtttttagaa acatggtttt gaaatgcttg tggattgagg gtaggaggtt 2100 tggatgggag tgagacagaa gtaagtgggg ttgcaaccac tgcaacggct tagacttcga 2160 ctcaggatcc agtcccttac acgtacctct catcagtgtc ctcttgctca aaaatctgtt 2220 tgatccctgt tacccagaga atatatacat tctttatctt gacattcaag gcatttctat 2280 cacatatttg atagttggtg ttcaaaaaaa cactagtttt gtgccagccg tgatgctcag 2340 gcttgaaatg cattattttg aatgtgaagt aaatactgta cctttatttg acaggctcaa 2400 agaggttatg tgcctgaagt cgcacagtga ataagctaaa acacctgctt ttaacaatgg 2460 taccatacaa ccactactcc attaactcca cccacctcct gcacccctcc ccacacacac 2520 aaaatgaacc acgttctttg tatgggccca atgagctgtc aagctgccct gtgttcattt 2580 catttggaat tgccccctct ggttcctctg tatactactg cttcatctct aaagacagct 2640 catcctcctc cttcacccct gaatttccag agcacttcat ctgctccttc atcacaagtc 2700 cagttttctg ccactagtct gaatttcatg agaagatgcc gatttggttc ctgtgggtcc 2760 tcagcactat tcagtacagt gcttgatgca cagcaggcac tcagaaaata ctggaggaaa 2820 taaaacacca aagatatttg tctctagagg ctatgctgac 2860 10 3046 DNA Homo sapiens misc_feature (1)..(3046) n = a,c,g,t any unknown or other 10 ggcaagaggc aagaggtagc aacagcgagc gtgccggtcg ctagtcgcgg gtccccgagt 60 gagcacgcca gggagcagga gaccaaacga cgggggtcgg agtcagagtc gcagtgggag 120 tccccggacc ggagcacgag cctgagcggg agagcgccgc tcgcacgccc gtcgccaccc 180 gcgtacccgg cgcagcagag ccaccagcgc agcttgccat ggagcccagc agcaagaagc 240 tgacgggtcg cctcatgctg gccgtgggag gagcagtgct tggctccctg cagtttggct 300 acaacactgg agtcatcaat gccccccaga aggtgatcga ggagttctac aaccagacat 360 gggtccaccg ctatggggag agcatcctgc ccaccacgct caccacgctc tggtccctct 420 cagtggccat cttttctgtt gggggcatga ttggctcctt ctctgtgggc cttttcgtta 480 accgctttgg ccggcggaat tcaatgctga tgatgaacct gctggccttc gtgtccgccg 540 tgctcatggg cttctcgaaa ctgggcaagt cctttgagat gctgatcctg ggccgcttca 600 tcatcggtgt gtactgcggc ctgaccacag gcttcgtgcc catgtatgtg ggtgaagtgt 660 cacccacagc ccttcgtggg gccctgggca ccctgcacca gctgggcatc gtcgtcggca 720 tcctcatcgc ccaggtgttc ggcctggact ccatcatggg caacaaggac ctgtggcccc 780 tgctgctgag catcatcttc atcccggccc tgctgcagtg catcgtgctg cccttctgcc 840 ccgagagtcc ccgcttcctg ctcatcaacc gcaacgagga gaaccgggcc aagagtgtgc 900 taaagaagct gcgcgggaca gctgacgtga cccatgacct gcaggagatg aaggaagaga 960 gtcggcagat gatgcgggag aagaaggtca ccatcctgga gctgttccgc tcccccgcct 1020 accgccagcc catcctcatc gctgtggtgc tgcagctgtc ccagcagctg tctggcatca 1080 acgctgtctt ctattactcc acgagcatct tcgagaaggc gggggtgcag cagcctgtgt 1140 atgccaccat tggctccggt atcgtcaaca cggccttcac tgtcgtgtcg ctgtttgtgg 1200 tggagcgagc aggccggcgg accctgcacc tcataggcct cgctggcatg gcgggttgtg 1260 ccatactcat gaccatcgcg ctacactgct ggagcagcta ccctggatgt cctatctgag 1320 catcgtggcc atctttggct ttgtggcctt ctttgaagtg ggtcctggcc ccatcccatg 1380 gttcatcgtg gctgaactct tcagccaggg tccacgtcca gctgccattg ccgttgcagg 1440 cttctccaac tggacctcaa atttcattgt gggcgggctc ctttctccag ccagcaatga 1500 tgtccagaag aatattcagg acttaacggc tccaggattt taacaaaagc aagactgttg 1560 ctcaaatcta ttcagacaag caacaggttt tataattttt ttattactga ttttgttatt 1620 tttatatcag cctgagtctc ctgtgcccac atcccaggct tcaccctgaa tggttccatg 1680 cctgagggtg gagactaagc cctgtcgaga cacttgcctt cttcacccag ctaatctgta 1740 gggctggacc tatgtcctaa ggacacacta atcgaactat gaactacaaa gcttctatcc 1800 caggaggtgg ctatggccac ccgttctgct ggcctggatc tccccactct aggggtcagg 1860 ctccattagg atttgccccc ttcccatctc ttcctaccca accactcaaa ttaatctttc 1920 tttacctgag accagttggg agcactggag tgcagggagg agaggggaag ggccagtctg 1980 ggctgccggg ttctagtctc ctttgcactg agggccacac tattaccatg agaagagggc 2040 ctgtgggagc ctgcaaactc actgctcaag aagacatgga gactcctgcc ctgttgtgta 2100 tagatgcaag atatttatat atatttttgg ttgtcaatat taaatacaga cactaagtta 2160 tagtatatct ggacaagcca acttgtaaat acaccacctc actcctgtta cttacctaaa 2220 cagatataaa tggctggttt ttagaaacat ggttttgaaa tgcttgtgga ttgagggtag 2280 gaggtttgga tgggagtgag acagaagtaa gtggggttgc aaccactgca acggcttaga 2340 cttcgactca ggatccagtc ccttacacgt acctctcatc agtgtcctct tgctcaaaaa 2400 tctgtttgat ccctgttacc cagagaatat atacattctt tatcttgaca ttcaaggcat 2460 ttctatcaca tatttgatag ttggtgttca aaaaaacact agttttgtgc cagccgtgat 2520 gctcaggctt gaaatgcatt attttgaatg tgaagtaaat actgtacctt tatttgacag 2580 gctcaaagag gttatgtgcc tgaagtcgca cagtgaataa gctaaaacac ctgcttttaa 2640 caatggtacc atacaaccac tactccatta actccaccca cctcctgcac ccctccccac 2700 acacacaaaa tgaaccacgt tctttgtatg ggcccaatga gctgtcaagc tgccctgtgt 2760 tcatttcatt tggaattgcc ccctctggtt cctctgtata ctactgcttc atctctaaag 2820 acagctcatc ctcctccttc acccctgaat ttccagagca cttcatctgc tccttcatca 2880 caagtccagt tttctgccac tagtctgaat ttcatgagaa gatgccgatt tggttcctgt 2940 gggtcctcag cactattcag tacagtgctt gatgcacagc aggcactcag aaaatactgg 3000 aggaaataaa acaccaaaga tatttgtctc tagaggctat gctgac 3046 11 1387 DNA Homo sapiens misc_feature (1)..(1387) n = a,c,g,t any unknown or other 11 tttctcgcat aatggctaaa agtaggtaga catgcaaaca atagcctaga gtgggagtta 60 ggaaaagtta aggcagagac atgtccatgt ataagctatg ctgtttttac aaaaaacaga 120 tgggtgttgg ctatttagag cttccctcat ggggtgtggt aactctaaga atgtgccaca 180 atgtcagccc tgtagaaaga taaatggaat gggttctgta ttgtccctag ttgttatttt 240 tttttatcat ccttaaaaca atgatgcaaa agggactcca ccaaaaacgt agatgtggaa 300 taaaaaaaag atagtttagg aatgtcatga agcagtcata tatcttttcc atcaggtgca 360 gtctccctgg ttgctgatgg agaaaatgac aaaaaaaaat actatactaa aaagcctatc 420 caaggaacag gttagtagga aatcacattc tgaagcactc attctgcctt tcttcagtgt 480 aagaaagttg ctcaaaagaa gaagcgtgac aacacaagct gctacaatgg ctacattctc 540 tacattcaat gtaagagaga aggagctatg gtcactccat gcaaaggcca gatagagatg 600 tggtgcgtat gtgcagagta cctcaagaaa tgaaagtcag catgtctctt ggaagctatg 660 aacactaatg tttaaaaaag gaaacagaaa acagaagaaa tcacttaagg agagctgtca 720 ttttctattg gtgaggattc ctgatcttgg ggaggttctg gaaagttcgt ctctgtttct 780 tcttcttcct cttcttggat tggaataatt tcaatgtctt cttcattctt tggttgggaa 840 gatgtttcag ttagcccaac cacttcttct tttatttcaa tagtctgttc ttttttttct 900 tctgctgaca ggagaactat gttagatttg ggtctggagc acgttctttt ccattcattc 960 tcaacgatgc cagctattac aagttcctgg aagaaggcaa agatcagcat cactgacaaa 1020 atgccctgaa aaacaagaga agaatgaagg tgaaaatgta ataatggcac aaagaacatt 1080 gttggtgttc agtaagttat tgttgactat aattgaacga ttaagagatc aattctttag 1140 acaagtaatg aatagctgtg agaactgcta gtacaggaga cagcatcttt ataaccctaa 1200 ctcttaacac aacttttggc acacaacaga tggttaatgt gtattgctga tagaaagtaa 1260 ggtatgaata atcagttgaa gaatcaattc tgtataggaa agaataagta atgagtctca 1320 aattaaattg tattcagcct tagttggtgt ggcatcatgc ctaggagacc tcttcatcct 1380 tgggaga 1387 12 1053 DNA Homo sapiens misc_feature (1)..(1053) n = a,c,g,t any unknown or other 12 agagcgagca ggggagagcg agaccagttt taaggggagg accggtgcga gtaaggcagc 60 cccgaggctc tgctcgccca ccacccaatc ctcgcctccc ttctgctcca ccttctctct 120 ctgccctcac ctctcccccg aaaaccccct atttagccaa aggaaggagg tcaggggaac 180 gctctcccct ccccttccaa aaaacaaaaa cagaaaaacc cttttccagg ccggggaaag 240 caggagggag aggggccgcc gggctggcca tggagctgct gtgccacgag gtggacccgg 300 tccgcagggc cgtgcgggac cgcaacctgc tccgagacga ccgcgtcctg cagaacctgc 360 tcaccatcga ggagcgctac cttccgcagt gctcctactt caagtgcgtg cagaaggaca 420 tccaacccta catgcgcaga atggtggcca cctggatgct ggaggtctgt gaggaacaga 480 agtgcgaaga agaggtcttc cctctggcca tgaattacct ggaccgtttc ttggctgggg 540 tcccgactcc gaagtcccat ctgcaactcc tgggtgctgt ctgcatgttc ctggcctcca 600 aactcaaaga gaccagcccg ctgaccgcgg agaagctgtg catttacacc gacaactcca 660 tcaagcctca ggagctgctg gagtgggaac tggtggtgct ggggaagttg aagtggaacc 720 tggcagctgt cactcctcat gacttcattg agcacatctt gcgcaagctg ccccagcagc 780 gggagaagct gtctctgatc cgcaagcatg ctcagacctt cattgctctg tgtgccacgg 840 ctcaacaggt cggacagggt aagggtaagg gatgtaacca ggagatgcca caggaacgtc 900 tgagaggtgt tagcaagtcc cagaggccag cgcccgactc catttcagcc tcgttcaggg 960 tggcacggag actcctgctg ctgcgtcacg tctgtcatgt tcagcactct tcccagacac 1020 acagtcttga ctaaagattg tcaggatctt gaa 1053 13 644 DNA Homo sapiens misc_feature (1)..(644 ) n = a,c,g,t any unknown or other 13 ccgtcagaaa tctaaacccg tgactatcat gggactcaaa accagcccaa aaaataagtc 60 aaaacgatta agagccagag aagcagtctt catacacgcg gccagccagc agacagagga 120 ctctcattaa ggaaggtgtc ctgtgccctg accctacaag atgccaagag aagatgctca 180 cttcatctat ggttacccca agaaggggca cggccactct tacaccacgg ctgaagaggc 240 cgctgggatc ggcatcctga cagtgatcct gggagtctta ctgctcatcg gctgttggta 300 ttgtagaaga cgaaatggat acagagcctt gatggataaa agtcttcatg ttggcactca 360 atgtgcctta acaagaagat gcccacaaga agggtttgat catcgggaca gcaaagtgtc 420 tcttcaagag aaaaactgtg aacctgtggt aggttaagat ccttcataag ggtattttca 480 tgaatggctg tttttaactc aagtgaatac aattatttcc atttaaaaag caaggacaat 540 gtgaatgtac tcattgccac tgaactatat acacctaaaa atggttaaaa tggcaacttt 600 tatgtgtatt ttatgagaat aaaaaataaa taataataaa aaac 644 14 750 DNA Homo sapiens misc_feature (1)..(750 ) n = a,c,g,t any unknown or other 14 ccgtcagaaa tctaaacccg tgactatcat gggactcaaa accagcccaa aaaataagtc 60 aaaacgatta agagccagag aagcagtctt catacacgcg gccagccagc agacagagga 120 ctctcattaa ggaaggtgtc ctgtgccctg accctacaag atgccaagag aagatgctca 180 cttcatctat ggttacccca agaaggggca cggccactct tacaccacgg ctgaagaggc 240 cgctgggatc ggcatcctga cagtgatcct gggagtctta ctgctcatcg gctgttggta 300 ttgtagaaga cgaaatggat acagagcctt gatggaaatc ctgggatgga gcgcagtggt 360 gatcatgagt cactgtagcc ttgacctcct gggctcaagc catcctcctg tctcagcctc 420 cagagtagct gggaccacag gataaaagtc ttcatgttgg cactcaatgt gccttaacaa 480 gaagatgccc acaagaaggg tttgatcatc gggacagcaa agtgtctctt caagagaaaa 540 actgtgaacc tgtggtaggt taagatcctt cataagggta ttttcatgaa tggctgtttt 600 taactcaagt gaatacaatt atttccattt aaaaagcaag gacaatgtga atgtactcat 660 tgccactgaa ctatatacac ctaaaaatgg ttaaaatggc aacttttatg tgtattttat 720 gagaataaaa aataaataat aataaaaaac 750 15 3521 DNA Homo sapiens misc_feature (1)..(3521) n = a,c,g,t any unknown or other 15 gctgggcaaa gccggtggca agggcctccc ctgccgctgt gccaggcagg cagtgccaaa 60 tccggggagc ctggagctgg ggggagggcc ggggacagcc cggccctgcc ccctcccccg 120 ctgggagccc agcaacttct gaggaaagtt tggcacccat ggcgtggcgg tgccccagga 180 tgggcagggt cccgctggcc tggtgcttgg cgctgtgcgg ctgggcgtgc atggccccca 240 ggggcacgca ggctgaagaa agtcccttcg tgggcaaccc agggaatatc acaggtgccc 300 ggggactcac gggcaccctt cggtgtcagc tccaggttca gggagagccc cccgaggtac 360 attggcttcg ggatggacag atcctggagc tcgcggacag cacccagacc caggtgcccc 420 tgggtgagga tgaacaggat gactggatag tggtcagcca gctcagaatc acctccctgc 480 agctttccga cacgggacag taccagtgtt tggtgtttct gggacatcag accttcgtgt 540 cccagcctgg ctatgttggg ctggagggct tgccttactt cctggaggag cccgaagaca 600 ggactgtggc cgccaacacc cccttcaacc tgagctgcca agctcaggga cccccagagc 660 ccgtggacct actctggctc caggatgctg tccccctggc cacggctcca ggtcacggcc 720 cccagcgcag cctgcatgtt ccagggctga acaagacatc ctctttctcc tgcgaagccc 780 ataacgccaa gggggtcacc acatcccgca cagccaccat cacagtgctc ccccagcagc 840 cccgtaacct ccacctggtc tcccgccaac ccacggagct ggaggtggct tggactccag 900 gcctgagcgg catctacccc ctgacccact gcaccctgca ggctgtgctg tcagacgatg 960 ggatgggcat ccaggcggga gaaccagacc ccccagagga gcccctcacc tcgcaagcat 1020 ccgtgccccc ccatcagctt cggctaggca gcctccatcc tcacccccct tatcacatcc 1080 gcgtggcatg caccagcagc cagggcccct catcctggac ccactggctt cctgtggaga 1140 cgccggaggg agtgcccctg ggcccccctg agaacattag tgctacgcgg aatgggagcc 1200 aggccttcgt gcattggcaa gagccccggg cgcccctgca gggtaccctg ttagggtacc 1260 ggctggcgta tcaaggccag gacaccccag aggtgctaat ggacataggg ctaaggcaag 1320 aggtgaccct ggagctgcag ggggacgggt ctgtgtccaa tctgacagtg tgtgtggcag 1380 cctacactgc tgctggggat ggaccctgga gcctcccagt acccctggag gcctggcgcc 1440 caggggaagc acagccagtc caccagctgg tgaaggaacc ttcaactcct gccttctcgt 1500 ggccctggtg gtatgtactg ctaggagcag tcgtggccgc tgcctgtgtc ctcatcttgg 1560 ctctcttcct tgtccaccgg cgaaagaagg agacccgtta tggagaagtg tttgaaccaa 1620 cagtggaaag aggtgaactg gtagtcaggt accgcgtgcg caagtcctac agtcgtcgga 1680 ccactgaagc taccttgaac agcctgggca tcagtgaaga gctgaaggag aagctgcggg 1740 atgtgatggt ggaccggcac aaggtggccc tggggaagac tctgggagag ggtgagtccc 1800 ccggcagcat acacacatcc ttctgaactt ctgagatcct gcacttccac actcccaccc 1860 aactatagga aatacagtcc ccacggccct ctgaggtcag tgtctccctc tggcccccca 1920 caggagagtt tggagctgtg atggaaggcc agctcaacca ggacgactcc atcctcaagg 1980 tggctgtgaa gacgatgaag attgccatct gcacgaggtc agagctggag gatttcctga 2040 gtgaagcggt ctgcatgaag gaatttgacc atcccaacgt catgaggctc atcggtgtct 2100 gtttccaggg ttctgaacga gagagcttcc cagcacctgt ggtcatctta cctttcatga 2160 aacatggaga cctacacagc ttcctcctct attcccggct cggggaccag ccagtgtacc 2220 tgcccactca gatgctagtg aagttcatgg cagacatcgc cagtggcatg gagtatctga 2280 gtaccaagag attcatacac cgggacctgg cggccaggaa ctgcatgctg aatgagaaca 2340 tgtccgtgtg tgtggcggac ttcgggctct ccaagaagat ctacaatggg gactactacc 2400 gccagggacg tatcgccaag atgccagtca agtggattgc cattgagagt ctagctgacc 2460 gtgtctacac cagcaagagc gatgtgtggt ccttcggggt gacaatgtgg gagattgcca 2520 caagaggcca aaccccatat ccgggcgtgg agaacagcga gatttatgac tatctgcgcc 2580 agggaaatcg cctgaagcag cctgcggact gtctggatgg actgtatgcc ttgatgtcgc 2640 ggtgctggga gctaaatccc caggaccggc caagttttac agagctgcgg gaagatttgg 2700 agaacacact gaaggccttg cctcctgccc aggagcctga cgaaatcctc tatgtcaaca 2760 tggatgaggg tggaggttat cctgaacccc ctggagctgc aggaggagct gaccccccaa 2820 cccagccaga ccctaaggat tcctgtagct gcctcactgc ggctgaggtc catcctgctg 2880 gacgctatgt cctctgccct tccacaaccc ctagccccgc tcagcctgct gataggggct 2940 ccccagcagc cccagggcag gaggatggtg cctgagacaa ccctccacct ggtactccct 3000 ctcaggatcc aagctaagca ctgccactgg ggaaaactcc accttcccac tttcccaccc 3060 cacgccttat ccccacttgc agccctgtct tcctacctat cccacctcca tcccagacag 3120 gtccctcccc ttctctgtgc agtagcatca ccttgaaagc agtagcatca ccatctgtaa 3180 aaggaagggg ttggattgca atatctgaag ccctcccagg tgttaacatt ccaagactct 3240 agagtccaag gtttaaagag tctagattca aaggttctag gtttcaaaga tgctgtgagt 3300 ctttggttct aaggacctga aattccaaag tctctaattc tattaaagtg ctaaggttct 3360 aaggcctaaa aaaaaaaaaa aaaaaaantc gagggggggg gccgggtacc caattcggcc 3420 tatagngagt cggtttaaaa atcantggcc gcggttnaaa agncggnnat tgggaaaacc 3480 tggggttaac caanttaatc gnctggagga aatccccttt c 3521 16 4282 DNA Homo sapiens misc_feature (1)..(4282) n = a,c,g,t any unknown or other 16 ttacagcaga aaggcccagg tcccggcgtg actccggccg gggcgacaca ggccgagtca 60 cttctctgcc cgtgcccggg tgtcctcatc gggggatggg tgcgccttcc acatcctgcc 120 caggactgaa ggagccgggc ccagcgagct cccgggaggt gtgtggacat cagccctgac 180 ggggaaggcg agccaggagc ctgcaggcct gaaccagggt gatgctgaag atgatgacct 240 tcttccaagg cctctagagc catcagcctg tgccaggcac cctcgacttg cctagaggcc 300 cccaaaagtt gcagtccaca tcagaggcag agtcagaggc ctccatgtcg gaggcctcct 360 ctgaggacct ggtgccaccc ctggaggctg gggcagcccc atatagggag gaggaagagg 420 cggcgaagaa gaagaaggag aagaagaaga agtccaaagg cctggccaat gtgttctgcg 480 tcttcaccaa agggaagaag aagaagggtc agcccagctc agcggagccc gaggacgcag 540 ccgggtccag gcaggggctg gatggcccgc cccccacagt ggaggagctg aaggcggcgc 600 tggagcgcgg gcagctggag gcggcgcggc cgctgctggc gctggagcgg gagctggcgg 660 cggcggcggc ggcgggcggt gtgagcgagg aggagctggt gcggcgccag agcaaggtgg 720 aggcgctgta cgagctgctg cgcgaccagg tgctgggcgt gctgcggcgg ccgctggagg 780 cgccgcccga gcggctgcgc caggcgctgg ccgtggtggc ggagcaggag cgcgaggacc 840 gccaggcggc ggcggcgggg ccgaggtccc cgagagcgtc tttctgcact tgggccgcac 900 catgaaggag gacctggagg ccgtggtgga gcggctgaag ccgctgttcc ccgccgagtt 960 cggcgtcgtg gcggcctacg ccgagagcta ccaccagcac ttcgcggccc acctggccgc 1020 cgtggcgcag ttcgagctgt gcgagcgcga cacctacatg ctgctgctct gggtgcagaa 1080 cctctacccc aatgacatca tcaacagccc caagctggtg ggtgagctgc agggtatggg 1140 gctcgggagc ctcctgcccc ccaggcagat ccgactgctg gaggccacat tcctgtccag 1200 tgaggcggcc aatgtgaggg agttgatgga ccgagctctg gagctagagg cacggcgctg 1260 ggctgaggat gtgcctcccc agaggctgga cggccactgc cacagcgagc tggccatcga 1320 catcatccag atcacctccc aggcccaggc caaggccgag agcatcacgc tggacttggg 1380 ctcacagata aagcgggtgc tgctggtgga gctgcctgcg ttcctgagga gctaccagcg 1440 cgcctttaat gaatttctgg agagaggcaa gcagctgacg aattacaggg ccaatgttat 1500 tgccaacatc aacaactgcc tgtccttccg gatgtccatg gagcagaatt ggcaggtacc 1560 ccaggacacc ctgagcctcc tgctgggccc cctgggtgag ctcaagagcc acggctttga 1620 caccctgctc cagaacctgc atgaggacct gaagccactg ttcaagaggt tcacgcacac 1680 ccgctgggcg gcccctgtgg agaccctgga aaacatcatc gccactgtag acacgaggct 1740 gcctgagttc tcagagctgc agggctgttt ccgggaggag ctcatggagg ccttgcacct 1800 gcacctggtg aaggagtaca tcatccaact cagcaagggg cgcctggtcc tcaagacggc 1860 cgagcagcag cagcagctgg ctgggtacat cctggccaat gctgacacca tccagcactt 1920 ctgcacccag cacggctccc cggcgacctg gctgcagcct gctctcccta cgctggccga 1980 gatcattcgc ctgcaggacc ccagtgccat caagattgag gtggccactt atgccacctg 2040 ctaccctgac ttcagcaaag gccacctgag cgctatcctg gccatcaagg ggaacctatc 2100 caacagtgag gtcaagcgca tccggagcat cttggacgtc agcatggggg cgcaggagcc 2160 ctcccggccc ctattttccc ttataaaggt tggttagctt ttcctgtggc ctgacctgcc 2220 tgtgagtgcc cagcaagcct tgggcacacc ccgctgggag ctgttaagag cagcgctggt 2280 tctcggttcc tcccgggtct cctgtgctct gatgctactt ctgcctagcc ctggcggagg 2340 tgcaggccct gtcagctgga actggacaga ccttggtttg tttacatgtc cgatgggggc 2400 aggagctccc atcctgggca gccaaccagg caacaccaag gactctttgt aaacgatagc 2460 tgatcgtgtg cacgcaagga aagaaccagg agggagagtg cagccaggct cagggatccc 2520 cggacacctc tgtccagagc ccctccacag tcggcctcat gactgtcctc ctcgtgggtg 2580 tggccgaggg ccctcttcag ctctctggag acaggggccg agcctcaccc atctgccctc 2640 tgcagcccag ggccgccgtg agcgggattc agcaatggtg gaatggaaga cagaactgga 2700 agagaaagaa ggaaaagatg agctctcgtc tggcaggggc ttttagggtc ctgtggcgag 2760 ctgtgagcac cgccagcgtt agacgtcaca tccaggtggc cccacggccc ctacaggctg 2820 gccctgcaat ggggccctga gccctccctc ttcatccccc aaggcctcaa ctagagggtg 2880 gtcccccgag ggcttggtgt ctactaccga aggcccaaga cctcctgggt cctctcaggc 2940 tcccccttcc ccaaggcagg gacaggccct gggggtgcca ccgtgggccc tgccacccag 3000 aagtctggct gaggtctggg caggggcagg gcaagcttga cctctcactg ttgacccttt 3060 ggcctctgta tttgtttcct attgccgtga caggtttcca caaacttcgt ggatcaaaac 3120 gaggtcttcc agttctgcgg gtcagaaggc tgacctgggg ctcaaatctg ggtgtcggca 3180 gtcctgcact ccttctggag gctctagggg agaattcatt tctggccttt tcatttttag 3240 aggctgaccg taattcttga cttcaggctc ctccatcttc agagccagct gtgggtagtt 3300 gaatcttttt cccgtcacct cattgaggcc tcccctctcc tgcctccctc caccactttt 3360 tttttttttt ttttgagaca gggtcttgct gtgttgccca ggctggagtg cagtggcctg 3420 gtcatggcat caaggctcac tgcagcctgg acctcctggt tcaagtgatc ctcttgtctc 3480 agtcccctga gacaatcccc cacgcccagc tacatatttt ttgtggatac agggtctcat 3540 tctgttgcct aggcttgtct ggaactcctg ggctcaaggg atcttgtagc cttagcctcc 3600 taaagtgctg ggattatagg catgagtcac tgtacccggc ctgctctacc gcttttaagg 3660 acgcttatga tcacattgcg cctacccaga gaacccaggt cgtctttcta ttttcaggtc 3720 agctgattag ccaccttagt tccatctgca actttagttc ccactggctg tgtaacctaa 3780 catagtcaca ggctctgggg actgtcacgt ggacatcttt gggaggccgt tattctgccc 3840 accgcaccct ccgttcatcc cctgccctgc cgggcacctc gctctacccc aggaaaatgt 3900 gagctcgttt tcctgctcgg catgtgctcc ccctaaggct ctgctcctcc ctgggcctga 3960 aagttccttc tcagcctgag agggggccct tcggatctca ggcatgactc agcccggctg 4020 atgcctctgc agtgctgagt caggatttgg ggccggctct cttgggtctg tccccttttc 4080 ccaggtactg ccttacaaag ctgtggccag gaagtggccg gtataaagga tgcccaaggt 4140 ctttgtacgt gtgtaggagt tagcgtgttt gatattgtta atataataat aattattttt 4200 tagagtactg cttttgtatg tatgttgaac aggatccagg tttttatagc ttgatataaa 4260 acagaattca aaagtgaaaa an 4282 17 3833 DNA Homo sapiens misc_feature (1)..(3833) n = a,c,g,t any unknown or other 17 ctacctccaa ccatgggcct tttgggaata ctttgttttt taatcttcct ggggaaaacc 60 tggggacagg agcaaacata tgtcatttca gcaccaaaaa tattccgtgt tggagcatct 120 gaaaatattg tgattcaagt ttatggatac actgaagcat ttgatgcaac aatctctatt 180 aaaagttatc ctgataaaaa atttagttac tcctcaggcc atgttcattt atcctcagag 240 aataaattcc aaaactctgc aatcttaaca atacaaccaa aacaattgcc tggaggacaa 300 aacccagttt cttatgtgta tttggaagtt gtatcaaagc atttttcaaa atcaaaaaga 360 atgccaataa cctatgacaa tggatttctc ttcattcata cagacaaacc tgtttatact 420 ccagaccagt cagtaaaagt tagagtttat tcgttgaatg acgacttgaa gccagccaaa 480 agagaaactg tcttaacctt catagatcct gaaggatcag aagttgacat ggtagaagaa 540 attgatcata ttggaattat ctcttttcct gacttcaaga ttccgtctaa tcctagatat 600 ggtatgtgga cgatcaaggc taaatataaa gaggactttt caacaactgg aaccgcatat 660 tttgaagtta aagaatatgt cttgccacat ttttctgtct caatcgagcc agaatataat 720 ttcattggtt acaagaactt taagaatttt gaaattacta taaaagcaag atatttttat 780 aataaagtag tcactgaggc tgacgtttat atcacatttg gaataagaga agacttaaaa 840 gatgatcaaa aagaaatgat gcaaacagca atgcaaaaca caatgttgat aaatggaatt 900 gctcaagtca catttgattc tgaaacagca gtcaaagaac tgtcatacta cagtttagaa 960 gatttaaaca acaagtacct ttatattgct gtaacagtca tagagtctac aggtggattt 1020 tctgaagagg cagaaatacc tggcatcaaa tatgtcctct ctccctacaa actgaatttg 1080 gttgctactc ctcttttcct gaagcctggg attccatatc ccatcaaggt gcaggttaaa 1140 gattcgcttg accagttggt aggaggagtc ccagtaatac tgaatgcaca aacaattgat 1200 gtaaaccaag agacatctga cttggatcca agcaaaagtg taacacgtgt tgatgatgga 1260 gtagcttcct ttgtgcttaa tctcccatct ggagtgacgg tgctggagtt taatgtcaaa 1320 actgatgctc cagatcttcc agaagaaaat caggccaggg aaggttaccg agcaatagca 1380 tactcatctc tcagccaaag ttacctttat attgattgga ctgataacca taaggctttg 1440 ctagtgggag aacatctgaa tattattgtt acccccaaaa gcccatatat tgacaaaata 1500 actcactata attacttgat tttatccaag ggcaaaatta tccactttgg cacgagggag 1560 aaattttcag atgcatctta tcaaagtata aacattccag taacacagaa catggttcct 1620 tcatcccgac ttctggtcta ttatatcgtc acaggagaac agacagcaga attagtgtct 1680 gattcagtct ggttaaatat tgaagaaaaa tgtggcaacc agctccaggt tcatctgtct 1740 cctgatgcag atgcatattc tccaggccaa actgtgtctc ttaatatggc aactggaatg 1800 gattcctggg tggcattagc agcagtggac agtgctgtgt atggagtcca aagaggagcc 1860 aaaaagccct tggaaagagt atttcaattc ttagagaaga gtgatctggg ctgtggggca 1920 ggtggtggcc tcaacaatgc caatgtgttc cacctagctg gacttacctt cctcactaat 1980 gcaaatgcag atgactccca agaaaatgat gaaccttgta aagaaattct caggccaaga 2040 agaacgctgc aaaagaagat agaagaaata gctgctaaat ataaacattc agtagtgaag 2100 aaatgttgtt acgatggagc ctgcgttaat aatgatgaaa cctgtgagca gcgagctgca 2160 cggattagtt tagggccaag atgcatcaaa gctttcactg aatgttgtgt cgtcgcaagc 2220 cagctccgtg ctaatatctc tcataaagac atgcaattgg gaaggctaca catgaagacc 2280 ctgttaccag taagcaagcc agaaattcgg agttattttc cagaaagctg gttgtgggaa 2340 gttcatcttg ttcccagaag aaaacagttg cagtttgccc tacctgattc tctaaccacc 2400 tgggaaattc aaggcattgg catttcaaac actggtatat gtgttgctga tactgtcaag 2460 gcaaaggtgt tcaaagatgt cttcctggaa atgaatatac catattctgt tgtacgagga 2520 gaacagatcc aattgaaagg aactgtttac aactatagga cttctgggat gcagttctgt 2580 gttaaaatgt ctgctgtgga gggaatctgc acttcggaaa gcccagtcat tgatcatcag 2640 ggcacaaagt cctccaaatg tgtgcgccag aaagtagagg gctcctccag tcacttggtg 2700 acattcactg tgcttcctct ggaaattggc cttcacaaca tcaatttttc actggagact 2760 tggtttggaa aagaaatctt agtaaaaaca ttacgagtgg tgccagaagg tgtcaaaagg 2820 gaaagctatt ctggtgttac tttggatcct aggggtattt atggtaccat tagcagacga 2880 aaggagttcc catacaggat acccttagat ttggtcccca aaacagaaat caaaaggatt 2940 ttgagtgtaa aaggactgct tgtaggtgag atcttgtctg cagttctaag tcaggaaggc 3000 atcaatatcc taacccacct ccccaaaggg agtgcagagg cggagctgat gagcgttgtc 3060 ccagtattct atgtttttca ctacctggaa acaggaaatc attggaacat ttttcattct 3120 gacccattaa ttgaaaagca gaaactgaag aaaaaattaa aagaagggat gttgagcatt 3180 atgtcctaca gaaatgctga ctactcttac agtgtgtgga agggtggaag tgctagcact 3240 tggttaacag cttttgcttt aagagtactt ggacaagtaa ataaatacgt agagcagaac 3300 caaaattcaa tttgtaattc tttattgtgg ctagttgaga attatcaatt agataatgga 3360 tctttcaagg aaaattcaca gtatcaacca ataaaattac agggtacctt gcctgttgaa 3420 gcccgagaga acagcttata tcttacagcc tttactgtga ttggaattag aaaggctttc 3480 gatatatgcc ccctggtgaa aatcgacaca gctctaatta aagctgacaa ctttctgctt 3540 gaaaatacac tgccagccca gagcaccttt acattggcca tttctgcgta tgctctttcc 3600 ctgggagata aaactcaccc acagtttcgt tcaattgttt cagctttgaa gagagaagct 3660 ttggttaaag atacgagtct cactgtgttt ccccggatga tctcaaatgc ctgggctcaa 3720 gcactcctac tgcctcagcc ttccaaagtg ctaggatcac aggcatgagc caccacacct 3780 gtcctctatt tattccttta ttcaataaat atgcattgag tatcctatgt aaa 3833 18 4871 DNA Homo sapiens misc_feature (1)..(4871) n = a,c,g,t any unknown or other 18 ctacctccaa ccatgggcct tttgggaata ctttgttttt taatcttcct ggggaaaacc 60 tggggacagg agcaaacata tgtcatttca gcaccaaaaa tattccgtgt tggagcatct 120 gaaaatattg tgattcaagt ttatggatac actgaagcat ttgatgcaac aatctctatt 180 aaaagttatc ctgataaaaa atttagttac tcctcaggcc atgttcattt atcctcagag 240 aataaattcc aaaactctgc aatcttaaca atacaaccaa aacaattgcc tggaggacaa 300 aacccagttt cttatgtgta tttggaagtt gtatcaaagc atttttcaaa atcaaaaaga 360 atgccaataa cctatgacaa tggatttctc ttcattcata cagacaaacc tgtttatact 420 ccagaccagt cagtaaaagt tagagtttat tcgttgaatg acgacttgaa gccagccaaa 480 agagaaactg tcttaacctt catagatcct gaaggatcag aagttgacat ggtagaagaa 540 attgatcata ttggaattat ctcttttcct gacttcaaga ttccgtctaa tcctagatat 600 ggtatgtgga cgatcaaggc taaatataaa gaggactttt caacaactgg aaccgcatat 660 tttgaagtta aagaatatgt cttgccacat ttttctgtct caatcgagcc agaatataat 720 ttcattggtt acaagaactt taagaatttt gaaattacta taaaagcaag atatttttat 780 aataaagtag tcactgaggc tgacgtttat atcacatttg gaataagaga agacttaaaa 840 gatgatcaaa aagaaatgat gcaaacagca atgcaaaaca caatgttgat aaatggaatt 900 gctcaagtca catttgattc tgaaacagca gtcaaagaac tgtcatacta cagtttagaa 960 gatttaaaca acaagtacct ttatattgct gtaacagtca tagagtctac aggtggattt 1020 tctgaagagg cagaaatacc tggcatcaaa tatgtcctct ctccctacaa actgaatttg 1080 gttgctactc ctcttttcct gaagcctggg attccatatc ccatcaaggt gcaggttaaa 1140 gattcgcttg accagttggt aggaggagtc ccagtaatac tgaatgcaca aacaattgat 1200 gtaaaccaag agacatctga cttggatcca agcaaaagtg taacacgtgt tgatgatgga 1260 gtagcttcct ttgtgcttaa tctcccatct ggagtgacgg tgctggagtt taatgtcaaa 1320 actgatgctc cagatcttcc agaagaaaat caggccaggg aaggttaccg agcaatagca 1380 tactcatctc tcagccaaag ttacctttat attgattgga ctgataacca taaggctttg 1440 ctagtgggag aacatctgaa tattattgtt acccccaaaa gcccatatat tgacaaaata 1500 actcactata attacttgat tttatccaag ggcaaaatta tccactttgg cacgagggag 1560 aaattttcag atgcatctta tcaaagtata aacattccag taacacagaa catggttcct 1620 tcatcccgac ttctggtcta ttatatcgtc acaggagaac agacagcaga attagtgtct 1680 gattcagtct ggttaaatat tgaagaaaaa tgtggcaacc agctccaggt tcatctgtct 1740 cctgatgcag atgcatattc tccaggccaa actgtgtctc ttaatatggc aactggaatg 1800 gattcctggg tggcattagc agcagtggac agtgctgtgt atggagtcca aagaggagcc 1860 aaaaagccct tggaaagagt atttcaattc ttagagaaga gtgatctggg ctgtggggca 1920 ggtggtggcc tcaacaatgc caatgtgttc cacctagctg gacttacctt cctcactaat 1980 gcaaatgcag atgactccca agaaaatgat gaaccttgta aagaaattct caggccaaga 2040 agaacgctgc aaaagaagat agaagaaata gctgctaaat ataaacattc agtagtgaag 2100 aaatgttgtt acgatggagc ctgcgttaat aatgatgaaa cctgtgagca gcgagctgca 2160 cggattagtt tagggccaag atgcatcaaa gctttcactg aatgttgtgt cgtcgcaagc 2220 cagctccgtg ctaatatctc tcataaagac atgcaattgg gaaggctaca catgaagacc 2280 ctgttaccag taagcaagcc agaaattcgg agttattttc cagaaagctg gttgtgggaa 2340 gttcatcttg ttcccagaag aaaacagttg cagtttgccc tacctgattc tctaaccacc 2400 tgggaaattc aaggcattgg catttcaaac actggtatat gtgttgctga tactgtcaag 2460 gcaaaggtgt tcaaagatgt cttcctggaa atgaatatac catattctgt tgtacgagga 2520 gaacagatcc aattgaaagg aactgtttac aactatagga cttctgggat gcagttctgt 2580 gttaaaatgt ctgctgtgga gggaatctgc acttcggaaa gcccagtcat tgatcatcag 2640 ggcacaaagt cctccaaatg tgtgcgccag aaagtagagg gctcctccag tcacttggtg 2700 acattcactg tgcttcctct ggaaattggc cttcacaaca tcaatttttc actggagact 2760 tggtttggaa aagaaatctt agtaaaaaca ttacgagtgg tgccagaagg tgtcaaaagg 2820 gaaagctatt ctggtgttac tttggatcct aggggtattt atggtaccat tagcagacga 2880 aaggagttcc catacaggat acccttagat ttggtcccca aaacagaaat caaaaggatt 2940 ttgagtgtaa aaggactgct tgtaggtgag atcttgtctg cagttctaag tcaggaaggc 3000 atcaatatcc taacccacct ccccaaaggg agtgcagagg cggagctgat gagcgttgtc 3060 ccagtattct atgtttttca ctacctggaa acaggaaatc attggaacat ttttcattct 3120 gacccattaa ttgaaaagca gaaactgaag aaaaaattaa aagaagggat gttgagcatt 3180 atgtcctaca gaaatgctga ctactcttac agtgtgtgga agggtggaag tgctagcact 3240 tggttaacag cttttgcttt aagagtactt ggacaagtaa ataaatacgt agagcagaac 3300 caaaattcaa tttgtaattc tttattgtgg ctagttgaga attatcaatt agataatgga 3360 tctttcaagg aaaattcaca gtatcaacca ataaaattac agggtacctt gcctgttgaa 3420 gcccgagaga acagcttata tcttacagcc tttactgtga ttggaattag aaaggctttc 3480 gatatatgcc ccctggtgaa aatcgacaca gctctaatta aagctgacaa ctttctgctt 3540 gaaaatacac tgccagccca gagcaccttt acattggcca tttctgcgta tgctctttcc 3600 ctgggagata aaactcaccc acagtttcgt tcaattgttt cagctttgaa gagagaagct 3660 ttggttaaag gtaatccacc catttatcgt ttttggaaag acaatcttca gcataaagac 3720 agctctgtac ctaacactgg tacggcacgt atggtagaaa caactgccta tgctttactc 3780 accagtctga acttgaaaga tataaattat gttaacccag tcatcaaatg gctatcagaa 3840 gagcagaggt atggaggtgg cttttattca acccaggaca cmatcaatgc cattgagggc 3900 ctgacggaat attcactcct ggttaaacaa ctccgcttga gtatggacat cgatgtttct 3960 tacaagcata aaggtgcctt acataattat aaaatgacag acaagaattt ccttgggagg 4020 ccagtagagg tgcttctcaa tgatgacctc attgtcagta caggatttgg cagtggcttg 4080 gctacagtac atgtaacaac tgtagttcac aaaaccagta cctctgagga agtttgcagc 4140 ttttatttga aaatcgatac tcaggatatt gaagcatccc actacagagg ctacggaaac 4200 tctgattaca aacgcatagt agcatgtgcc agctacaagc ccagcaggga agaatcatca 4260 tctggatcct ctcatgcggt gatggacatc tccttgccta ctggaatcag tgcaaatgaa 4320 gaagacttaa aagcccttgt ggaaggggtg gatcaactat tcactgatta ccaaatcaaa 4380 gatggacatg ttattctgca actgaattcg attccctcca gtgatttcct ttgtgtacga 4440 ttccggatat ttgaactctt tgaagttggg tttctcagtc ctgccacttt cacagtgtac 4500 gaataccaca gaccagataa acagtgtacc atgttttata gcacttccaa tatcaaaatt 4560 cagaaagtct gtgaaggagc cgcgtgcaag tgtgtagaag ctgattgtgg gcaaatgcag 4620 gaagaattgg atctgacaat ctctgcagag acaagaaaac aaacagcatg taaaccagag 4680 attgcatatg cttataaagt tagcatcaca tccatcactg tagaaaatgt ttttgtcaag 4740 tacaaggcaa cccttctgga tatctacaaa actggtgaga attcattcgt tcattcgttc 4800 cttcattcag caactattta gtactgacta tgtgccaggc attatattaa acacagaaga 4860 tacaactcaa a 4871 19 1298 DNA Homo sapiens misc_feature (1)..(1298) n = a,c,g,t any unknown or other 19 aagaggctca gggctgtggg aggcacattt ttctctgaaa agcagtttgg atgaggaaga 60 gatttggcag ttggaagaga gaagaagtca ctacagggta ctgaggaaaa gctttgctga 120 aattggagat caaataccag ctctgccagt aagaagttgc atctcccagt gaaatgctgc 180 tgctgccatt tcaactgtta gctgttctct ttcctggtgg taacagtgaa catgccttcc 240 aggggccgac ctcctttcat gttatccaga cctcgtcctt taccaatagt acctgggcac 300 aaactcaagg ctcaggctgg ttggatgatt tgcagattca tggctgggat agcgactcag 360 gcactgccat attcctgaag ccttggtcta aaggtaactt tagtgataag gaggttgctg 420 agttagagga gatattccga gtctacatct ttggattcgc tcgagaagta caagactttg 480 ccggtgattt ccagatgaaa taccccttcg agatccaggg catagcaggc tgtgagctac 540 attctggagg tgccatagta agcttcctga ggggagctct aggaggattg gatttcctga 600 gtgtcaagaa tgcttcatgt gtgccttccc cagaaggtgg cagcagggca cagaaattct 660 gtgcactaat catacaatat caaggtatca tggaaactgt gagaattctc ctctatgaaa 720 cctgcccccg atatctcttg ggcgtcctca atgcaggaaa agcagatctg caaagacaag 780 tgaagcctga ggcctggctg tccagtggcc ccagtcctgg acctggccgt ctgcagcttg 840 tgtgccatgt ctcaggattc tacccaaagc ccgtgtgggt gatgtggatg cggggaaacc 900 ccacctccat tggctcaatt gttttggcaa taatagtgcc ttccttgctc cttttgctat 960 gccttgcatt atggtatatg aggcgccggt catatcagaa tatcccatga gccatcatca 1020 tgtctcctct cccattcgca ataagtacca agaagcccaa gatatcagcc caaaagtcaa 1080 tcttatcata tttcaaatga ttttcaaatt tgatgaaatc agagttttca tgtattttaa 1140 aataaattat tatttaaaca tcagcaaaaa agtacttaaa actgtaaatt tattatgaga 1200 ctgtactaac agtgtgattc accctgattt tacacacatt aaaatgttag aaaaaatgtg 1260 tctcaaaata aatgaaatat aatacatatg acttaaaa 1298 20 7746 DNA Homo sapiens misc_feature (1)..(7747) n = a,c,g,t any unknown or other 20 accggccaca gcctgcctac tgtcacccgc ctctcccgcg cgcagataca cgcccccgcc 60 tccgtgggca caaaggcagc gctgctgggg aactcggggg aacgcgcacg tgggaaccgc 120 cgcagctcca cactccaggt acttcttcca aggacctagg tctctcgccc atcggaaaga 180 aaataattct ttcaagaaga tcagggacaa ctgatttgaa gtctactctg tgcttctaaa 240 tccccaattc tgctgaaagt gaatccctag agccctagag ccccagcagc acccagccaa 300 acccacctcc accatggggg ccatgactca gctgttggca ggtgtctttc ttgctttcct 360 tgccctcgct accgaaggtg gggtcctcaa gaaagtcatc cggcacaagc gacagagtgg 420 ggtgaacgcc accctgccag aagagaacca gccagtggtg tttaaccacg tttacaacat 480 caagctgcca gtgggatccc agtgttcggt ggatctggag tcagccagtg gggagaaaga 540 cctggcaccg ccttcagagc ccagcgaaag ctttcaggag cacacagtag atggggaaaa 600 ccagattgtc ttcacacatc gcatcaacat cccccgccgg gcctgtggct gtgccgcagc 660 ccctgatgtt aaggagctgc tgagcagact ggaggagctg gagaacctgg tgtcttccct 720 gagggagcaa tgtactgcag gagcaggctg ctgtctccag cctgccacag gccgcttgga 780 caccaggccc ttctgtagcg gtcggggcaa cttcagcact gaaggatgtg gctgtgtctg 840 cgaacctggc tggaaaggcc ccaactgctc tgagcccgaa tgtccaggca actgtcacct 900 tcgaggccgg tgcattgatg ggcagtgcat ctgtgacgac ggcttcacgg gcgaggactg 960 cagccagctg gcttgcccca gcgactgcaa tgaccagggc aagtgcgtga atggagtctg 1020 catctgtttc gaaggctacg ccggggctga ctgcagccgt gaaatctgcc cagtgccctg 1080 cagtgaggag cacggcacat gtgtagatgg cttgtgtgtg tgccacgatg gctttgcagg 1140 cgatgactgc aacaagcctc tgtgtctcaa caattgctac aaccgtggac gatgcgtgga 1200 gaatgagtgc gtgtgtgatg agggtttcac gggcgaagac tgcagtgagc tcatctgccc 1260 caatgactgc ttcgaccggg gccgctgcat caatggcacc tgctactgcg aagaaggctt 1320 cacaggtgaa gactgcggga aacccacctg cccacatgcc tgccacaccc agggccggtg 1380 tgaggagggg cagtgtgtat gtgatgaggg ctttgccggt gtggactgca gcgagaagag 1440 gtgtcctgct gactgtcaca atcgtggccg ctgtgtagac gggcggtgtg agtgtgatga 1500 tggtttcact ggagctgact gtggggagct caagtgtccc aatggctgca gtggccatgg 1560 ccgctgtgtc aatgggcagt gtgtgtgtga tgagggctat actggggagg actgcagcca 1620 gctacggtgc cccaatgact gtcacagtcg gggccgctgt gtcgagggca aatgtgtatg 1680 tgagcaaggc ttcaagggct atgactgcag tgacatgagc tgccctaatg actgtcacca 1740 gcacggccgc tgtgtgaatg gcatgtgtgt ttgtgatgac ggctacacag gggaagactg 1800 ccgggatcgc caatgcccca gggactgcag caacaggggc ctctgtgtgg acggacagtg 1860 cgtctgtgag gacggcttca ccggccctga ctgtgcagaa ctctcctgtc caaatgactg 1920 ccatggccag ggtcgctgtg tgaatgggca gtgcgtgtgc catgaaggat ttatgggcaa 1980 agactgcaag gagcaaagat gtcccagtga ctgtcatggc cagggccgct gcgtggacgg 2040 ccagtgcatc tgccacgagg gcttcacagg cctggactgt ggccagcact cctgccccag 2100 tgactgcaac aacttaggac aatgcgtctc gggccgctgc atctgcaacg agggctacag 2160 cggagaagac tgctcagagg tgtctcctcc caaagacctc gttgtgacag aagtgacgga 2220 agagacggtc aacctggcct gggacaatga gatgcgggtc acagagtacc ttgtcgtgta 2280 cacgcccacc cacgagggtg gtctggaaat gcagttccgt gtgcctgggg accagacgtc 2340 caccatcatc caggagctgg arcctggtgt ggagtacttt atccgtgtat ttgccatcct 2400 ggagaacaag aagagcattc ctgtcagcgc cagggtggcc acgtacttac ctgcacctga 2460 aggcctgaaa ttcaagtcca tcaaggagac atctgtggaa gtggagtggg atcctctaga 2520 cattgctttt gaaacctggg agatcatctt ccggaatatg aataaagaag atgagggaga 2580 gatcaccaaa agcctgagga ggccagagac ctcttaccgg caaactggtc tagctcctgg 2640 gcaagagtat gagatatctc tgcacatagt gaaaaacaat acccggggcc ctggcctgaa 2700 gagggtgacc accacacgct tggatgcccc cagccagatc gaggtgaaag atgtcacaga 2760 caccactgcc ttgatcacct ggttcaagcc cctggctgag atcgatggca ttgagctgac 2820 ctacggcatc aaagacgtgc caggagaccg taccaccatc gatctcacag aggacgagaa 2880 ccagtactcc atcgggaacc tgaagcctga cactgagtac gaggtgtccc tcatctcccg 2940 cagaggtgac atgtcaagca acccagccaa agagaccttc acaacaggcc tcgatgctcc 3000 caggaatctt cgacgtgttt cccagacaga taacagcatc accctggaat ggaggaatgg 3060 caaggcagct attgacagtt acagaattaa gtatgccccc atctctggag gggaccacgc 3120 tgaggttgat gttccaaaga gccaacaagc cacaaccaaa accacactca caggtctgag 3180 gccgggaact gaatatggga ttggagtttc tgctgtgaag gaagacaagg agagcaatcc 3240 agcgaccatc aacgcagcca cagagttgga cacgcccaag gaccttcagg tttctgaaac 3300 tgcagagacc agcctgaccc tgctctggaa gacaccgttg gccaaatttg accgctaccg 3360 cctcaattac agtctcccca caggccagtg ggtgggagtg cagcttccaa gaaacaccac 3420 ttcctatgtc ctgagaggcc tggaaccagg acaggagtac aatgtcctcc tgacagccga 3480 gaaaggcaga cacaagagca agcccgcacg tgtgaaggca tccactgaac aagcccctga 3540 gctggaaaac ctcaccgtga ctgaggttgg ctgggatggc ctcagactca actggaccgc 3600 rgctgaccag gcctatgagc actttatcat tcaggtgcag gaggccaaca aggtggaggc 3660 agctcggaac ctcaccgtgc ctggcagcct tcgggctgtg gacataccgg gcctcaaggc 3720 tgctacgcct tatacagtct ccatctatgg ggtgatccag ggctatagaa caccagtgct 3780 ctctgctgag gcctccacag gggaaactcc caatttggga gaggtcgtgg tggccgaggt 3840 gggctgggat gccctcaaac tcaactggac tgctccagaa ggggcctatg agtacttttt 3900 cattcaggtg caggaggctg acacagtaga ggcagcccag aacctcaccg tcccaggagg 3960 actgaggtcc acagacctgc ctgggctcaa agcagccact cattatacca tcaccatccg 4020 cggggtcact caggacttca gcacaacccc tctctctgtt gaagtcttga cagaggaggt 4080 tccagatatg ggaaacctca cagtgaccga ggttagctgg gatgctctca gactgaactg 4140 gaccacgcca gatggaacct atgaccagtt tactattcag gtccaggagg ctgaccaggt 4200 ggaagaggct cacaatctca cggttcctgg cagcctgcgt tccatggaaa tcccaggcct 4260 cagggctggc actccttaca cagtcaccct gcacggcgag gtcaggggcc acagcactcg 4320 accccttgct gtagaggtcg tcacagagga tctcccacag ctgggagatt tagccgtgtc 4380 tgaggttggc tgggatggcc tcagactcaa ctggaccgca gctgacaatg cctatgagca 4440 ctttgtcatt caggtgcagg aggtcaacaa agtggaggca gcccagaacc tcacgttgcc 4500 tggcagcctc agggctgtgg acatcccggg cctcgaggct gccacgcctt atagagtctc 4560 catctatggg gtgatccggg gctatagaac accagtactc tctgctgagg cctccacagc 4620 caaagaacct gaaattggaa acttaaatgt ttctgacata actcccgaga gcttcaatct 4680 ctcctggatg gctaccgatg ggatcttcga gacctttacc attgaaatta ttgattccaa 4740 taggttgctg gagactgtgg aatataatat ctctggtgct gaacgaactg cccatatctc 4800 agggctaccc cctagtactg attttattgt ctacctctct ggacttgctc ccagcatccg 4860 gaccaaaacc atcagtgcca cagccacgac agaggccctg ccccttctgg aaaacctaac 4920 catttccgac attaatccct acgggttcac agtttcctgg atggcatcgg agaatgcctt 4980 tgacagcttt ctagtaacgg tggtggattc tgggaagctg ctggaccccc aggaattcac 5040 actttcagga acccagagga agctggagct tagaggcctc ataactggca ttggctatga 5100 ggttatggtc tctggcttca cccaagggca tcaaaccaag cccttgaggg ctgagattgt 5160 tacagaagcc gaaccggaag ttgacaacct tctggtttca gatgccaccc cagacggttt 5220 ccgtctgtcc tggacagctg atgaaggggt cttcgacaat tttgttctca aaatcagaga 5280 taccaaaaag cagtctgagc cactggaaat aaccctactt gcccccgaac gtaccaggga 5340 cttaacaggt ctcagagagg ctactgaata cgaaattgaa ctctatggaa taagcaaagg 5400 aaggcgatcc cagacagtca gtgctatagc aacaacagcc atgggctccc caaaggaagt 5460 cattttctca gacatcactg aaaattcggc tactgtcagc tggagggcac ccacggccca 5520 agtggagagc ttccggatta cctatgtgcc cattacagga ggtacaccct ccatggtaac 5580 tgtggacgga accaagactc agaccaggct ggtgaaactc atacctggcg tggagtacct 5640 tgtcagcatc atcgccatga agggctttga ggaaagtgaa cctgtctcag ggtcattcac 5700 cacagctctg gatggcccat ctggcctggt gacagccaac atcactgact cagaagcctt 5760 ggccaggtgg cagccagcca ttgccactgt ggacagttat gtcatctcct acacaggcga 5820 gaaagtgcca gaaattacac gcacggtgtc cgggaacaca gtggagtatg ctctgaccga 5880 cctcgagcct gccacggaat acacactgag aatctttgca gagaaagggc cccagaagag 5940 ctcaaccatc agtcaccggt tacctgctgg tctatgaatc agtggatggc acagtcaagg 6000 aagtcattgt gggtccagat accacctcct acagcctggc agacctgagc ccatccaccc 6060 actacacagc caagatccag gcactcaatg ggcccctgag gagcaatatg atccagacca 6120 tcttcaccac aattggactc ctgtacccct tccccaagga ctgctcccaa gcaatgctga 6180 atggagacac gacctctggc ctctacacca tttatctgaa tggtgataag gctcaggcgc 6240 tggaagtctt ctgtgacatg acctctgatg ggggtggatg gattgtgttc ctgagacgca 6300 aaaacggacg cgagaacttc taccaaaact ggaaggcata tgctgctgga tttggggacc 6360 gcagagaaga attctggctt gggctggaca acctgaacaa aatcacagcc caggggcagt 6420 acgagctccg ggtggacctg cgggaccatg gggagacagc ctttgctgtc tatgacaagt 6480 tcagcgtggg agatgccaag actcgctaca agctgaaggt ggaggggtac agtgggacag 6540 caggtgactc catggcctac cacaatggca gatccttctc cacctttgac aaggacacag 6600 attcagccat caccaactgt gctctgtcct acaaaggggc tttctggtac aggaactgtc 6660 accgtgtcaa cctgatgggg agatatgggg acaataacca cagtcagggc gttaactggt 6720 tccactggaa gggccacgaa cactcaatcc agtttgctga gatgaagctg agaccaagca 6780 acttcagaaa tcttgaaggc aggcgcaaac gggcataaat tccagggacc actgggtgag 6840 agaggaataa ggcccagagc gaggaaagga ttttaccaaa gcatcaatac aaccagccca 6900 accatcggtc cacacctggg catttggtga gagtcaaagc tgaccatgga tccctggggc 6960 caacggcaac agcatgggcc tcacctcctc tgtgatttct ttctttgcac caaagacatc 7020 agtctccaac atgtttctgt tttgttgttt gattcagcaa aaatctccca gtgacaacat 7080 cgcaatagtt ttttacttct cttaggtggc tctgggaatg ggagaggggt aggatgtaca 7140 ggggtagttt gttttagaac cagccgtatt ttacatgaag ctgtataatt aattgtcatt 7200 atttttgtta gcaaagatta aatgtgtcat tggaagccat cccttttttt acatttcata 7260 caacagaaac cagaaaagca atactgtttc cattttaagg atatgattaa tattattaat 7320 ataataatga tgatgatgat gatgaaaact aaggattttt caagagatct ttctttccaa 7380 aacatttctg gacagtacct gattgtattt tttttttaaa taaaagcaca agtacttttg 7440 agtttgttat tttgctttga attgttgagt ctgaatttca ccaaagcyaa tcatttgaac 7500 aaagcgggga atgttgggat aggaaaggta agtagggata gtggtcaagt gggaggggtg 7560 gaaaggagac taaagactgg gagagaggga agcacttttt ttaaataaag ttgaacacac 7620 ttgggaaaag cttacaggcc aggcctgtaa tcccaacact ttgggaggcc aaggtgggag 7680 gatagcttaa ccccaggagt ttgagaccag cctgagcaac atagtgagaa cttgtctcta 7740 cagaaa 7746 21 2291 DNA Homo sapiens misc_feature (1)..(2291) n = a,c,g,t any unknown or other 21 ccgggctgat ccgagccgag cgggccgtat ctccttgtcg gcgccgctga ttcccggctc 60 tgcggaggcc tctaggcagc cgcgcagctt ccgtgtttgc tgcgcccgca ctgcgattta 120 caaccctgaa gaatctccct atccctattt tgtccccctg cagtaataaa tcccattatg 180 gagatctcga aactttataa agggatatag tttgaattct atggagtgta attttgtgta 240 tgaattatat ttttaaaaca ttgaagagtt ttcagaaaga aggctagtag agttgattac 300 tgatacttta tgctaagcag tacttttttg gtagtacaat attttgttag gcgtttctga 360 taacactaga aaggacaagt tttatcttgt gataaattga ttaatgttta caacatgact 420 gataattata gctgaatagt ccttaaatga tgaacaggtt atttagtttt taaatgcagt 480 gtaaaaagtg tgctgtggaa attttatggc taactaagtt tatggagaaa ataccttcag 540 ttgatcaaga ataatagtgg tatacaaagt taggaagaaa gtcaacatga tgctgcagga 600 aatggaaaca aatacaaatg atatttaaca aagatagagt ttacagtttt tgaactttaa 660 gccaaattca tttgacatca agcactatag caggcacagg ttcaacaaag cttgtgggta 720 ttgacttccc ccaaaagttg tcagctgaag taatttagcc cacttaagta aatactatga 780 tgataagctg tgtgaactta gcttttaaat agtgtgacca tatgaaggtt ttaattactt 840 ttgtttattg gaataaaatg agattttttg ggttgtcatg ttaaagtgct tatagggaaa 900 gaagcctgca tataattttt taccttgtgg cataatcagt aattggtctg ttattcaggc 960 ttcatagctt gtaaccaaat ataaataaaa ggcataattt aggtattcta tagttgctta 1020 gaattttgtt aatataaatc tctgtgaaaa atcaaggagt tttaatattt tcagaagtgc 1080 atccaccttt cagggcttta agttagtatt actcaagatt atgaacaaat agcacttagg 1140 ttacctgaaa gagttactac aaccccaaag agttgtgttc taagtagtat cttggtaatt 1200 cagagagata ctcatcctac ctgaatataa actgagataa atccagtaaa gaaagtgtag 1260 taaattctac ataagagtct atcattgatt tctttttgtg gtaaaaatct tagttcatgt 1320 gaagaaattt catgtgaatg ttttagctat caaacagtac tgtcacctac tcatgcacaa 1380 aactgcctcc caaagacttt tcccaggtcc ctcgtatcaa aacattaaga gtataatgga 1440 agatagcacg atcttgtcag attggacaaa cagcaacaaa caaaaaatga agtatgactt 1500 ttcctgtgaa ctctacagaa tgtctacata ttcaactttc cccgccgggg tgcctgtctc 1560 agaaaggagt cttgctcgtg ctggtttcta ttatactggt gtgaatgaca aggtcaaatg 1620 cttctgttgt ggcctgatgc tggataactg gaaactagga gacagtccta ttcaaaagca 1680 taaacagcta tatcctagct gtagctttat tcagaatctg gtttcagcta gtctgggatc 1740 cacctctaag aatacgtctc caatgagaaa cagttttgca cattcattat ctcccacctt 1800 ggaacatagt agcttgttca gtggttctta ctccagcctt tctccaaacc ctcttaattc 1860 tagagcagtt gaagacatct cttcatcgag gactaacccc tacagttatg caatgagtac 1920 tgaagaagcc agatttctta cctaccatat gtggccatta acttttttgt caccatcaga 1980 attggcaaga gctggttttt attatatagg acctggagat agggtagcct gctttgcctg 2040 tggtgggaag ctcagtaact gggaaccgaa ggataatgct atgtcagaac acctgagaca 2100 ttttcccaac tgtccatttt tggaaaattc tctagaaact ctgaggttta gcatttcaaa 2160 tctgagcatg cagacacatg cagctcgaat gagaacattt atgtactggc catctagtgt 2220 tccagttcag cctgagcagc ttgcaagtgc tggtttttat tatgtgggta agaaactgaa 2280 tctgctaatt a 2291 22 1194 DNA Homo sapiens misc_feature (1)..(1194) n = a,c,g,t any unknown or other 22 ggaaacgggt gaagaagggg aggcggcagg gaagggggtg ggggcctggc gggggcatcc 60 ggcggagctg gggtccccgg gctccgtccg gaggaagcga cgctgcgctc gctgggcagt 120 cggaggggac gggacgcacc ggagggcagg cggactcgcc ctgtcggtga ctgcgccgtc 180 cgggcccgtc ctgcctggcc gcaggtgccc tggatgaggc cgccccgcgc gccccaaacg 240 attttataat caatggataa agtgggaaaa atgtggaata acttcaaata caggtgtcag 300 aatctcttcg gtcatgaggg aggaagccgt agtgaaaatg tggacatgaa ctccaacaga 360 tgtttgtctg tcaaagagaa aaacatcagc ataggagact caactcctca gcaacaaagc 420 agtcccttaa gagaaaatat tgccttacaa ctgggattaa gcccttcgaa gaattcttca 480 aggagaaatc aaaattgtgc cacagaaatc cctcaaattg ttgaaataag catcgaaaag 540 gataatgatt cttgtgttac cccaggaaca agacttgcac gaagagattc ctactctcga 600 catgctccat ggggtgggaa gaaaaaacat tcctgttcta caaagaccca gagttcattg 660 gatgctgata aaaagtttgg tagaactcga agtggacttc aaaggagaga gaggcgctac 720 ggcgtaagtt ctgtacacga catggacagt gtttccagca gaactgtagg aagtcgctct 780 ctaagacaga ggttgcagga tactgtgggc ttgtgttttc ccatgagaac ttacagcaag 840 cagtcaaagc ctctcttttc caataaaaga aaaatccatc tctctgaatt aatgcttgag 900 aaatgccctt ttcctgctgg ctcagattta gcccaaaaat ggcatttgat taaacagcat 960 acagctcctg tgagcccaca ttcaacattt tttgatacrt ttgatccatc tttggtttct 1020 acagaagatg aagaagatag gcttagagag agaaggcgcc cagttgttcg agaccagcct 1080 ggacaacatg gcgagatccc atctccacaa aagaaataca aaactagttg ggcatggtgg 1140 cgtgtgcctc cagtcccagc taccagggag gccgaggtga gaagacagat ggag 1194 23 1546 DNA Homo sapiens misc_feature (1)..(1546) n = a,c,g,t any unknown or other 23 cagaagcccg gtcagcgcac gtgcccgcga gacctgcaaa cttgtgccac cggctctgcc 60 cgtccccggg gagcccgaac gccccgcagc cctcacccct cccgccagtc tccagccatg 120 gtgaacagca gagctgaaaa tggaaattgg caggtaccac tggatgtacc caggctcaaa 180 gaaccaccag taccatcccg tgccaaccct gggggacagg gctagcccct tgagcagtcc 240 aggctgcttt gaatgctgca tcaagtgtct gggaggagtc ccctacgcct ccctggtggc 300 caccatcctc tgcttctccg gggtggcctt attctgcggc tgtgggcatg tggctctcgc 360 aggcaccgtg gcgattcttg agcaacactt ctccaccaac gccagtgacc atgccttgct 420 gagcgaggtg atacaactga tgcagtatgt catctatgga attgcgtcct ttttcttctt 480 gtatgggatc attctgttgg cagaaggctt ttacaccaca agtgcagtga aagaactgca 540 cggtgagttt aaaacaaccg cttgtggccg atgcatcagt ggaatgttcg ttttcctcac 600 ctatgtgctt ggagtggcct ggctgggtgt gtttggtttc tcagcggtgc ccgtgtttat 660 gttctacaac atatggtcaa cttgtgaagt catcaagtca ccgcagacca acgggaccac 720 gggtgtggag cagatctgtg tggatatccg acaatacggt atcattcctt ggaatgcttt 780 ccccggaaaa atatgtggct ctgccctgga gaacatctgc aacacaaacg agttctacat 840 gtcctatcac ctgttcattg tggcctgtgc aggagctggt gccaccgtca ttgccctgct 900 gatctacatg atggctacta catataacta tgcggttttg aagtttaaga gtcgggaaga 960 ttgctgcact aaattctaaa ttgcataagg agttttagag agctatgctc tgtagcatga 1020 aatatcactg acactccaga ctaaagcaga gtctaggttt ctgcaatttt gttacagtaa 1080 tttgtaaata gctttagtaa actcaccttg catggtagat taataagatg acttactgta 1140 catgaattac acaataatga gatctggtgg ctatttccac attttgaaaa ggattcagtt 1200 atttactgac agtggtgagc atccttttta aaataatgtt ctcatactta aacattagag 1260 agcagtatct ttaaatgaat tattaacact ttggaatact tacattttct gttatttttg 1320 attgcctgat aaccagtttc aatgatgaaa atgaaaacaa gtgctgaaga tgaaatggaa 1380 gagaaccgtt ttaatctgga ttttgttttg tcacacctgg aaaatacttt gcaaatatgt 1440 tctaaattga aaacaatttt tttatgatca catggttcac taccaaatga ccctcaaata 1500 agccagatga aaatttgaag aaaaaggtca cccagttctc tggaan 1546 24 2747 DNA Homo sapiens misc_feature (1)..(2747) n = a,c,g,t any unknown or other 24 25 2534 DNA Homo sapiens misc_feature (1)..(2534) n = a,c,g,t any unknown or other 25 gtccgccaaa acctgcgcgg atagggaaga acagcacccc ggcgccgatt gccgtaccaa 60 acaagcctaa cgtccgccgg gccccggacg ccgcgcggaa aagatacctg atcagagaag 120 cagtttgatg tactaaaggc ttctcgattg ggagacagga aacctgggtg tcagtgccgg 180 gtctgccact gaatttctgt gtgacctttg tcagagtact gtacttccag agcgttggtt 240 tccacatcta ccctataaag cagcctgcat gtttctctca ttctctcgtt cgaggagttg 300 gaggatagct gctgcctgat ggaaaggcaa aaaagtccgc aggcatagag agtggaaaga 360 aggaacagca tactaggctg gtttgaaaaa caatcaattg ctagatgaat ttacaaccaa 420 ttttctggat tggactgatc agttcagttt gctgtgtgtt tgctcaaaca gatgaaaata 480 gatgtttaaa agcaaatgcc aaatcatgtg gagaatgtat acaagcaggg ccaaattgtg 540 ggtggtgcac aaattcaaca tttttacagg aaggaatgcc tacttctgca cgatgtgatg 600 atttagaagc cttaaaaaag aagggttgcc ctccagatga catagaaaat cccagaggct 660 ccaaagatat aaagaaaaat aaaaatgtaa ccaaccgtag caaaggaaca gcagagaagc 720 tcaagccaga ggatattact cagatccaac cacagcagtt ggttttgcga ttaagatcag 780 gggagccaca gacatttaca ttaaaattca agagagctga agactatccc attgacctct 840 actaccttat ggacctgtct tactcaatga aagacgattt ggagaatgta aaaagtcttg 900 gaacagatct gatgaatgaa atgaggagga ttacttcgga cttcagaatt ggatttggct 960 catttgtgga aaagactgtg atgccttaca ttagcacaac accagctaag ctcaggaacc 1020 cttgcacaag tgaacagaac tgcaccagcc catttagcta caaaaatgtg ctcagtctta 1080 ctaataaagg agaagtattt aatgaacttg ttggaaaaca gcgcatatct ggaaatttgg 1140 attctccaga aggtggtttc gatgccatca tgcaagttgc agtttgtgga tcactgattg 1200 gctggaggaa tgttacacgg ctgctggtgt tttccacaga tgccgggttt cactttgctg 1260 gagatgggaa acttggtggc attgttttac caaatgatgg acaatgtcac ctggaaaata 1320 atatgtacac aatgagccat tattatgatt atccttctat tgctcacctt gtccagaaac 1380 tgagtgaaaa taatattcag acaatttttg cagttactga agaatttcag cctgtttaca 1440 aggagctgaa aaacttgatc cctaagtcag cagtaggaac attatctgca aattctagca 1500 atgtaattca gttgatcatt gatgcataca attccctttc ctcagaagtc attttggaaa 1560 acggcaaatt gtcagaagga gtaacaataa gttacaaatc ttactgcaag aacggggtga 1620 atggaacagg ggaaaatgga agaaaatgtt ccaatatttc cattggagat gaggttcaat 1680 ttgaaattag cataacttca aataagtgtc caaaaaagga ttctgacagc tttaaaatta 1740 ggcctctggg ctttacggag gaagtagagg ttattcttca gtacatctgt gaatgtgaat 1800 gccaaagcga aggcatccct gaaagtccca agtgtcatga aggaaatggg acatttgagt 1860 gtggcgcgtg caggtgcaat gaagggcgtg ttggtagaca ttgtgaatgc agcacagatg 1920 aagttaacag tgaagacatg gatgcttact gcaggaaaga aaacagttca gaaatctgca 1980 gtaacaatgg agagtgcgtc tgcggacagt gtgtttgtag gaagagggat aaagaatgtg 2040 ttcagtgcag agccttcaat aaaggagaaa agaaagacac atgcacacag gaatgttcct 2100 attttaacat taccaaggta gaaagtcggg acaaattacc ccagccggtc caacctgatc 2160 ctgtgtccca ttgtaaggag aaggatgttg acgactgttg gttctatttt acgtattcag 2220 tgaatgggaa caacgaggtc atggttcatg ttgtggagaa tccagagtgt cccactggtc 2280 cagacatcat tccaattgta gctggtgtgg ttgctggaat tgttcttatt ggccttgcat 2340 tactgctgat atggaagctt ttaatgataa ttcatgacag aaggtggttc ctaaatacct 2400 tttagtttaa aaaaaaatgc agataaaggc tacctctgaa ttctcaatag attcatcatg 2460 tttgctctta agtgtagctg tccacactga aaacagccaa tatgttgcct gaataaactg 2520 aattgtgaac atct 2534 26 3293 DNA Homo sapiens misc_feature (1)..(3293) n = a,c,g,t any unknown or other 26 gtccgccaaa acctgcgcgg atagggaaga acagcacccc ggcgccgatt gccgtaccaa 60 acaagcctaa cgtccgccgg gccccggacg ccgcgcggaa aagatacctg atcagagaag 120 cagtttgatg tactaaaggc ttctcgattg ggagacagga aacctgggtg tcagtgccgg 180 gtctgccact gaatttctgt gtgacctttg tcagagtact gtacttccag agcgttggtt 240 tccacatcta ccctataaag cagcctgcat gtttctctca ttctctcgtt cgaggagttg 300 gaggatagct gctgcctgat ggaaaggcaa aaaagtccgc aggcatagag agtggaaaga 360 aggaacagca tactaggctg gtttgaaaaa caatcaattg ctagatgaat ttacaaccaa 420 ttttctggat tggactgatc agttcagttt gctgtgtgtt tgctcaaaca gatgaaaata 480 gatgtttaaa agcaaatgcc aaatcatgtg gagaatgtat acaagcaggg ccaaattgtg 540 ggtggtgcac aaattcaaca tttttacagg aaggaatgcc tacttctgca cgatgtgatg 600 atttagaagc cttaaaaaag aagggttgcc ctccagatga catagaaaat cccagaggct 660 ccaaagatat aaagaaaaat aaaaatgtaa ccaaccgtag caaaggaaca gcagagaagc 720 tcaagccaga ggatattact cagatccaac cacagcagtt ggttttgcga ttaagatcag 780 gggagccaca gacatttaca ttaaaattca agagagctga agactatccc attgacctct 840 actaccttat ggacctgtct tactcaatga aagacgattt ggagaatgta aaaagtcttg 900 gaacagatct gatgaatgaa attagcataa cttcaaataa gtgtccaaaa aaggattctg 960 acagctttaa aattaggcct ctgggcttta cggaggaagt agaggttatt cttcagtaca 1020 tctgtgaatg tgaatgccaa agcgaaggca tccctgaaag tcccaagtgt catgaaggaa 1080 atgggacatt tgagtgtggc gcgtgcaggt gcaatgaagg gcgtgttggt agacattgtg 1140 aatgcagcac agatgaagtt aacagtgaag acatggatgc ttactgcagg aaagaaaaca 1200 gttcagaaat ctgcagtaac aatggagagt gcgtctgcgg acagtgtgtt tgtaggaaga 1260 gggataatac aaatgaaatt tattctggca aattctgcga gtgtgataat ttcaactgtg 1320 atagatccaa tggcttaatt tgtggaggaa atggtgtttg caagtgtcgt gtgtgtgagt 1380 gcaaccccaa ctacactggc agtgcatgtg actgttcttt ggatactagt acttgtgaag 1440 ccagcaacgg acagatctgc aatggccggg gcatctgcga gtgtggtgtc tgtaagtgta 1500 cagatccgaa gtttcaaggg caaacgtgtg agatgtgtca gacctgcctt ggtgtctgtg 1560 ctgagcataa agaatgtgtt cagtgcagag ccttcaataa aggagaaaag aaagacacat 1620 gcacacagga atgttcctat tttaacatta ccaaggtaga aagtcgggac aaattacccc 1680 agccggtcca acctgatcct gtgtcccatt gtaaggagaa ggatgttgac gactgttggt 1740 tctattttac gtattcagtg aatgggaaca acgaggtcat ggttcatgtt gtggagaatc 1800 cagagtgtcc cactggtcca gacatcattc caattgtagc tggtgtggtt gctggaattg 1860 ttcttattgg ccttgcatta ctgctgatat ggaagctttt aatgataatt catgacagaa 1920 gggagtttgc taaatttgaa aaggagaaaa tgaatgccaa atgggacacg ggtgaaaatc 1980 ctatttataa gagtgccgta acaactgtgg tcaatccgaa gtatgaggga aaatgagtac 2040 tgcccgtgca aatcccacaa cactgaatgc aaagtagcaa tttccatagt cacagttagg 2100 tagctttagg gcaatattgc catggtttta ctcatgtgca ggttttgaaa atgtacaata 2160 tgtataattt ttaaaatgtt ttattatttt gaaaataatg ttgtaattca tgccagggac 2220 tgacaaaaga cttgagacag gatggttatt cttgtcagct aaggtcacat tgtgcctttt 2280 tgaccttttc ttcctggact attgaaatca agcttattgg attaagtgat atttctatag 2340 cgattgaaag ggcaatagtt aaagtaatga gcatgatgag agtttctgtt aatcatgtat 2400 taaaactgat ttttagcttt acaaatatgt cagtttgcag ttatgcagaa tccaaagtaa 2460 atgtcctgct agctagttaa ggattgtttt aaatctgtta ttttgctatt tgcctgttag 2520 acatgactga tgacatatct gaaagacaag tatgttgaga gttgctggtg taaaatacgt 2580 ttgaaatagt tgatctacaa aggccatggg aaaaattcag agagttagga aggaaaaacc 2640 aatagcttta aaacctgtgt gccattttaa gagttactta atgtttggta acttttatgc 2700 cttcacttta caaattcaag ccttagataa aagaaccgag caattttctg ctaaaaagtc 2760 cttgatttag cactatttac atacaggcca tactttacaa agtatttgct gaatggggac 2820 cttttgagtt gaatttattt tattattttt attttgttta atgtctggtg ctttctatca 2880 cctcttctaa tcttttaatg tatttgtttg caattttggg gtaagacttt ttttatgagt 2940 actttttctt tgaagtttta gcggtcaatt tgccttttta atgaacatgt gaagttatac 3000 tgtggctatg caacagctct cacctacgcg agtcttactt tgagttagtg ccataacaga 3060 ccactgtatg tttacttctc accatttgag ttgcccatct tgtttcacac tagtcacatt 3120 cttgttttaa gtgcctttag ttttaacagt tcacttttta cagtgctatt tactgaagtt 3180 atttattaaa tatgcctaaa atacttaaat cggatgtctt gactctgatg tattttatca 3240 ggttgtgtgc atgaaatttt tatagattaa agaagttgag gaaaagcaaa aaa 3293 27 800 DNA Homo sapiens misc_feature (1)..(800 ) n = a,c,g,t any unknown or other 27 gagacattcc ggtgggggac tctggccagc ccgagcaacg tggatcctga gagcactccc 60 aggtaggcat ttgccccggt gggacgcctt gccagagcag tgtgtggcag gcccccgtgg 120 aggatcaaca cagtggctga acactgggaa ggaactggta cttggagtct ggacatctga 180 aacttggctc tgaaactgcg gagcggccac cggacgcctt ctggagcagg tagcagcatg 240 cagccgcctc caagtctgtg cggacgcgcc ctggttgcgc tggttcttgc ctgcggcctg 300 tcgcggatct ggggagagga gagaggcttc ccgcctgaca gggccactcc gcttttgcaa 360 accgcagaga taatgacgcc acccactaag accttatggc ccaagggttc caacgccagt 420 ctggcgcggt cgttggcacc tgcggaggtg cctaaaggag acaggacggc aggatctccg 480 ccacgcacca tctcccctcc cccgtgccaa ggacccatcg agatcaagga gactttcaaa 540 tacatcaaca cggttgtgtc ctgccttgtg ttcgtgctgg ggatcatcgg gaactccaca 600 cttctgagaa ttatctacaa gaacaagtgc atgcgaaacg gtcccaatat cttgatcgcc 660 agcttggctc tgggagacct gctgcacatc gtcattgaca tccctatcaa tgtctacaag 720 ctgctggcag aggactggcc atttggagct gagatgtgcc aggtaggagc gttcacccac 780 ccagaggagg gttgccacag 800 28 582 DNA Homo sapiens misc_feature (1)..(582 ) n = a,c,g,t any unknown or other 28 ggcacgatgc ccggagccgg ccgcagcagc atggctcacg ggcccggcgc gctgatgctc 60 aagtgcgtgg tggtcggcga cggggcggtg ggcaagacgt gcctactcat gagctatgcc 120 aacgacgcct tcccggagga gtacgtgccc accgtcttcg accactacgc agtcagcgtc 180 accgtggggg gcaagcagta cctcctagga ctctatgaca cggccggaca gagataggag 240 catgctgcta tgtggaatgt tcagctttaa cccagaaggg attgaagact gtttttgatg 300 aggctatcat agccatttta actccaaaga aacacactgt aaaaaaaaga ataggatcaa 360 gatgtataaa ctgttgttta attacgtgag aaacatcttc agtggccaag gaaactgtcc 420 atttctctca gaaagcaaat gaaatgctac agctataccc agacctttta taggccattt 480 ccagcagttt aaaaggtttc cctttcagct atgagactgg ctcatagagg ctgtaatgtt 540 gatacaccag tttcacgctc acaccagtga agacttcgaa tt 582 29 972 DNA Homo sapiens misc_feature (1)..(972 ) n = a,c,g,t any unknown or other 29 gtcctcaaga ctagaaagca tgaagcaggg gaggcgtttt gaaagcttaa ggacaaaaga 60 ccatgggcct ggatggctga ttccgggatc ggcatcgtaa tttgttgaga aggaggccgt 120 gctgtgctgc cagttattaa tgggtttaat cggttgatac acagccctac tggcctaacc 180 agtagcccag ggcccgagag gatttgcagg tcgtgtcaga atttgattga agttccttcc 240 acttggcata aggagacacc atcagcctga ttgagagggt catggtgaga tggagcccgc 300 caaggtggca gcgctgagct gaccacacca ccggccatag agtgggagcc tttcctgccc 360 gcttaactgc agctaatatc aaaagcactg gtatgggctg tctatctgtg ctggaacctg 420 agtttatctt tgtctgcaat tacgattctt ctgggtttat tttgccagct cattatccag 480 ccccctggaa tcaggcctcc caaatttagc aggtgctggg gaggacccta gggagtggtt 540 tatgggggct agctggtgaa actgcccttt cctttctgtt ctatgagtgt gatggtgttt 600 gagaaaatgt ggggctatgg ttcaggcgca cttcacatgt gcaaagatgg agaaagcact 660 cacctacacg tttaggctca gaatattgat tgaaacattt tgaatgatca aaaataaaat 720 gttattttta aagtttctct ctgagatttt gcttaagttt tggtagatat tcttaagttt 780 tagtgacctc agtttgggaa ttaagtaagc taaacattgt gtccttatta ttagttatat 840 aaaactatgc tttagacttt gttagaaact tctgccccac cttgactgac tccttttcca 900 tttctggttg tacaaaatga attcacactt taatgctatg gccaccttta aataaagtac 960 agcgtgacta aa 972 30 557 DNA Homo sapiens misc_feature (1)..(557 ) n = a,c,g,t any unknown or other 30 gtcctcaaga ctagaaagca tgaagcaggg gaggcgtttt gaaagcttaa ggacaaaaga 60 ccatgggcct ggatggctga ttccgggatc ggcatcgtaa tttgttgaga aggaggccgt 120 gctgtgctgc cagttattaa tgggtttaat cggttgatac acagccctac tggcctaacc 180 agtagcccag ggcccgagag gatttgcagg tcgtgtcaga atttgattga agttccttcc 240 acttggcata aggagacacc atcagcctga ttgagagggt catggtgaga tggagcccgc 300 caaggtggca gcgctgagct gaccacacca ccggccatag agtgggagcc tttcctgccc 360 gcttaactgc agctaatatc aaaagcactg gtatgggctg tctatctgtg ctggaacctg 420 agtttatctt tgtctgcaat tacgattctt ctgggcagtt tcaccagcta gcccccataa 480 accactccct agggtcctcc ccagcacctg ctaaatttgg gaggcctgat tccagggggt 540 cggataatga gctggca 557 31 548 DNA Homo sapiens misc_feature (1)..(548 ) n = a,c,g,t any unknown or other 31 tgtaagtggc ctctctnctg gaatnagtat aattccaact ttcccggaaa ttctcagttg 60 tgcacatgaa aatgggtttn aagagggatt aagtacattg ggacttgtat caggtctttt 120 tagtgcaatg tggtcaattg gtgcttttat gggaccaacg ctgggtggat ttctgtatga 180 gaaaattggt tttgaatggg cagcagctat acaaggtcta tgggctctga taagtgtgag 240 taatcagtct tttatttgca ttttccttat atttgtggaa aaacttgact tggaaaattt 300 acattaatca gtacttttaa ttgtgtttaa gggattagcc atgggcttgt tttatctact 360 ggagtattca aggagaaaaa ggtatgggtc aattttgggg gctttttttc tctctttaaa 420 agttagccag tgcaagtggg aaaataaata acattttaca tttattcttc cgtcagtggg 480 atttctaagc actctggagg gcttcatcag ttgggtagga tacttttttt aatttttatt 540 ttttgagg 548 32 1257 DNA Homo sapiens misc_feature (1)..(1257) n = a,c,g,t any unknown or other 32 tgtaagtggc ctctctnctg gaatnagtat aattccaact ttcccggaaa ttctcagttg 60 tgcacatgaa aatgggtttn aagagggatt aagtacattg ggacttgtat caggtctttt 120 tagtgcaatg tggtcaattg gtgcttttat gggaccaacg ctgggtggat ttctgtatga 180 gaaaattggt tttgaatggg cagcagctat acaaggtcta tgggctctga taagtggatt 240 agccatgggc ttgttttatc tactggagta ttcaaggaga aaaaggtcta aatctcaaaa 300 catcctcagc acagaggagg aacgaactac tctcttgcct aatgaaacct agtccgatgg 360 atcctggatt gatacaaggt tgagaaatga atgctcctgg ccttaaacat caccgtagga 420 agggttttta aaattttacg cgcaaaactc cgtggacccc gtgccagtgt cttggaagtg 480 tcaacgtgtt tttggatgat cctgtattgg gctgtactta ctgtgatact gaaaagctgt 540 cctgctgaag cagctatatt tgaaatatta agtatgaaag gagtaattaa aaacaagcaa 600 aacaaaacaa gacttagttt ttaaatgacc aaacttgtcc ttaaagatgt tgttattaac 660 tcgagttagt tcttatttcc tctgtttatt ttttattcta agtacactga ttctgtgaat 720 gtaccttttt tattaacagg gaaagaaatg aattaatttg atatgctcta aatacataaa 780 ggtgcttcaa aatatgtaga aacattacta tgaaatcagt ttttaaaaga tatactttct 840 ctttgtcctg aggtttttcg gtcttgttca aaaggaagaa ttcttgcctg ccatacagaa 900 actctctagc actccctgac cttaagcttt tctaaaaatt ctgtttgtgt gaaaagtaca 960 agaataacaa tacttacaac ttccattttt gtaacctacg ttcacttatg atctggattt 1020 ataaacatta cttggtataa cgtttttcat ttcctttaat gtctctgttt tttggctcta 1080 ccatctgttt tgtttttgtt tttatctata tcttggtaga tgtatttcat ccctagagca 1140 ggtcagcctc cttcccctaa tgcgaatgct tgttttgtta gggaagggct tcctccaact 1200 tcgtgtgaaa ttgtgatgtt gaagtgaata aatgtctatt gtgtaactct caaaaaa 1257 33 1090 DNA Homo sapiens misc_feature (1)..(1090) n = a,c,g,t any unknown or other 33 tgtaagtggc ctctctnctg gaatnagtat aattccaact ttcccggaaa ttctcagttg 60 tgcacatgaa aatgggtttn aagagggatt aagtacattg ggacttgtat caggtctttt 120 tagtgcaatg tggtcaattg gtgcttttat gggaccaacg ctgggtggat ttctgtatga 180 gaaaattggt tttgaatggg cagcagctat acaaggtcta tgggctctga taagtggatt 240 agccatgggc ttgttttatc tactggagta ttcaaggaga aaaaggtcta aatctcaaaa 300 catcctcagc acagaggagg aacgaactac tctcttgcct aatgaaacct agtccgatgg 360 atcctggatt gatacaaggt tgagaaatga atgctcctgg ccttaaacat caccgtagga 420 agggttttta aaattttacg cgcaaaactc cgtggacccc gtgccagtgt cttggaagtg 480 tcaacgtgtt tttggatgat cctgtattgg gctgtactta ctgtgatact gaaaagctgt 540 cctgctgaag cagctatatt tgaaatatta cttggtataa cgtttttcat ttcctttaat 600 gtctctgttt tttggctcta ccatctatgt agaaacatta ctatgaaatc agtttttaaa 660 agatatactt tctctttgtc ctgaggtttt tcggtcttgt tcaaaaggaa gaattcttgc 720 ctgccataca gaaactctct agcactccct gaccttaagc ttttctaaaa attctgtttg 780 tgtgaaaagt acaagaataa caatacttac aacttccatt tttgtaacct acgttcactt 840 atgatctgga tttataaaca ttacttggta taacgttttt catttccttt aatgtctctg 900 ttttttggct ctaccatctg ttttgttttt gtttttatct atatcttggt agatgtattt 960 catccctaga gcaggtcagc ctccttcccc taatgcgaat gcttgttttg ttagggaagg 1020 gcttcctcca acttcgtgtg aaattgtgat gttgaagtga ataaatgtct attgtgtaac 1080 tctcaaaaaa 1090 34 452 DNA Homo sapiens misc_feature (1)..(452 ) n = a,c,g,t any unknown or other 34 tgtaagtggc ctctctnctg gaatnagtat aattccaact ttcccggaaa ttctcagttg 60 tgcacatgaa aatgggtttn aagagggatt aagtacattg ggacttgtat caggtctttt 120 tagtgcaatg tggtcaattg gtgcttttat gggaccaacg ctgggtggat ttctgtatga 180 gaaaattggt tttgaatggg cagcagctat acaaggtcta tgggctctga taagtggatt 240 agccatgggc ttgttttatc tactggagta ttcaaggaga aaaaggtatg ggtcaatttt 300 gggggctttt tttctctctt taaaagttag ccagtgcaag tgggaaaata aataacattt 360 tacatttatt cttccgtcag tgggatttct aagcactctg gagggcttca tcagttgggt 420 aggatacttt ttttaatttt tattttttga gg 452 35 1353 DNA Homo sapiens misc_feature (1)..(1353) n = a,c,g,t any unknown or other 35 tgtaagtggc ctctctnctg gaatnagtat aattccaact ttcccggaaa ttctcagttg 60 tgcacatgaa aatgggtttn aagagggatt aagtacattg ggacttgtat caggtctttt 120 tagtgcaatg tggtcaattg gtgcttttat gggaccaacg ctgggtggat ttctgtatga 180 gaaaattggt tttgaatggg cagcagctat acaaggtcta tgggctctga taagtgtgag 240 taatcagtct tttatttgca ttttccttat atttgtggaa aaacttgact tggaaaattt 300 acattaatca gtacttttaa ttgtgtttaa gggattagcc atgggcttgt tttatctact 360 ggagtattca aggagaaaaa ggtctaaatc tcaaaacatc ctcagcacag aggaggaacg 420 aactactctc ttgcctaatg aaacctagtc cgatggatcc tggattgata caaggttgag 480 aaatgaatgc tcctggcctt aaacatcacc gtaggaaggg tttttaaaat tttacgcgca 540 aaactccgtg gaccccgtgc cagtgtcttg gaagtgtcaa cgtgtttttg gatgatcctg 600 tattgggctg tacttactgt gatactgaaa agctgtcctg ctgaagcagc tatatttgaa 660 atattaagta tgaaaggagt aattaaaaac aagcaaaaca aaacaagact tagtttttaa 720 atgaccaaac ttgtccttaa agatgttgtt attaactcga gttagttctt atttcctctg 780 tttatttttt attctaagta cactgattct gtgaatgtac cttttttatt aacagggaaa 840 gaaatgaatt aatttgatat gctctaaata cataaaggtg cttcaaaata tgtagaaaca 900 ttactatgaa atcagttttt aaaagatata ctttctcttt gtcctgaggt ttttcggtct 960 tgttcaaaag gaagaattct tgcctgccat acagaaactc tctagcactc cctgacctta 1020 agcttttcta aaaattctgt ttgtgtgaaa agtacaagaa taacaatact tacaacttcc 1080 atttttgtaa cctacgttca cttatgatct ggatttataa acattacttg gtataacgtt 1140 tttcatttcc tttaatgtct ctgttttttg gctctaccat ctgttttgtt tttgttttta 1200 tctatatctt ggtagatgta tttcatccct agagcaggtc agcctccttc ccctaatgcg 1260 aatgcttgtt ttgttaggga agggcttcct ccaacttcgt gtgaaattgt gatgttgaag 1320 tgaataaatg tctattgtgt aactctcaaa aaa 1353 36 1186 DNA Homo sapiens misc_feature (1)..(1186) n = a,c,g,t any unknown or other 36 tgtaagtggc ctctctnctg gaatnagtat aattccaact ttcccggaaa ttctcagttg 60 tgcacatgaa aatgggtttn aagagggatt aagtacattg ggacttgtat caggtctttt 120 tagtgcaatg tggtcaattg gtgcttttat gggaccaacg ctgggtggat ttctgtatga 180 gaaaattggt tttgaatggg cagcagctat acaaggtcta tgggctctga taagtgtgag 240 taatcagtct tttatttgca ttttccttat atttgtggaa aaacttgact tggaaaattt 300 acattaatca gtacttttaa ttgtgtttaa gggattagcc atgggcttgt tttatctact 360 ggagtattca aggagaaaaa ggtctaaatc tcaaaacatc ctcagcacag aggaggaacg 420 aactactctc ttgcctaatg aaacctagtc cgatggatcc tggattgata caaggttgag 480 aaatgaatgc tcctggcctt aaacatcacc gtaggaaggg tttttaaaat tttacgcgca 540 aaactccgtg gaccccgtgc cagtgtcttg gaagtgtcaa cgtgtttttg gatgatcctg 600 tattgggctg tacttactgt gatactgaaa agctgtcctg ctgaagcagc tatatttgaa 660 atattacttg gtataacgtt tttcatttcc tttaatgtct ctgttttttg gctctaccat 720 ctatgtagaa acattactat gaaatcagtt tttaaaagat atactttctc tttgtcctga 780 ggtttttcgg tcttgttcaa aaggaagaat tcttgcctgc catacagaaa ctctctagca 840 ctccctgacc ttaagctttt ctaaaaattc tgtttgtgtg aaaagtacaa gaataacaat 900 acttacaact tccatttttg taacctacgt tcacttatga tctggattta taaacattac 960 ttggtataac gtttttcatt tcctttaatg tctctgtttt ttggctctac catctgtttt 1020 gtttttgttt ttatctatat cttggtagat gtatttcatc cctagagcag gtcagcctcc 1080 ttcccctaat gcgaatgctt gttttgttag ggaagggctt cctccaactt cgtgtgaaat 1140 tgtgatgttg aagtgaataa atgtctattg tgtaactctc aaaaaa 1186 37 499 DNA Homo sapiens misc_feature (1)..(499 ) n = a,c,g,t any unknown or other 37 gcaggagtga gactgtctta atgttacact cagctctagg aaaaggaaga ggtaagaaat 60 caaaacaaat ctatgaaaag tagagtgagg gagaaattac tcctcagatt cttgcaaata 120 ctcttaagtg catgtaatca aacatttgaa aagaacctag tactaaaggg gtgtcactgt 180 tttcatcccc tccscktcat gttctctctc cktctcttta gcaggacccc aacttcagag 240 ggtgcagcct ctgaaagaga ctgtgaatct atatatacca tttctgggac gaattcatct 300 tctgaggcct cacacactcc acatcttcca tctgaattgc ctcctagata tgaagaaaaa 360 gaaaatgctg cagctacatt cttgcctcta tcttctgagc cttccccacc gtaaactatg 420 gactctagtt cagttttata tgcaatggat cactatttta tttaattttt tttaaataaa 480 aaatacaata gcattggca 499 38 2449 DNA Homo sapiens misc_feature (1)..(2449) n = a,c,g,t any unknown or other 38 gtggtgcctg tggaggttcg agtccaagga cgtggcttga agccgggagc tggggcgccg 60 gagtccacgc accggggatg gaggcgctgg gtgacctgga gggaccacgc gcaccaggag 120 gtgatgatcc tgcaggaagt gcaggagaga cccccgggtg gctttcgaga gaacaggttt 180 ttgtactgat atcggcagct tcggtgaact taggttccat gatgtgctat tctatacttg 240 gaccgttttt ccccaaagag gctgaaaaga agggagccag caatacaatt atcggtatga 300 tctttggatg ttttgctttg ttcgagttgc tggcatcctt ggtatttgga aactatcttg 360 tacatattgg agcaaaattt atgtttgtag caggaatgtt tgtctcagga ggagttacaa 420 ttctctttgg tgtattggac cgagttccag atgggccagt atttattgct atgtgttttc 480 tagtgagagt aatggatgca gttagctttg ctgcagcaat gactgcatct tcttctatcc 540 tggcaaaggc ttttccaaat aacgtggcta cggtattggg aagtcttgag actttttctg 600 gactggggct aatactaggt cctcctgtag gtggcttttt gtatcaatcc tttggctatg 660 aagtgccttt tattgttctg ggatgcgtcg ttttgctgat ggtaccactc aatatgtata 720 ttttacccaa ttacgagtct gatccaggtg aacactcatt ctggaaactg atcgctttac 780 ccaaagttgg ccttatagcc ttcgtcatca actcactcag ctcgtgtttt ggcttcctcg 840 atcctactct gtctctcttt gttttggaga agttcaattt accagctgga tatgtgggac 900 tagtattcct gggtatggca ctgtcctatg ccatctcttc accactattt ggtctcctaa 960 gtgataaaag gccacctcta aggaaatggc ttctggtgtt tggcaactta atcacagccg 1020 ggtgctacat gctcttaggg cctgtcccaa tcttgcatat taaaagtcag ctctggctgc 1080 tggtgctgat attagttgta agtggcctct ctgctggaat gagtataatt ccaactttcc 1140 cggaaattct cagttgtgca catgaaaatg ggtttgaaga gggattaagt acattgggac 1200 ttgtatcagg tctttttagt gcaatgtggt caattggtgc ttttatggga ccaacgctgg 1260 gtggatttct gtatgagaaa attggttttg aatgggcagc agctatacaa ggtctatggg 1320 ctctgataag tgtgagtaat cagtctttta tttgcatttt ccttatattt gtggaaaaac 1380 ttgacttgga aaatttacat taatcagtac ttttaattgt gtttaaggga ttagccatgg 1440 gcttgtttta tctactggag tattcaagga gaaaaaggtc taaatctcaa aacatcctca 1500 gcacagagga ggaacgaact actctcttgc ctaatgaaac ctagtccgat ggatcctgga 1560 ttgatacaag gttgagaaat gaatgctcct ggccttaaac atcaccgtag gaagggtttt 1620 taaaatttta cgcgcaaaac tccgtggacc ccgtgccagt gtcttggaag tgtcaacgtg 1680 tttttggatg atcctgtatt gggctgtact tactgtgata ctgaaaagct gtcctgctga 1740 agcagctata tttgaaatat taagtatgaa aggagtaatt aaaaacaagc aaaacaaaac 1800 aagacttagt ttttaaatga ccaaacttgt ccttaaagat gttgttatta actcgagtta 1860 gttcttattt cctctgttta ttttttattc taagtacact gattctgtga atgtaccttt 1920 tttattaaca gggaaagaaa tgaattaatt tgatatgctc taaatacata aaggtgcttc 1980 aaaatatgta gaaacattac tatgaaatca gtttttaaaa gatatacttt ctctttgtcc 2040 tgaggttttt cggtcttgtt caaaaggaag aattcttgcc tgccatacag aaactctcta 2100 gcactccctg accttaagct tttctaaaaa ttctgtttgt gtgaaaagta caagaataac 2160 aatacttaca acttccattt ttgtaaccta cgttcactta tgatctggat ttataaacat 2220 tacttggtat aacgtttttc atttccttta atgtctctgt tttttggctc taccatctgt 2280 tttgtttttg tttttatcta tatcttggta gatgtatttc atccctagag caggtcagcc 2340 tccttcccct aatgcgaatg cttgttttgt tagggaaggg cttcctccaa cttcgtgtga 2400 aattgtgatg ttgaagtgaa taaatgtcta ttgtgtaact ctcaaaaaa 2449 39 2836 DNA Homo sapiens misc_feature (1)..(2836) n = a,c,g,t any unknown or other 39 atgggctcga gcggccgccc gggcaggtgg cgcttggcac gtgccagcgc tgtgaatcca 60 gtgggcagat actgttagac tgaaatctat tataatgctg aaggctggaa gtctgaagtc 120 aaggtgttgg gagtgttggt tccttctgag ggtgtgagga agaatccatt tcacacatct 180 ttcctagctt ctggaggagc caaatgaaaa cagaaccaca tcttgaaagg gctgaaagac 240 aacttgctac ccatatttct atattcaatg aaaggctctt ccagaatgaa gacaaaatga 300 tgacattcag agctaaacaa aaactaacag aactcatcac cagaagactc atacttgaag 360 aaatgttaca gaaagttact catgtcgaag aaaaatgata tcagatggaa aatttagatg 420 ttctagaagg aatgaagaac actgaaaatg atataatgcg tatgacaact aaagaatgaa 480 ggatgaagag agaagaggtg gctgctgggt gatgatcctg caggaagtgc aggagagacc 540 cccgggtggc tttcgagaga acaggttttt gtactgatat cggcagcttc ggtgaactta 600 ggttccatga tgtgctattc tatacttgga ccgtttttcc ccaaagaggc tgaaaagaag 660 ggagccagca atacaattat cggtatgatc tttggatgtt ttgctttgtt cgagttgctg 720 gcatccttgg tatttggaaa ctatcttgta catattggag caaaatttat gtttgtagca 780 ggaatgtttg tctcaggagg agttacaatt ctctttggtg tattggaccg agttccagat 840 gggccagtat ttattgctat gtgttttcta gtgagagtaa tggatgcagt tagctttgct 900 gcagcaatga ctgcatcttc ttctatcctg gcaaaggctt ttccaaataa cgtggctacg 960 gtattgggaa gtcttgagac tttttctgga ctggggctaa tactaggtcc tcctgtaggt 1020 ggctttttgt atcaatcctt tggctatgaa gtgcctttta ttgttctggg atgcgtcgtt 1080 ttgctgatgg taccactcaa tatgtatatt ttacccaatt acgagtctga tccaggtgaa 1140 cactcattct ggaaactgat cgctttaccc aaagttggcc ttatagcctt cgtcatcaac 1200 tcactcagct cgtgttttgg cttcctcgat cctactctgt ctctctttgt tttggagaag 1260 ttcaatttac cagctggata tgtgggacta gtattcctgg gtatggcact gtcctatgcc 1320 atctcttcac cactatttgg tctcctaagt gataaaaggc cacctctaag gaaatggctt 1380 ctggtgtttg gcaacttaat cacagccggg tgctacatgc tcttagggcc tgtcccaatc 1440 ttgcatatta aaagtcagct ctggctgctg gtgctgatat tagttgtaag tggcctctct 1500 gctggaatga gtataattcc aactttcccg gaaattctca gttgtgcaca tgaaaatggg 1560 tttgaagagg gattaagtac attgggactt gtatcaggtc tttttagtgc aatgtggtca 1620 attggtgctt ttatgggacc aacgctgggt ggatttctgt atgagaaaat tggttttgaa 1680 tgggcagcag ctatacaagg tctatgggct ctgataagtg tgagtaatca gtcttttatt 1740 tgcattttcc ttatatttgt ggaaaaactt gacttggaaa atttacatta atcagtactt 1800 ttaattgtgt ttaagggatt agccatgggc ttgttttatc tactggagta ttcaaggaga 1860 aaaaggtcta aatctcaaaa catcctcagc acagaggagg aacgaactac tctcttgcct 1920 aatgaaacct agtccgatgg atcctggatt gatacaaggt tgagaaatga atgctcctgg 1980 ccttaaacat caccgtagga agggttttta aaattttacg cgcaaaactc cgtggacccc 2040 gtgccagtgt cttggaagtg tcaacgtgtt tttggatgat cctgtattgg gctgtactta 2100 ctgtgatact gaaaagctgt cctgctgaag cagctatatt tgaaatatta agtatgaaag 2160 gagtaattaa aaacaagcaa aacaaaacaa gacttagttt ttaaatgacc aaacttgtcc 2220 ttaaagatgt tgttattaac tcgagttagt tcttatttcc tctgtttatt ttttattcta 2280 agtacactga ttctgtgaat gtaccttttt tattaacagg gaaagaaatg aattaatttg 2340 atatgctcta aatacataaa ggtgcttcaa aatatgtaga aacattacta tgaaatcagt 2400 ttttaaaaga tatactttct ctttgtcctg aggtttttcg gtcttgttca aaaggaagaa 2460 ttcttgcctg ccatacagaa actctctagc actccctgac cttaagcttt tctaaaaatt 2520 ctgtttgtgt gaaaagtaca agaataacaa tacttacaac ttccattttt gtaacctacg 2580 ttcacttatg atctggattt ataaacatta cttggtataa cgtttttcat ttcctttaat 2640 gtctctgttt tttggctcta ccatctgttt tgtttttgtt tttatctata tcttggtaga 2700 tgtatttcat ccctagagca ggtcagcctc cttcccctaa tgcgaatgct tgttttgtta 2760 gggaagggct tcctccaact tcgtgtgaaa ttgtgatgtt gaagtgaata aatgtctatt 2820 gtgtaactct caaaaa 2836 40 2217 DNA Homo sapiens misc_feature (1)..(2217) n = a,c,g,t any unknown or other 40 gcacgtgcca gcgctgtgaa tccagtgggc agatactgtt agactggtga tgatcctgca 60 ggaagtgcag gagagacccc cgggtggctt tcgagagaac aggtttttgt actgatatcg 120 gcagcttcgg tgaacttagg ttccatgatg tgctattcta tacttggacc gtttttcccc 180 aaagaggctg aaaagaaggg agccagcaat acaattatcg gtatgatctt tggatgtttt 240 gctttgttcg agttgctggc atccttggta tttggaaact atcttgtaca tattggagca 300 aaatttatgt ttgtagcagg aatgtttgtc tcaggaggag ttacaattct ctttggtgta 360 ttggaccgag ttccagatgg gccagtattt attgctatgt gttttctagt gagagtaatg 420 gatgcagtta gctttgctgc agcaatgact gcatcttctt ctatcctggc aaaggctttt 480 ccaaataacg tggctacggt attgggaagt cttgagactt tttctggact ggggctaata 540 ctaggtcctc ctgtaggtgg ctttttgtat caatcctttg gctatgaagt gcctcttatt 600 gttctgggat gcgtcgtttt gctgatggta ccactcaata tgtatatttt acccaattac 660 gagtctgatc caggtgaaca ctcattctgg aaactgatcg ctttacccaa agttggcctt 720 atagccttcg tcatcaactc actcagctcg tgttttggct tcctcgatcc tactctgtct 780 ctctttgttt tggagaagtt caatttacca gctggatatg tgggactagt attcctgggt 840 atggcactgt cctatgccat ctcttcacca ctatttggtc tcctaagtga taaaaggcca 900 cctctaagga aatggcttct ggtgtttggc aacttaatca cagccgggtg ctacatgctc 960 ttagggcctg tcccaatctt gcatattaaa agtcagctct ggctgctggt gctgatatta 1020 gttgtaagtg gcctctctgc tggaatgagt ataattccaa ctttcccgga aattctcagt 1080 tgtgcacatg aaaatgggtt tgaagaggga ttaagtacat tgggacttgt atcaggtctt 1140 tttagtgcaa tgtggtcaat tggtgctttt atgggaccaa cgctgggtgg atttctgtat 1200 gagaaaattg gttttgaatg ggcagcagct atacaaggtc tatgggctct gataagtgga 1260 ttagccatgg gcttgtttta tctactggag tattcaagga gaaaaaggtc taaatctcaa 1320 aacatcctca gcacagagga ggaacgaact actctcttgc ctaatgaaac ctagtccgat 1380 ggatcctgga ttgatacaag gttgagaaat gaatgctcct ggccttaaac atcaccgtag 1440 gaagggtttt taaaatttta cgcgcaaaac tccgtggacc ccgtgccagt gtcttggaag 1500 tgtcaacgtg tttttggatg atcctgtatt gggctgtact tactgtgata ctgaaaagct 1560 gtcctgctga agcagctata tttgaaatat taagtatgaa aggagtaatt aaaaacaagc 1620 aaaccaaaac aagacttagt ttttaaatga ccaaacttgt ccttaaagat gttgttatta 1680 actcgagtta gttcttattt cctctgtcta ttttttattc taagtacact gattctgtga 1740 atgtaccttt tttattaaca gggaaagaaa tgaattaatt tgatatgctc taaatacata 1800 aaggtgcttc aaaatatgta gaaacattac tatgaaatca gtttttaaaa gatatacttt 1860 ctctttgtcc tgaggttttt cggtcttgtt caaaaggaag aattcttgcc tgccatacag 1920 aaactctcta gcactccctg accttaagct tttctaaaaa ttctgtttgt gtgaaaagta 1980 caagaataac aatacttaca acttccattt ttgtaaccta cgttcactta tgatctggat 2040 ttataaacat tacttggtat aacgtttttc atttccttta atgtctctgt tttttggctc 2100 taccatctgt tttgtttttg tttttatcta tatcttggta gatgtatttc atccctagag 2160 caggtcagcc tccttcccct aatgcgaatg cttgttttgt tagggaaggg caagggc 2217 41 2449 DNA Homo sapiens misc_feature (1)..(2449) n = a,c,g,t any unknown or other 41 gtggtgcctg tggaggttcg agtccaagga cgtggcttga agccgggagc tggggcgccg 60 gagtccacgc accggggatg gaggcgctgg gtgacctgga gggaccacgc gcaccaggag 120 gtgatgatcc tgcaggaagt gcaggagaga cccccgggtg gctttcgaga gaacaggttt 180 ttgtactgat atcggcagct tcggtgaact taggttccat gatgtgctat tctatacttg 240 gaccgttttt ccccaaagag gctgaaaaga agggagccag caatacaatt atcggtatga 300 tctttggatg ttttgctttg ttcgagttgc tggcatcctt ggtatttgga aactatcttg 360 tacatattgg agcaaaattt atgtttgtag caggaatgtt tgtctcagga ggagttacaa 420 ttctctttgg tgtattggac cgagttccag atgggccagt atttattgct atgtgttttc 480 tagtgagagt aatggatgca gttagctttg ctgcagcaat gactgcatct tcttctatcc 540 tggcaaaggc ttttccaaat aacgtggcta cggtattggg aagtcttgag actttttctg 600 gactggggct aatactaggt cctcctgtag gtggcttttt gtatcaatcc tttggctatg 660 aagtgccttt tattgttctg ggatgcgtcg ttttgctgat ggtaccactc aatatgtata 720 ttttacccaa ttacgagtct gatccaggtg aacactcatt ctggaaactg atcgctttac 780 ccaaagttgg ccttatagcc ttcgtcatca actcactcag ctcgtgtttt ggcttcctcg 840 atcctactct gtctctcttt gttttggaga agttcaattt accagctgga tatgtgggac 900 tagtattcct gggtatggca ctgtcctatg ccatctcttc accactattt ggtctcctaa 960 gtgataaaag gccacctcta aggaaatggc ttctggtgtt tggcaactta atcacagccg 1020 ggtgctacat gctcttaggg cctgtcccaa tcttgcatat taaaagtcag ctctggctgc 1080 tggtgctgat attagttgta agtggcctct ctgctggaat gagtataatt ccaactttcc 1140 cggaaattct cagttgtgca catgaaaatg ggtttgaaga gggattaagt acattgggac 1200 ttgtatcagg tctttttagt gcaatgtggt caattggtgc ttttatggga ccaacgctgg 1260 gtggatttct gtatgagaaa attggttttg aatgggcagc agctatacaa ggtctatggg 1320 ctctgataag tgtgagtaat cagtctttta tttgcatttt ccttatattt gtggaaaaac 1380 ttgacttgga aaatttacat taatcagtac ttttaattgt gtttaaggga ttagccatgg 1440 gcttgtttta tctactggag tattcaagga gaaaaaggtc taaatctcaa aacatcctca 1500 gcacagagga ggaacgaact actctcttgc ctaatgaaac ctagtccgat ggatcctgga 1560 ttgatacaag gttgagaaat gaatgctcct ggccttaaac atcaccgtag gaagggtttt 1620 taaaatttta cgcgcaaaac tccgtggacc ccgtgccagt gtcttggaag tgtcaacgtg 1680 tttttggatg atcctgtatt gggctgtact tactgtgata ctgaaaagct gtcctgctga 1740 agcagctata tttgaaatat taagtatgaa aggagtaatt aaaaacaagc aaaacaaaac 1800 aagacttagt ttttaaatga ccaaacttgt ccttaaagat gttgttatta actcgagtta 1860 gttcttattt cctctgttta ttttttattc taagtacact gattctgtga atgtaccttt 1920 tttattaaca gggaaagaaa tgaattaatt tgatatgctc taaatacata aaggtgcttc 1980 aaaatatgta gaaacattac tatgaaatca gtttttaaaa gatatacttt ctctttgtcc 2040 tgaggttttt cggtcttgtt caaaaggaag aattcttgcc tgccatacag aaactctcta 2100 gcactccctg accttaagct tttctaaaaa ttctgtttgt gtgaaaagta caagaataac 2160 aatacttaca acttccattt ttgtaaccta cgttcactta tgatctggat ttataaacat 2220 tacttggtat aacgtttttc atttccttta atgtctctgt tttttggctc taccatctgt 2280 tttgtttttg tttttatcta tatcttggta gatgtatttc atccctagag caggtcagcc 2340 tccttcccct aatgcgaatg cttgttttgt tagggaaggg cttcctccaa cttcgtgtga 2400 aattgtgatg ttgaagtgaa taaatgtcta ttgtgtaact ctcaaaaaa 2449 42 252 PRT Homo sapiens misc_feature (1)..(252) Xaa = any amino acid, unknown, or other 42 Met Leu Cys Cys Met Arg Arg Thr Lys Gln Val Glu Lys Asn Asp Asp 1 5 10 15 Asp Gln Lys Ile Glu Gln Asp Gly Ile Lys Pro Glu Asp Lys Ala His 20 25 30 Lys Ala Ala Thr Lys Ile Gln Ala Ser Phe Arg Gly His Ile Thr Arg 35 40 45 Lys Lys Leu Lys Gly Glu Lys Lys Asp Asp Val Gln Ala Ala Glu Ala 50 55 60 Glu Ala Asn Lys Lys Asp Glu Ala Pro Val Ala Asp Gly Val Glu Lys 65 70 75 80 Lys Gly Glu Gly Thr Thr Thr Ala Glu Ala Ala Pro Ala Thr Gly Ser 85 90 95 Lys Pro Asp Glu Pro Gly Lys Ala Gly Glu Thr Pro Ser Glu Glu Lys 100 105 110 Lys Gly Glu Gly Asp Ala Ala Thr Glu Gln Ala Ala Pro Gln Ala Pro 115 120 125 Ala Ser Ser Glu Glu Lys Ala Gly Ser Ala Glu Thr Glu Ser Ala Thr 130 135 140 Lys Ala Ser Thr Asp Asn Ser Pro Ser Ser Lys Ala Glu Asp Ala Pro 145 150 155 160 Ala Lys Glu Glu Pro Lys Gln Ala Asp Val Pro Ser Phe Gly Val Phe 165 170 175 Pro Asn Pro Leu Gly Ala Leu Leu Leu Ala Ala Val Thr Ala Ala Ala 180 185 190 Ala Thr Thr Pro Ala Ala Glu Asp Ala Ala Ala Lys Ala Thr Ala Gln 195 200 205 Pro Pro Thr Glu Thr Gly Glu Ser Ser Gln Ala Glu Glu Asn Ile Glu 210 215 220 Ala Val Asp Glu Thr Lys Pro Lys Glu Ser Ala Arg Gln Asp Glu Gly 225 230 235 240 Lys Glu Glu Glu Pro Glu Ala Asp Gln Glu His Ala 245 250 43 267 PRT Homo sapiens misc_feature (1)..(267 ) Xaa = any amino acid, unknown, or other 43 Met Pro Pro Arg Thr Pro Leu Phe Thr Phe Ala Trp Glu Ala Leu Arg 1 5 10 15 Lys Asn Leu Gln Arg Ala Val Arg Pro Ser Pro Tyr Ser Leu Gly Phe 20 25 30 Leu Thr Phe Trp Ile Gln Gly Val Glu Lys Asn Asp Asp Asp Gln Lys 35 40 45 Ile Glu Gln Asp Gly Ile Lys Pro Glu Asp Lys Ala His Lys Ala Ala 50 55 60 Thr Lys Ile Gln Ala Ser Phe Arg Gly His Ile Thr Arg Lys Lys Leu 65 70 75 80 Lys Gly Glu Lys Lys Asp Asp Val Gln Ala Ala Glu Ala Glu Ala Asn 85 90 95 Lys Lys Asp Glu Ala Pro Val Ala Asp Gly Val Glu Lys Lys Gly Glu 100 105 110 Gly Thr Thr Thr Ala Glu Ala Ala Pro Ala Thr Gly Ser Lys Pro Asp 115 120 125 Glu Pro Gly Lys Ala Gly Glu Thr Pro Ser Glu Glu Lys Lys Gly Glu 130 135 140 Gly Asp Ala Ala Thr Glu Gln Ala Ala Pro Gln Ala Pro Ala Ser Ser 145 150 155 160 Glu Glu Lys Ala Gly Ser Ala Glu Thr Glu Ser Ala Thr Lys Ala Ser 165 170 175 Thr Asp Asn Ser Pro Ser Ser Lys Ala Glu Asp Ala Pro Ala Lys Glu 180 185 190 Glu Pro Lys Gln Ala Asp Val Pro Ala Ala Val Thr Ala Ala Ala Ala 195 200 205 Thr Thr Pro Ala Ala Glu Asp Ala Ala Ala Lys Ala Thr Ala Gln Pro 210 215 220 Pro Thr Glu Thr Gly Glu Ser Ser Gln Ala Glu Glu Asn Ile Glu Ala 225 230 235 240 Val Asp Glu Thr Lys Pro Lys Glu Ser Ala Arg Gln Asp Glu Gly Lys 245 250 255 Glu Glu Glu Pro Glu Ala Asp Gln Glu His Ala 260 265 44 123 PRT Homo sapiens misc_feature (1)..(123 ) Xaa = any amino acid, unknown, or other 44 Met Ala Glu Ser Asp Trp Asp Thr Val Thr Val Leu Arg Lys Lys Gly 1 5 10 15 Pro Thr Ala Ala Gln Ala Lys Ser Lys Gln Ala Ile Leu Ala Ala Gln 20 25 30 Arg Arg Gly Glu Asp Val Glu Thr Ser Lys Lys Trp Ala Ala Gly Gln 35 40 45 Asn Lys Gln His Ser Ile Thr Lys Asn Thr Ala Lys Leu Asp Arg Glu 50 55 60 Thr Glu Glu Leu His His Asp Arg Val Thr Leu Glu Val Gly Lys Val 65 70 75 80 Ile Gln Gln Gly Arg Gln Ser Lys Gly Leu Thr Gln Lys Asp Leu Ala 85 90 95 Thr Lys Ile Asn Glu Lys Pro Gln Val Ile Ala Asp Tyr Glu Ser Gly 100 105 110 Arg Ala Ile Pro Lys His Leu Val Ile Gly Arg 115 120 45 97 PRT Homo sapiens misc_feature (1)..(97 ) Xaa = any amino acid, unknown, or other 45 Met Ala Glu Ser Asp Trp Asp Thr Val Thr Val Leu Arg Lys Lys Gly 1 5 10 15 Pro Thr Ala Ala Gln Ala Lys Ser Lys Gln Ala Ile Leu Ala Ala Gln 20 25 30 Arg Arg Gly Glu Asp Val Glu Thr Ser Lys Lys Trp Ala Ala Gly Gln 35 40 45 Asn Lys Gln His Ser Ile Thr Lys Asn Thr Ala Lys Leu Asp Arg Glu 50 55 60 Thr Glu Glu Leu His His Asp Arg Tyr Leu Ser Gly Ser Asp His Ser 65 70 75 80 Arg Arg Gln Gly Tyr Glu Arg Thr Ala Arg Asn Ile Ser Lys Val Ser 85 90 95 Leu 46 141 PRT Homo sapiens misc_feature (1)..(141 ) Xaa = any amino acid, unknown, or other 46 Met Ala Glu Ser Asp Trp Asp Thr Val Thr Val Leu Arg Lys Lys Gly 1 5 10 15 Pro Thr Ala Ala Gln Ala Lys Ser Lys Gln Ala Ile Leu Ala Ala Gln 20 25 30 Arg Arg Gly Glu Asp Val Glu Thr Ser Lys Lys Trp Ala Ala Gly Gln 35 40 45 Asn Lys Gln His Ser Ile Thr Lys Asn Thr Ala Lys Leu Asp Arg Glu 50 55 60 Thr Glu Glu Leu His His Asp Arg Val Thr Leu Glu Val Gly Lys Val 65 70 75 80 Ile Gln Gln Gly Arg Gln Ser Lys Gly Leu Thr Gln Lys Asp Leu Ala 85 90 95 Thr Lys Ile Asn Glu Lys Pro Gln Val Ile Ala Asp Tyr Glu Ser Gly 100 105 110 Arg Ala Ile Pro Asn Asn Gln Val Leu Gly Lys Ile Glu Arg Ala Ile 115 120 125 Asp Val Gly Thr Arg Ser Ala Arg Val Leu Arg Ala Gln 130 135 140 47 471 PRT Homo sapiens misc_feature (1)..(471 ) Xaa = any amino acid, unknown, or other 47 Met Glu Pro Ser Ser Lys Lys Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55 60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser 65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185 190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro 195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310 315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr 340 345 350 Ile Ala Ala Thr Leu Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr 420 425 430 Val Phe Ile Ile Phe Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr 435 440 445 Tyr Phe Lys Val Pro Glu Thr Lys Gly Arg Thr Phe Asp Glu Ile Ala 450 455 460 Ser Gly Phe Ala Ala Gly Phe 465 470 48 501 PRT Homo sapiens misc_feature (1)..(501 ) Xaa = any amino acid, unknown, or other 48 Met Glu Pro Ser Ser Lys Lys Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55 60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser 65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185 190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro 195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310 315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr 340 345 350 Ile Ala Ala Thr Leu Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr 420 425 430 Val Phe Ile Ile Phe Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr 435 440 445 Tyr Phe Lys Val Pro Glu Thr Lys Gly Arg Thr Phe Asp Glu Ile Ala 450 455 460 Ser Gly Phe Arg Gln Gly Gly Ala Ser Gln Ser Asp Lys Thr Pro Ala 465 470 475 480 Leu Leu Cys Ile Asp Ala Arg Tyr Leu Tyr Ile Phe Leu Val Val Asn 485 490 495 Ile Lys Tyr Arg His 500 49 471 PRT Homo sapiens misc_feature (1)..(471 ) Xaa = any amino acid, unknown, or other 49 Met Glu Pro Ser Ser Lys Lys Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55 60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser 65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185 190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro 195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310 315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr 340 345 350 Ile Ala Ala Thr Leu Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr 420 425 430 Val Phe Ile Ile Phe Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr 435 440 445 Trp Arg Leu Ser Pro Val Glu Thr Leu Ala Phe Phe Thr Gln Leu Ile 450 455 460 Cys Arg Ala Gly Pro Met Ser 465 470 50 455 PRT Homo sapiens misc_feature (1)..(455 ) Xaa = any amino acid, unknown, or other 50 Met Glu Pro Ser Ser Lys Lys Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55 60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser 65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185 190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro 195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310 315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr 340 345 350 Ile Ala Ala Thr Leu Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr 420 425 430 Val Phe Ile Ile Phe Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr 435 440 445 Thr Tyr Val Leu Arg Thr His 450 455 51 441 PRT Homo sapiens misc_feature (1)..(441 ) Xaa = any amino acid, unknown, or other 51 Met Glu Pro Ser Ser Lys Lys Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55 60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser 65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185 190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro 195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310 315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr 340 345 350 Ile Ala Ala Thr Leu Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val Gly Gly Leu Leu Ser Pro Ala Ser Asn Asp Val Gln Lys Asn 420 425 430 Ile Gln Asp Leu Thr Ala Pro Gly Phe 435 440 52 124 PRT Homo sapiens misc_feature (1)..(124 ) Xaa = any amino acid, unknown, or other 52 Met Phe Phe Val Pro Leu Leu His Phe His Leu His Ser Ser Leu Val 1 5 10 15 Phe Gln Gly Ile Leu Ser Val Met Leu Ile Phe Ala Phe Phe Gln Glu 20 25 30 Leu Val Ile Ala Gly Ile Val Glu Asn Glu Trp Lys Arg Thr Cys Ser 35 40 45 Arg Pro Lys Ser Asn Ile Val Leu Leu Ser Ala Glu Glu Lys Lys Glu 50 55 60 Gln Thr Ile Glu Ile Lys Glu Glu Val Val Gly Leu Thr Glu Thr Ser 65 70 75 80 Ser Gln Pro Lys Asn Glu Glu Asp Ile Glu Ile Ile Pro Ile Gln Glu 85 90 95 Glu Glu Glu Glu Glu Thr Glu Thr Asn Phe Pro Glu Pro Pro Gln Asp 100 105 110 Gln Glu Ser Ser Pro Ile Glu Asn Asp Ser Ser Pro 115 120 53 254 PRT Homo sapiens misc_feature (1)..(254 ) Xaa = any amino acid, unknown, or other 53 Met Glu Leu Leu Cys His Glu Val Asp Pro Val Arg Arg Ala Val Arg 1 5 10 15 Asp Arg Asn Leu Leu Arg Asp Asp Arg Val Leu Gln Asn Leu Leu Thr 20 25 30 Ile Glu Glu Arg Tyr Leu Pro Gln Cys Ser Tyr Phe Lys Cys Val Gln 35 40 45 Lys Asp Ile Gln Pro Tyr Met Arg Arg Met Val Ala Thr Trp Met Leu 50 55 60 Glu Val Cys Glu Glu Gln Lys Cys Glu Glu Glu Val Phe Pro Leu Ala 65 70 75 80 Met Asn Tyr Leu Asp Arg Phe Leu Ala Gly Val Pro Thr Pro Lys Ser 85 90 95 His Leu Gln Leu Leu Gly Ala Val Cys Met Phe Leu Ala Ser Lys Leu 100 105 110 Lys Glu Thr Ser Pro Leu Thr Ala Glu Lys Leu Cys Ile Tyr Thr Asp 115 120 125 Asn Ser Ile Lys Pro Gln Glu Leu Leu Glu Trp Glu Leu Val Val Leu 130 135 140 Gly Lys Leu Lys Trp Asn Leu Ala Ala Val Thr Pro His Asp Phe Ile 145 150 155 160 Glu His Ile Leu Arg Lys Leu Pro Gln Gln Arg Glu Lys Leu Ser Leu 165 170 175 Ile Arg Lys His Ala Gln Thr Phe Ile Ala Leu Cys Ala Thr Ala Gln 180 185 190 Gln Val Gly Gln Gly Lys Gly Lys Gly Cys Asn Gln Glu Met Pro Gln 195 200 205 Glu Arg Leu Arg Gly Val Ser Lys Ser Gln Arg Pro Ala Pro Asp Ser 210 215 220 Ile Ser Ala Ser Phe Arg Val Ala Arg Arg Leu Leu Leu Leu Arg His 225 230 235 240 Val Cys His Val Gln His Ser Ser Gln Thr His Ser Leu Asp 245 250 54 98 PRT Homo sapiens misc_feature (1)..(98 ) Xaa = any amino acid, unknown, or other 54 Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly 1 5 10 15 His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile 20 25 30 Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys 35 40 45 Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val 50 55 60 Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp 65 70 75 80 His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val 85 90 95 Val Gly 55 94 PRT Homo sapiens misc_feature (1)..(94 ) Xaa = any amino acid, unknown, or other 55 Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly 1 5 10 15 His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile 20 25 30 Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys 35 40 45 Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Glu Ile Leu Gly Trp Ser 50 55 60 Ala Val Val Ile Met Ser His Cys Ser Leu Asp Leu Leu Gly Ser Ser 65 70 75 80 His Pro Pro Val Ser Ala Ser Arg Val Ala Gly Thr Thr Gly 85 90 56 548 PRT Homo sapiens misc_feature (1)..(548 ) Xaa = any amino acid, unknown, or other 56 Met Gly Arg Val Pro Leu Ala Trp Cys Leu Ala Leu Cys Gly Trp Ala 1 5 10 15 Cys Met Ala Pro Arg Gly Thr Gln Ala Glu Glu Ser Pro Phe Val Gly 20 25 30 Asn Pro Gly Asn Ile Thr Gly Ala Arg Gly Leu Thr Gly Thr Leu Arg 35 40 45 Cys Gln Leu Gln Val Gln Gly Glu Pro Pro Glu Val His Trp Leu Arg 50 55 60 Asp Gly Gln Ile Leu Glu Leu Ala Asp Ser Thr Gln Thr Gln Val Pro 65 70 75 80 Leu Gly Glu Asp Glu Gln Asp Asp Trp Ile Val Val Ser Gln Leu Arg 85 90 95 Ile Thr Ser Leu Gln Leu Ser Asp Thr Gly Gln Tyr Gln Cys Leu Val 100 105 110 Phe Leu Gly His Gln Thr Phe Val Ser Gln Pro Gly Tyr Val Gly Leu 115 120 125 Glu Gly Leu Pro Tyr Phe Leu Glu Glu Pro Glu Asp Arg Thr Val Ala 130 135 140 Ala Asn Thr Pro Phe Asn Leu Ser Cys Gln Ala Gln Gly Pro Pro Glu 145 150 155 160 Pro Val Asp Leu Leu Trp Leu Gln Asp Ala Val Pro Leu Ala Thr Ala 165 170 175 Pro Gly His Gly Pro Gln Arg Ser Leu His Val Pro Gly Leu Asn Lys 180 185 190 Thr Ser Ser Phe Ser Cys Glu Ala His Asn Ala Lys Gly Val Thr Thr 195 200 205 Ser Arg Thr Ala Thr Ile Thr Val Leu Pro Gln Gln Pro Arg Asn Leu 210 215 220 His Leu Val Ser Arg Gln Pro Thr Glu Leu Glu Val Ala Trp Thr Pro 225 230 235 240 Gly Leu Ser Gly Ile Tyr Pro Leu Thr His Cys Thr Leu Gln Ala Val 245 250 255 Leu Ser Asp Asp Gly Met Gly Ile Gln Ala Gly Glu Pro Asp Pro Pro 260 265 270 Glu Glu Pro Leu Thr Ser Gln Ala Ser Val Pro Pro His Gln Leu Arg 275 280 285 Leu Gly Ser Leu His Pro His Pro Pro Tyr His Ile Arg Val Ala Cys 290 295 300 Thr Ser Ser Gln Gly Pro Ser Ser Trp Thr His Trp Leu Pro Val Glu 305 310 315 320 Thr Pro Glu Gly Val Pro Leu Gly Pro Pro Glu Asn Ile Ser Ala Thr 325 330 335 Arg Asn Gly Ser Gln Ala Phe Val His Trp Gln Glu Pro Arg Ala Pro 340 345 350 Leu Gln Gly Thr Leu Leu Gly Tyr Arg Leu Ala Tyr Gln Gly Gln Asp 355 360 365 Thr Pro Glu Val Leu Met Asp Ile Gly Leu Arg Gln Glu Val Thr Leu 370 375 380 Glu Leu Gln Gly Asp Gly Ser Val Ser Asn Leu Thr Val Cys Val Ala 385 390 395 400 Ala Tyr Thr Ala Ala Gly Asp Gly Pro Trp Ser Leu Pro Val Pro Leu 405 410 415 Glu Ala Trp Arg Pro Gly Glu Ala Gln Pro Val His Gln Leu Val Lys 420 425 430 Glu Pro Ser Thr Pro Ala Phe Ser Trp Pro Trp Trp Tyr Val Leu Leu 435 440 445 Gly Ala Val Val Ala Ala Ala Cys Val Leu Ile Leu Ala Leu Phe Leu 450 455 460 Val His Arg Arg Lys Lys Glu Thr Arg Tyr Gly Glu Val Phe Glu Pro 465 470 475 480 Thr Val Glu Arg Gly Glu Leu Val Val Arg Tyr Arg Val Arg Lys Ser 485 490 495 Tyr Ser Arg Arg Thr Thr Glu Ala Thr Leu Asn Ser Leu Gly Ile Ser 500 505 510 Glu Glu Leu Lys Glu Lys Leu Arg Asp Val Met Val Asp Arg His Lys 515 520 525 Val Ala Leu Gly Lys Thr Leu Gly Glu Gly Glu Ser Pro Gly Ser Ile 530 535 540 His Thr Ser Phe 545 57 617 PRT Homo sapiens misc_feature (1)..(617 ) Xaa = any amino acid, unknown, or other 57 Met Ser Glu Ala Ser Ser Glu Asp Leu Val Pro Pro Leu Glu Ala Gly 1 5 10 15 Ala Ala Pro Tyr Arg Glu Glu Glu Glu Ala Ala Lys Lys Lys Lys Glu 20 25 30 Lys Lys Lys Lys Ser Lys Gly Leu Ala Asn Val Phe Cys Val Phe Thr 35 40 45 Lys Gly Lys Lys Lys Lys Gly Gln Pro Ser Ser Ala Glu Pro Glu Asp 50 55 60 Ala Ala Gly Ser Arg Gln Gly Leu Asp Gly Pro Pro Pro Thr Val Glu 65 70 75 80 Glu Leu Lys Ala Ala Leu Glu Arg Gly Gln Leu Glu Ala Ala Arg Pro 85 90 95 Leu Leu Ala Leu Glu Arg Glu Leu Ala Ala Ala Ala Ala Ala Gly Gly 100 105 110 Val Ser Glu Glu Glu Leu Val Arg Arg Gln Ser Lys Val Glu Ala Leu 115 120 125 Tyr Glu Leu Leu Arg Asp Gln Val Leu Gly Val Leu Arg Arg Pro Leu 130 135 140 Glu Ala Pro Pro Glu Arg Leu Arg Gln Ala Leu Ala Val Val Ala Glu 145 150 155 160 Gln Glu Arg Glu Asp Arg Gln Ala Ala Ala Ala Gly Pro Glu Val Pro 165 170 175 Glu Ser Val Phe Leu His Leu Gly Arg Thr Met Lys Glu Asp Leu Glu 180 185 190 Ala Val Val Glu Arg Leu Lys Pro Leu Phe Pro Ala Glu Phe Gly Val 195 200 205 Val Ala Ala Tyr Ala Glu Ser Tyr His Gln His Phe Ala Ala His Leu 210 215 220 Ala Ala Val Ala Gln Phe Glu Leu Cys Glu Arg Asp Thr Tyr Met Leu 225 230 235 240 Leu Leu Trp Val Gln Asn Leu Tyr Pro Asn Asp Ile Ile Asn Ser Pro 245 250 255 Lys Leu Val Gly Glu Leu Gln Gly Met Gly Leu Gly Ser Leu Leu Pro 260 265 270 Pro Arg Gln Ile Arg Leu Leu Glu Ala Thr Phe Leu Ser Ser Glu Ala 275 280 285 Ala Asn Val Arg Glu Leu Met Asp Arg Ala Leu Glu Leu Glu Ala Arg 290 295 300 Arg Trp Ala Glu Asp Val Pro Pro Gln Arg Leu Asp Gly His Cys His 305 310 315 320 Ser Glu Leu Ala Ile Asp Ile Ile Gln Ile Thr Ser Gln Ala Gln Ala 325 330 335 Lys Ala Glu Ser Ile Thr Leu Asp Leu Gly Ser Gln Ile Lys Arg Val 340 345 350 Leu Leu Val Glu Leu Pro Ala Phe Leu Arg Ser Tyr Gln Arg Ala Phe 355 360 365 Asn Glu Phe Leu Glu Arg Gly Lys Gln Leu Thr Asn Tyr Arg Ala Asn 370 375 380 Val Ile Ala Asn Ile Asn Asn Cys Leu Ser Phe Arg Met Ser Met Glu 385 390 395 400 Gln Asn Trp Gln Val Pro Gln Asp Thr Leu Ser Leu Leu Leu Gly Pro 405 410 415 Leu Gly Glu Leu Lys Ser His Gly Phe Asp Thr Leu Leu Gln Asn Leu 420 425 430 His Glu Asp Leu Lys Pro Leu Phe Lys Arg Phe Thr His Thr Arg Trp 435 440 445 Ala Ala Pro Val Glu Thr Leu Glu Asn Ile Ile Ala Thr Val Asp Thr 450 455 460 Arg Leu Pro Glu Phe Ser Glu Leu Gln Gly Cys Phe Arg Glu Glu Leu 465 470 475 480 Met Glu Ala Leu His Leu His Leu Val Lys Glu Tyr Ile Ile Gln Leu 485 490 495 Ser Lys Gly Arg Leu Val Leu Lys Thr Ala Glu Gln Gln Gln Gln Leu 500 505 510 Ala Gly Tyr Ile Leu Ala Asn Ala Asp Thr Ile Gln His Phe Cys Thr 515 520 525 Gln His Gly Ser Pro Ala Thr Trp Leu Gln Pro Ala Leu Pro Thr Leu 530 535 540 Ala Glu Ile Ile Arg Leu Gln Asp Pro Ser Ala Ile Lys Ile Glu Val 545 550 555 560 Ala Thr Tyr Ala Thr Cys Tyr Pro Asp Phe Ser Lys Gly His Leu Ser 565 570 575 Ala Ile Leu Ala Ile Lys Gly Asn Leu Ser Asn Ser Glu Val Lys Arg 580 585 590 Ile Arg Ser Ile Leu Asp Val Ser Met Gly Ala Gln Glu Pro Ser Arg 595 600 605 Pro Leu Phe Ser Leu Ile Lys Val Gly 610 615 58 1251 PRT Homo sapiens misc_feature (1)..(1251) Xaa = any amino acid, unknown, or other 58 Met Gly Leu Leu Gly Ile Leu Cys Phe Leu Ile Phe Leu Gly Lys Thr 1 5 10 15 Trp Gly Gln Glu Gln Thr Tyr Val Ile Ser Ala Pro Lys Ile Phe Arg 20 25 30 Val Gly Ala Ser Glu Asn Ile Val Ile Gln Val Tyr Gly Tyr Thr Glu 35 40 45 Ala Phe Asp Ala Thr Ile Ser Ile Lys Ser Tyr Pro Asp Lys Lys Phe 50 55 60 Ser Tyr Ser Ser Gly His Val His Leu Ser Ser Glu Asn Lys Phe Gln 65 70 75 80 Asn Ser Ala Ile Leu Thr Ile Gln Pro Lys Gln Leu Pro Gly Gly Gln 85 90 95 Asn Pro Val Ser Tyr Val Tyr Leu Glu Val Val Ser Lys His Phe Ser 100 105 110 Lys Ser Lys Arg Met Pro Ile Thr Tyr Asp Asn Gly Phe Leu Phe Ile 115 120 125 His Thr Asp Lys Pro Val Tyr Thr Pro Asp Gln Ser Val Lys Val Arg 130 135 140 Val Tyr Ser Leu Asn Asp Asp Leu Lys Pro Ala Lys Arg Glu Thr Val 145 150 155 160 Leu Thr Phe Ile Asp Pro Glu Gly Ser Glu Val Asp Met Val Glu Glu 165 170 175 Ile Asp His Ile Gly Ile Ile Ser Phe Pro Asp Phe Lys Ile Pro Ser 180 185 190 Asn Pro Arg Tyr Gly Met Trp Thr Ile Lys Ala Lys Tyr Lys Glu Asp 195 200 205 Phe Ser Thr Thr Gly Thr Ala Tyr Phe Glu Val Lys Glu Tyr Val Leu 210 215 220 Pro His Phe Ser Val Ser Ile Glu Pro Glu Tyr Asn Phe Ile Gly Tyr 225 230 235 240 Lys Asn Phe Lys Asn Phe Glu Ile Thr Ile Lys Ala Arg Tyr Phe Tyr 245 250 255 Asn Lys Val Val Thr Glu Ala Asp Val Tyr Ile Thr Phe Gly Ile Arg 260 265 270 Glu Asp Leu Lys Asp Asp Gln Lys Glu Met Met Gln Thr Ala Met Gln 275 280 285 Asn Thr Met Leu Ile Asn Gly Ile Ala Gln Val Thr Phe Asp Ser Glu 290 295 300 Thr Ala Val Lys Glu Leu Ser Tyr Tyr Ser Leu Glu Asp Leu Asn Asn 305 310 315 320 Lys Tyr Leu Tyr Ile Ala Val Thr Val Ile Glu Ser Thr Gly Gly Phe 325 330 335 Ser Glu Glu Ala Glu Ile Pro Gly Ile Lys Tyr Val Leu Ser Pro Tyr 340 345 350 Lys Leu Asn Leu Val Ala Thr Pro Leu Phe Leu Lys Pro Gly Ile Pro 355 360 365 Tyr Pro Ile Lys Val Gln Val Lys Asp Ser Leu Asp Gln Leu Val Gly 370 375 380 Gly Val Pro Val Ile Leu Asn Ala Gln Thr Ile Asp Val Asn Gln Glu 385 390 395 400 Thr Ser Asp Leu Asp Pro Ser Lys Ser Val Thr Arg Val Asp Asp Gly 405 410 415 Val Ala Ser Phe Val Leu Asn Leu Pro Ser Gly Val Thr Val Leu Glu 420 425 430 Phe Asn Val Lys Thr Asp Ala Pro Asp Leu Pro Glu Glu Asn Gln Ala 435 440 445 Arg Glu Gly Tyr Arg Ala Ile Ala Tyr Ser Ser Leu Ser Gln Ser Tyr 450 455 460 Leu Tyr Ile Asp Trp Thr Asp Asn His Lys Ala Leu Leu Val Gly Glu 465 470 475 480 His Leu Asn Ile Ile Val Thr Pro Lys Ser Pro Tyr Ile Asp Lys Ile 485 490 495 Thr His Tyr Asn Tyr Leu Ile Leu Ser Lys Gly Lys Ile Ile His Phe 500 505 510 Gly Thr Arg Glu Lys Phe Ser Asp Ala Ser Tyr Gln Ser Ile Asn Ile 515 520 525 Pro Val Thr Gln Asn Met Val Pro Ser Ser Arg Leu Leu Val Tyr Tyr 530 535 540 Ile Val Thr Gly Glu Gln Thr Ala Glu Leu Val Ser Asp Ser Val Trp 545 550 555 560 Leu Asn Ile Glu Glu Lys Cys Gly Asn Gln Leu Gln Val His Leu Ser 565 570 575 Pro Asp Ala Asp Ala Tyr Ser Pro Gly Gln Thr Val Ser Leu Asn Met 580 585 590 Ala Thr Gly Met Asp Ser Trp Val Ala Leu Ala Ala Val Asp Ser Ala 595 600 605 Val Tyr Gly Val Gln Arg Gly Ala Lys Lys Pro Leu Glu Arg Val Phe 610 615 620 Gln Phe Leu Glu Lys Ser Asp Leu Gly Cys Gly Ala Gly Gly Gly Leu 625 630 635 640 Asn Asn Ala Asn Val Phe His Leu Ala Gly Leu Thr Phe Leu Thr Asn 645 650 655 Ala Asn Ala Asp Asp Ser Gln Glu Asn Asp Glu Pro Cys Lys Glu Ile 660 665 670 Leu Arg Pro Arg Arg Thr Leu Gln Lys Lys Ile Glu Glu Ile Ala Ala 675 680 685 Lys Tyr Lys His Ser Val Val Lys Lys Cys Cys Tyr Asp Gly Ala Cys 690 695 700 Val Asn Asn Asp Glu Thr Cys Glu Gln Arg Ala Ala Arg Ile Ser Leu 705 710 715 720 Gly Pro Arg Cys Ile Lys Ala Phe Thr Glu Cys Cys Val Val Ala Ser 725 730 735 Gln Leu Arg Ala Asn Ile Ser His Lys Asp Met Gln Leu Gly Arg Leu 740 745 750 His Met Lys Thr Leu Leu Pro Val Ser Lys Pro Glu Ile Arg Ser Tyr 755 760 765 Phe Pro Glu Ser Trp Leu Trp Glu Val His Leu Val Pro Arg Arg Lys 770 775 780 Gln Leu Gln Phe Ala Leu Pro Asp Ser Leu Thr Thr Trp Glu Ile Gln 785 790 795 800 Gly Ile Gly Ile Ser Asn Thr Gly Ile Cys Val Ala Asp Thr Val Lys 805 810 815 Ala Lys Val Phe Lys Asp Val Phe Leu Glu Met Asn Ile Pro Tyr Ser 820 825 830 Val Val Arg Gly Glu Gln Ile Gln Leu Lys Gly Thr Val Tyr Asn Tyr 835 840 845 Arg Thr Ser Gly Met Gln Phe Cys Val Lys Met Ser Ala Val Glu Gly 850 855 860 Ile Cys Thr Ser Glu Ser Pro Val Ile Asp His Gln Gly Thr Lys Ser 865 870 875 880 Ser Lys Cys Val Arg Gln Lys Val Glu Gly Ser Ser Ser His Leu Val 885 890 895 Thr Phe Thr Val Leu Pro Leu Glu Ile Gly Leu His Asn Ile Asn Phe 900 905 910 Ser Leu Glu Thr Trp Phe Gly Lys Glu Ile Leu Val Lys Thr Leu Arg 915 920 925 Val Val Pro Glu Gly Val Lys Arg Glu Ser Tyr Ser Gly Val Thr Leu 930 935 940 Asp Pro Arg Gly Ile Tyr Gly Thr Ile Ser Arg Arg Lys Glu Phe Pro 945 950 955 960 Tyr Arg Ile Pro Leu Asp Leu Val Pro Lys Thr Glu Ile Lys Arg Ile 965 970 975 Leu Ser Val Lys Gly Leu Leu Val Gly Glu Ile Leu Ser Ala Val Leu 980 985 990 Ser Gln Glu Gly Ile Asn Ile Leu Thr His Leu Pro Lys Gly Ser Ala 995 1000 1005 Glu Ala Glu Leu Met Ser Val Val Pro Val Phe Tyr Val Phe His Tyr 1010 1015 1020 Leu Glu Thr Gly Asn His Trp Asn Ile Phe His Ser Asp Pro Leu Ile 1025 1030 1035 1040 Glu Lys Gln Lys Leu Lys Lys Lys Leu Lys Glu Gly Met Leu Ser Ile 1045 1050 1055 Met Ser Tyr Arg Asn Ala Asp Tyr Ser Tyr Ser Val Trp Lys Gly Gly 1060 1065 1070 Ser Ala Ser Thr Trp Leu Thr Ala Phe Ala Leu Arg Val Leu Gly Gln 1075 1080 1085 Val Asn Lys Tyr Val Glu Gln Asn Gln Asn Ser Ile Cys Asn Ser Leu 1090 1095 1100 Leu Trp Leu Val Glu Asn Tyr Gln Leu Asp Asn Gly Ser Phe Lys Glu 1105 1110 1115 1120 Asn Ser Gln Tyr Gln Pro Ile Lys Leu Gln Gly Thr Leu Pro Val Glu 1125 1130 1135 Ala Arg Glu Asn Ser Leu Tyr Leu Thr Ala Phe Thr Val Ile Gly Ile 1140 1145 1150 Arg Lys Ala Phe Asp Ile Cys Pro Leu Val Lys Ile Asp Thr Ala Leu 1155 1160 1165 Ile Lys Ala Asp Asn Phe Leu Leu Glu Asn Thr Leu Pro Ala Gln Ser 1170 1175 1180 Thr Phe Thr Leu Ala Ile Ser Ala Tyr Ala Leu Ser Leu Gly Asp Lys 1185 1190 1195 1200 Thr His Pro Gln Phe Arg Ser Ile Val Ser Ala Leu Lys Arg Glu Ala 1205 1210 1215 Leu Val Lys Asp Thr Ser Leu Thr Val Phe Pro Arg Met Ile Ser Asn 1220 1225 1230 Ala Trp Ala Gln Ala Leu Leu Leu Pro Gln Pro Ser Lys Val Leu Gly 1235 1240 1245 Ser Gln Ala 1250 59 1602 PRT Homo sapiens misc_feature (1)..(1602) Xaa = any amino acid, unknown, or other 59 Met Gly Leu Leu Gly Ile Leu Cys Phe Leu Ile Phe Leu Gly Lys Thr 1 5 10 15 Trp Gly Gln Glu Gln Thr Tyr Val Ile Ser Ala Pro Lys Ile Phe Arg 20 25 30 Val Gly Ala Ser Glu Asn Ile Val Ile Gln Val Tyr Gly Tyr Thr Glu 35 40 45 Ala Phe Asp Ala Thr Ile Ser Ile Lys Ser Tyr Pro Asp Lys Lys Phe 50 55 60 Ser Tyr Ser Ser Gly His Val His Leu Ser Ser Glu Asn Lys Phe Gln 65 70 75 80 Asn Ser Ala Ile Leu Thr Ile Gln Pro Lys Gln Leu Pro Gly Gly Gln 85 90 95 Asn Pro Val Ser Tyr Val Tyr Leu Glu Val Val Ser Lys His Phe Ser 100 105 110 Lys Ser Lys Arg Met Pro Ile Thr Tyr Asp Asn Gly Phe Leu Phe Ile 115 120 125 His Thr Asp Lys Pro Val Tyr Thr Pro Asp Gln Ser Val Lys Val Arg 130 135 140 Val Tyr Ser Leu Asn Asp Asp Leu Lys Pro Ala Lys Arg Glu Thr Val 145 150 155 160 Leu Thr Phe Ile Asp Pro Glu Gly Ser Glu Val Asp Met Val Glu Glu 165 170 175 Ile Asp His Ile Gly Ile Ile Ser Phe Pro Asp Phe Lys Ile Pro Ser 180 185 190 Asn Pro Arg Tyr Gly Met Trp Thr Ile Lys Ala Lys Tyr Lys Glu Asp 195 200 205 Phe Ser Thr Thr Gly Thr Ala Tyr Phe Glu Val Lys Glu Tyr Val Leu 210 215 220 Pro His Phe Ser Val Ser Ile Glu Pro Glu Tyr Asn Phe Ile Gly Tyr 225 230 235 240 Lys Asn Phe Lys Asn Phe Glu Ile Thr Ile Lys Ala Arg Tyr Phe Tyr 245 250 255 Asn Lys Val Val Thr Glu Ala Asp Val Tyr Ile Thr Phe Gly Ile Arg 260 265 270 Glu Asp Leu Lys Asp Asp Gln Lys Glu Met Met Gln Thr Ala Met Gln 275 280 285 Asn Thr Met Leu Ile Asn Gly Ile Ala Gln Val Thr Phe Asp Ser Glu 290 295 300 Thr Ala Val Lys Glu Leu Ser Tyr Tyr Ser Leu Glu Asp Leu Asn Asn 305 310 315 320 Lys Tyr Leu Tyr Ile Ala Val Thr Val Ile Glu Ser Thr Gly Gly Phe 325 330 335 Ser Glu Glu Ala Glu Ile Pro Gly Ile Lys Tyr Val Leu Ser Pro Tyr 340 345 350 Lys Leu Asn Leu Val Ala Thr Pro Leu Phe Leu Lys Pro Gly Ile Pro 355 360 365 Tyr Pro Ile Lys Val Gln Val Lys Asp Ser Leu Asp Gln Leu Val Gly 370 375 380 Gly Val Pro Val Ile Leu Asn Ala Gln Thr Ile Asp Val Asn Gln Glu 385 390 395 400 Thr Ser Asp Leu Asp Pro Ser Lys Ser Val Thr Arg Val Asp Asp Gly 405 410 415 Val Ala Ser Phe Val Leu Asn Leu Pro Ser Gly Val Thr Val Leu Glu 420 425 430 Phe Asn Val Lys Thr Asp Ala Pro Asp Leu Pro Glu Glu Asn Gln Ala 435 440 445 Arg Glu Gly Tyr Arg Ala Ile Ala Tyr Ser Ser Leu Ser Gln Ser Tyr 450 455 460 Leu Tyr Ile Asp Trp Thr Asp Asn His Lys Ala Leu Leu Val Gly Glu 465 470 475 480 His Leu Asn Ile Ile Val Thr Pro Lys Ser Pro Tyr Ile Asp Lys Ile 485 490 495 Thr His Tyr Asn Tyr Leu Ile Leu Ser Lys Gly Lys Ile Ile His Phe 500 505 510 Gly Thr Arg Glu Lys Phe Ser Asp Ala Ser Tyr Gln Ser Ile Asn Ile 515 520 525 Pro Val Thr Gln Asn Met Val Pro Ser Ser Arg Leu Leu Val Tyr Tyr 530 535 540 Ile Val Thr Gly Glu Gln Thr Ala Glu Leu Val Ser Asp Ser Val Trp 545 550 555 560 Leu Asn Ile Glu Glu Lys Cys Gly Asn Gln Leu Gln Val His Leu Ser 565 570 575 Pro Asp Ala Asp Ala Tyr Ser Pro Gly Gln Thr Val Ser Leu Asn Met 580 585 590 Ala Thr Gly Met Asp Ser Trp Val Ala Leu Ala Ala Val Asp Ser Ala 595 600 605 Val Tyr Gly Val Gln Arg Gly Ala Lys Lys Pro Leu Glu Arg Val Phe 610 615 620 Gln Phe Leu Glu Lys Ser Asp Leu Gly Cys Gly Ala Gly Gly Gly Leu 625 630 635 640 Asn Asn Ala Asn Val Phe His Leu Ala Gly Leu Thr Phe Leu Thr Asn 645 650 655 Ala Asn Ala Asp Asp Ser Gln Glu Asn Asp Glu Pro Cys Lys Glu Ile 660 665 670 Leu Arg Pro Arg Arg Thr Leu Gln Lys Lys Ile Glu Glu Ile Ala Ala 675 680 685 Lys Tyr Lys His Ser Val Val Lys Lys Cys Cys Tyr Asp Gly Ala Cys 690 695 700 Val Asn Asn Asp Glu Thr Cys Glu Gln Arg Ala Ala Arg Ile Ser Leu 705 710 715 720 Gly Pro Arg Cys Ile Lys Ala Phe Thr Glu Cys Cys Val Val Ala Ser 725 730 735 Gln Leu Arg Ala Asn Ile Ser His Lys Asp Met Gln Leu Gly Arg Leu 740 745 750 His Met Lys Thr Leu Leu Pro Val Ser Lys Pro Glu Ile Arg Ser Tyr 755 760 765 Phe Pro Glu Ser Trp Leu Trp Glu Val His Leu Val Pro Arg Arg Lys 770 775 780 Gln Leu Gln Phe Ala Leu Pro Asp Ser Leu Thr Thr Trp Glu Ile Gln 785 790 795 800 Gly Ile Gly Ile Ser Asn Thr Gly Ile Cys Val Ala Asp Thr Val Lys 805 810 815 Ala Lys Val Phe Lys Asp Val Phe Leu Glu Met Asn Ile Pro Tyr Ser 820 825 830 Val Val Arg Gly Glu Gln Ile Gln Leu Lys Gly Thr Val Tyr Asn Tyr 835 840 845 Arg Thr Ser Gly Met Gln Phe Cys Val Lys Met Ser Ala Val Glu Gly 850 855 860 Ile Cys Thr Ser Glu Ser Pro Val Ile Asp His Gln Gly Thr Lys Ser 865 870 875 880 Ser Lys Cys Val Arg Gln Lys Val Glu Gly Ser Ser Ser His Leu Val 885 890 895 Thr Phe Thr Val Leu Pro Leu Glu Ile Gly Leu His Asn Ile Asn Phe 900 905 910 Ser Leu Glu Thr Trp Phe Gly Lys Glu Ile Leu Val Lys Thr Leu Arg 915 920 925 Val Val Pro Glu Gly Val Lys Arg Glu Ser Tyr Ser Gly Val Thr Leu 930 935 940 Asp Pro Arg Gly Ile Tyr Gly Thr Ile Ser Arg Arg Lys Glu Phe Pro 945 950 955 960 Tyr Arg Ile Pro Leu Asp Leu Val Pro Lys Thr Glu Ile Lys Arg Ile 965 970 975 Leu Ser Val Lys Gly Leu Leu Val Gly Glu Ile Leu Ser Ala Val Leu 980 985 990 Ser Gln Glu Gly Ile Asn Ile Leu Thr His Leu Pro Lys Gly Ser Ala 995 1000 1005 Glu Ala Glu Leu Met Ser Val Val Pro Val Phe Tyr Val Phe His Tyr 1010 1015 1020 Leu Glu Thr Gly Asn His Trp Asn Ile Phe His Ser Asp Pro Leu Ile 1025 1030 1035 1040 Glu Lys Gln Lys Leu Lys Lys Lys Leu Lys Glu Gly Met Leu Ser Ile 1045 1050 1055 Met Ser Tyr Arg Asn Ala Asp Tyr Ser Tyr Ser Val Trp Lys Gly Gly 1060 1065 1070 Ser Ala Ser Thr Trp Leu Thr Ala Phe Ala Leu Arg Val Leu Gly Gln 1075 1080 1085 Val Asn Lys Tyr Val Glu Gln Asn Gln Asn Ser Ile Cys Asn Ser Leu 1090 1095 1100 Leu Trp Leu Val Glu Asn Tyr Gln Leu Asp Asn Gly Ser Phe Lys Glu 1105 1110 1115 1120 Asn Ser Gln Tyr Gln Pro Ile Lys Leu Gln Gly Thr Leu Pro Val Glu 1125 1130 1135 Ala Arg Glu Asn Ser Leu Tyr Leu Thr Ala Phe Thr Val Ile Gly Ile 1140 1145 1150 Arg Lys Ala Phe Asp Ile Cys Pro Leu Val Lys Ile Asp Thr Ala Leu 1155 1160 1165 Ile Lys Ala Asp Asn Phe Leu Leu Glu Asn Thr Leu Pro Ala Gln Ser 1170 1175 1180 Thr Phe Thr Leu Ala Ile Ser Ala Tyr Ala Leu Ser Leu Gly Asp Lys 1185 1190 1195 1200 Thr His Pro Gln Phe Arg Ser Ile Val Ser Ala Leu Lys Arg Glu Ala 1205 1210 1215 Leu Val Lys Gly Asn Pro Pro Ile Tyr Arg Phe Trp Lys Asp Asn Leu 1220 1225 1230 Gln His Lys Asp Ser Ser Val Pro Asn Thr Gly Thr Ala Arg Met Val 1235 1240 1245 Glu Thr Thr Ala Tyr Ala Leu Leu Thr Ser Leu Asn Leu Lys Asp Ile 1250 1255 1260 Asn Tyr Val Asn Pro Val Ile Lys Trp Leu Ser Glu Glu Gln Arg Tyr 1265 1270 1275 1280 Gly Gly Gly Phe Tyr Ser Thr Gln Asp Thr Ile Asn Ala Ile Glu Gly 1285 1290 1295 Leu Thr Glu Tyr Ser Leu Leu Val Lys Gln Leu Arg Leu Ser Met Asp 1300 1305 1310 Ile Asp Val Ser Tyr Lys His Lys Gly Ala Leu His Asn Tyr Lys Met 1315 1320 1325 Thr Asp Lys Asn Phe Leu Gly Arg Pro Val Glu Val Leu Leu Asn Asp 1330 1335 1340 Asp Leu Ile Val Ser Thr Gly Phe Gly Ser Gly Leu Ala Thr Val His 1345 1350 1355 1360 Val Thr Thr Val Val His Lys Thr Ser Thr Ser Glu Glu Val Cys Ser 1365 1370 1375 Phe Tyr Leu Lys Ile Asp Thr Gln Asp Ile Glu Ala Ser His Tyr Arg 1380 1385 1390 Gly Tyr Gly Asn Ser Asp Tyr Lys Arg Ile Val Ala Cys Ala Ser Tyr 1395 1400 1405 Lys Pro Ser Arg Glu Glu Ser Ser Ser Gly Ser Ser His Ala Val Met 1410 1415 1420 Asp Ile Ser Leu Pro Thr Gly Ile Ser Ala Asn Glu Glu Asp Leu Lys 1425 1430 1435 1440 Ala Leu Val Glu Gly Val Asp Gln Leu Phe Thr Asp Tyr Gln Ile Lys 1445 1450 1455 Asp Gly His Val Ile Leu Gln Leu Asn Ser Ile Pro Ser Ser Asp Phe 1460 1465 1470 Leu Cys Val Arg Phe Arg Ile Phe Glu Leu Phe Glu Val Gly Phe Leu 1475 1480 1485 Ser Pro Ala Thr Phe Thr Val Tyr Glu Tyr His Arg Pro Asp Lys Gln 1490 1495 1500 Cys Thr Met Phe Tyr Ser Thr Ser Asn Ile Lys Ile Gln Lys Val Cys 1505 1510 1515 1520 Glu Gly Ala Ala Cys Lys Cys Val Glu Ala Asp Cys Gly Gln Met Gln 1525 1530 1535 Glu Glu Leu Asp Leu Thr Ile Ser Ala Glu Thr Arg Lys Gln Thr Ala 1540 1545 1550 Cys Lys Pro Glu Ile Ala Tyr Ala Tyr Lys Val Ser Ile Thr Ser Ile 1555 1560 1565 Thr Val Glu Asn Val Phe Val Lys Tyr Lys Ala Thr Leu Leu Asp Ile 1570 1575 1580 Tyr Lys Thr Gly Glu Asn Ser Phe Val His Ser Phe Leu His Ser Ala 1585 1590 1595 1600 Thr Ile 60 278 PRT Homo sapiens misc_feature (1)..(278 ) Xaa = any amino acid, unknown, or other 60 Met Leu Leu Leu Pro Phe Gln Leu Leu Ala Val Leu Phe Pro Gly Gly 1 5 10 15 Asn Ser Glu His Ala Phe Gln Gly Pro Thr Ser Phe His Val Ile Gln 20 25 30 Thr Ser Ser Phe Thr Asn Ser Thr Trp Ala Gln Thr Gln Gly Ser Gly 35 40 45 Trp Leu Asp Asp Leu Gln Ile His Gly Trp Asp Ser Asp Ser Gly Thr 50 55 60 Ala Ile Phe Leu Lys Pro Trp Ser Lys Gly Asn Phe Ser Asp Lys Glu 65 70 75 80 Val Ala Glu Leu Glu Glu Ile Phe Arg Val Tyr Ile Phe Gly Phe Ala 85 90 95 Arg Glu Val Gln Asp Phe Ala Gly Asp Phe Gln Met Lys Tyr Pro Phe 100 105 110 Glu Ile Gln Gly Ile Ala Gly Cys Glu Leu His Ser Gly Gly Ala Ile 115 120 125 Val Ser Phe Leu Arg Gly Ala Leu Gly Gly Leu Asp Phe Leu Ser Val 130 135 140 Lys Asn Ala Ser Cys Val Pro Ser Pro Glu Gly Gly Ser Arg Ala Gln 145 150 155 160 Lys Phe Cys Ala Leu Ile Ile Gln Tyr Gln Gly Ile Met Glu Thr Val 165 170 175 Arg Ile Leu Leu Tyr Glu Thr Cys Pro Arg Tyr Leu Leu Gly Val Leu 180 185 190 Asn Ala Gly Lys Ala Asp Leu Gln Arg Gln Val Lys Pro Glu Ala Trp 195 200 205 Leu Ser Ser Gly Pro Ser Pro Gly Pro Gly Arg Leu Gln Leu Val Cys 210 215 220 His Val Ser Gly Phe Tyr Pro Lys Pro Val Trp Val Met Trp Met Arg 225 230 235 240 Gly Asn Pro Thr Ser Ile Gly Ser Ile Val Leu Ala Ile Ile Val Pro 245 250 255 Ser Leu Leu Leu Leu Leu Cys Leu Ala Leu Trp Tyr Met Arg Arg Arg 260 265 270 Ser Tyr Gln Asn Ile Pro 275 61 2167 PRT Homo sapiens misc_feature (1)..(2167) Xaa = any amino acid, unknown, or other 61 Met Gly Ala Met Thr Gln Leu Leu Ala Gly Val Phe Leu Ala Phe Leu 1 5 10 15 Ala Leu Ala Thr Glu Gly Gly Val Leu Lys Lys Val Ile Arg His Lys 20 25 30 Arg Gln Ser Gly Val Asn Ala Thr Leu Pro Glu Glu Asn Gln Pro Val 35 40 45 Val Phe Asn His Val Tyr Asn Ile Lys Leu Pro Val Gly Ser Gln Cys 50 55 60 Ser Val Asp Leu Glu Ser Ala Ser Gly Glu Lys Asp Leu Ala Pro Pro 65 70 75 80 Ser Glu Pro Ser Glu Ser Phe Gln Glu His Thr Val Asp Gly Glu Asn 85 90 95 Gln Ile Val Phe Thr His Arg Ile Asn Ile Pro Arg Arg Ala Cys Gly 100 105 110 Cys Ala Ala Ala Pro Asp Val Lys Glu Leu Leu Ser Arg Leu Glu Glu 115 120 125 Leu Glu Asn Leu Val Ser Ser Leu Arg Glu Gln Cys Thr Ala Gly Ala 130 135 140 Gly Cys Cys Leu Gln Pro Ala Thr Gly Arg Leu Asp Thr Arg Pro Phe 145 150 155 160 Cys Ser Gly Arg Gly Asn Phe Ser Thr Glu Gly Cys Gly Cys Val Cys 165 170 175 Glu Pro Gly Trp Lys Gly Pro Asn Cys Ser Glu Pro Glu Cys Pro Gly 180 185 190 Asn Cys His Leu Arg Gly Arg Cys Ile Asp Gly Gln Cys Ile Cys Asp 195 200 205 Asp Gly Phe Thr Gly Glu Asp Cys Ser Gln Leu Ala Cys Pro Ser Asp 210 215 220 Cys Asn Asp Gln Gly Lys Cys Val Asn Gly Val Cys Ile Cys Phe Glu 225 230 235 240 Gly Tyr Ala Gly Ala Asp Cys Ser Arg Glu Ile Cys Pro Val Pro Cys 245 250 255 Ser Glu Glu His Gly Thr Cys Val Asp Gly Leu Cys Val Cys His Asp 260 265 270 Gly Phe Ala Gly Asp Asp Cys Asn Lys Pro Leu Cys Leu Asn Asn Cys 275 280 285 Tyr Asn Arg Gly Arg Cys Val Glu Asn Glu Cys Val Cys Asp Glu Gly 290 295 300 Phe Thr Gly Glu Asp Cys Ser Glu Leu Ile Cys Pro Asn Asp Cys Phe 305 310 315 320 Asp Arg Gly Arg Cys Ile Asn Gly Thr Cys Tyr Cys Glu Glu Gly Phe 325 330 335 Thr Gly Glu Asp Cys Gly Lys Pro Thr Cys Pro His Ala Cys His Thr 340 345 350 Gln Gly Arg Cys Glu Glu Gly Gln Cys Val Cys Asp Glu Gly Phe Ala 355 360 365 Gly Val Asp Cys Ser Glu Lys Arg Cys Pro Ala Asp Cys His Asn Arg 370 375 380 Gly Arg Cys Val Asp Gly Arg Cys Glu Cys Asp Asp Gly Phe Thr Gly 385 390 395 400 Ala Asp Cys Gly Glu Leu Lys Cys Pro Asn Gly Cys Ser Gly His Gly 405 410 415 Arg Cys Val Asn Gly Gln Cys Val Cys Asp Glu Gly Tyr Thr Gly Glu 420 425 430 Asp Cys Ser Gln Leu Arg Cys Pro Asn Asp Cys His Ser Arg Gly Arg 435 440 445 Cys Val Glu Gly Lys Cys Val Cys Glu Gln Gly Phe Lys Gly Tyr Asp 450 455 460 Cys Ser Asp Met Ser Cys Pro Asn Asp Cys His Gln His Gly Arg Cys 465 470 475 480 Val Asn Gly Met Cys Val Cys Asp Asp Gly Tyr Thr Gly Glu Asp Cys 485 490 495 Arg Asp Arg Gln Cys Pro Arg Asp Cys Ser Asn Arg Gly Leu Cys Val 500 505 510 Asp Gly Gln Cys Val Cys Glu Asp Gly Phe Thr Gly Pro Asp Cys Ala 515 520 525 Glu Leu Ser Cys Pro Asn Asp Cys His Gly Gln Gly Arg Cys Val Asn 530 535 540 Gly Gln Cys Val Cys His Glu Gly Phe Met Gly Lys Asp Cys Lys Glu 545 550 555 560 Gln Arg Cys Pro Ser Asp Cys His Gly Gln Gly Arg Cys Val Asp Gly 565 570 575 Gln Cys Ile Cys His Glu Gly Phe Thr Gly Leu Asp Cys Gly Gln His 580 585 590 Ser Cys Pro Ser Asp Cys Asn Asn Leu Gly Gln Cys Val Ser Gly Arg 595 600 605 Cys Ile Cys Asn Glu Gly Tyr Ser Gly Glu Asp Cys Ser Glu Val Ser 610 615 620 Pro Pro Lys Asp Leu Val Val Thr Glu Val Thr Glu Glu Thr Val Asn 625 630 635 640 Leu Ala Trp Asp Asn Glu Met Arg Val Thr Glu Tyr Leu Val Val Tyr 645 650 655 Thr Pro Thr His Glu Gly Gly Leu Glu Met Gln Phe Arg Val Pro Gly 660 665 670 Asp Gln Thr Ser Thr Ile Ile Gln Glu Leu Glu Pro Gly Val Glu Tyr 675 680 685 Phe Ile Arg Val Phe Ala Ile Leu Glu Asn Lys Lys Ser Ile Pro Val 690 695 700 Ser Ala Arg Val Ala Thr Tyr Leu Pro Ala Pro Glu Gly Leu Lys Phe 705 710 715 720 Lys Ser Ile Lys Glu Thr Ser Val Glu Val Glu Trp Asp Pro Leu Asp 725 730 735 Ile Ala Phe Glu Thr Trp Glu Ile Ile Phe Arg Asn Met Asn Lys Glu 740 745 750 Asp Glu Gly Glu Ile Thr Lys Ser Leu Arg Arg Pro Glu Thr Ser Tyr 755 760 765 Arg Gln Thr Gly Leu Ala Pro Gly Gln Glu Tyr Glu Ile Ser Leu His 770 775 780 Ile Val Lys Asn Asn Thr Arg Gly Pro Gly Leu Lys Arg Val Thr Thr 785 790 795 800 Thr Arg Leu Asp Ala Pro Ser Gln Ile Glu Val Lys Asp Val Thr Asp 805 810 815 Thr Thr Ala Leu Ile Thr Trp Phe Lys Pro Leu Ala Glu Ile Asp Gly 820 825 830 Ile Glu Leu Thr Tyr Gly Ile Lys Asp Val Pro Gly Asp Arg Thr Thr 835 840 845 Ile Asp Leu Thr Glu Asp Glu Asn Gln Tyr Ser Ile Gly Asn Leu Lys 850 855 860 Pro Asp Thr Glu Tyr Glu Val Ser Leu Ile Ser Arg Arg Gly Asp Met 865 870 875 880 Ser Ser Asn Pro Ala Lys Glu Thr Phe Thr Thr Gly Leu Asp Ala Pro 885 890 895 Arg Asn Leu Arg Arg Val Ser Gln Thr Asp Asn Ser Ile Thr Leu Glu 900 905 910 Trp Arg Asn Gly Lys Ala Ala Ile Asp Ser Tyr Arg Ile Lys Tyr Ala 915 920 925 Pro Ile Ser Gly Gly Asp His Ala Glu Val Asp Val Pro Lys Ser Gln 930 935 940 Gln Ala Thr Thr Lys Thr Thr Leu Thr Gly Leu Arg Pro Gly Thr Glu 945 950 955 960 Tyr Gly Ile Gly Val Ser Ala Val Lys Glu Asp Lys Glu Ser Asn Pro 965 970 975 Ala Thr Ile Asn Ala Ala Thr Glu Leu Asp Thr Pro Lys Asp Leu Gln 980 985 990 Val Ser Glu Thr Ala Glu Thr Ser Leu Thr Leu Leu Trp Lys Thr Pro 995 1000 1005 Leu Ala Lys Phe Asp Arg Tyr Arg Leu Asn Tyr Ser Leu Pro Thr Gly 1010 1015 1020 Gln Trp Val Gly Val Gln Leu Pro Arg Asn Thr Thr Ser Tyr Val Leu 1025 1030 1035 1040 Arg Gly Leu Glu Pro Gly Gln Glu Tyr Asn Val Leu Leu Thr Ala Glu 1045 1050 1055 Lys Gly Arg His Lys Ser Lys Pro Ala Arg Val Lys Ala Ser Thr Glu 1060 1065 1070 Gln Ala Pro Glu Leu Glu Asn Leu Thr Val Thr Glu Val Gly Trp Asp 1075 1080 1085 Gly Leu Arg Leu Asn Trp Thr Ala Ala Asp Gln Ala Tyr Glu His Phe 1090 1095 1100 Ile Ile Gln Val Gln Glu Ala Asn Lys Val Glu Ala Ala Arg Asn Leu 1105 1110 1115 1120 Thr Val Pro Gly Ser Leu Arg Ala Val Asp Ile Pro Gly Leu Lys Ala 1125 1130 1135 Ala Thr Pro Tyr Thr Val Ser Ile Tyr Gly Val Ile Gln Gly Tyr Arg 1140 1145 1150 Thr Pro Val Leu Ser Ala Glu Ala Ser Thr Gly Glu Thr Pro Asn Leu 1155 1160 1165 Gly Glu Val Val Val Ala Glu Val Gly Trp Asp Ala Leu Lys Leu Asn 1170 1175 1180 Trp Thr Ala Pro Glu Gly Ala Tyr Glu Tyr Phe Phe Ile Gln Val Gln 1185 1190 1195 1200 Glu Ala Asp Thr Val Glu Ala Ala Gln Asn Leu Thr Val Pro Gly Gly 1205 1210 1215 Leu Arg Ser Thr Asp Leu Pro Gly Leu Lys Ala Ala Thr His Tyr Thr 1220 1225 1230 Ile Thr Ile Arg Gly Val Thr Gln Asp Phe Ser Thr Thr Pro Leu Ser 1235 1240 1245 Val Glu Val Leu Thr Glu Glu Val Pro Asp Met Gly Asn Leu Thr Val 1250 1255 1260 Thr Glu Val Ser Trp Asp Ala Leu Arg Leu Asn Trp Thr Thr Pro Asp 1265 1270 1275 1280 Gly Thr Tyr Asp Gln Phe Thr Ile Gln Val Gln Glu Ala Asp Gln Val 1285 1290 1295 Glu Glu Ala His Asn Leu Thr Val Pro Gly Ser Leu Arg Ser Met Glu 1300 1305 1310 Ile Pro Gly Leu Arg Ala Gly Thr Pro Tyr Thr Val Thr Leu His Gly 1315 1320 1325 Glu Val Arg Gly His Ser Thr Arg Pro Leu Ala Val Glu Val Val Thr 1330 1335 1340 Glu Asp Leu Pro Gln Leu Gly Asp Leu Ala Val Ser Glu Val Gly Trp 1345 1350 1355 1360 Asp Gly Leu Arg Leu Asn Trp Thr Ala Ala Asp Asn Ala Tyr Glu His 1365 1370 1375 Phe Val Ile Gln Val Gln Glu Val Asn Lys Val Glu Ala Ala Gln Asn 1380 1385 1390 Leu Thr Leu Pro Gly Ser Leu Arg Ala Val Asp Ile Pro Gly Leu Glu 1395 1400 1405 Ala Ala Thr Pro Tyr Arg Val Ser Ile Tyr Gly Val Ile Arg Gly Tyr 1410 1415 1420 Arg Thr Pro Val Leu Ser Ala Glu Ala Ser Thr Ala Lys Glu Pro Glu 1425 1430 1435 1440 Ile Gly Asn Leu Asn Val Ser Asp Ile Thr Pro Glu Ser Phe Asn Leu 1445 1450 1455 Ser Trp Met Ala Thr Asp Gly Ile Phe Glu Thr Phe Thr Ile Glu Ile 1460 1465 1470 Ile Asp Ser Asn Arg Leu Leu Glu Thr Val Glu Tyr Asn Ile Ser Gly 1475 1480 1485 Ala Glu Arg Thr Ala His Ile Ser Gly Leu Pro Pro Ser Thr Asp Phe 1490 1495 1500 Ile Val Tyr Leu Ser Gly Leu Ala Pro Ser Ile Arg Thr Lys Thr Ile 1505 1510 1515 1520 Ser Ala Thr Ala Thr Thr Glu Ala Leu Pro Leu Leu Glu Asn Leu Thr 1525 1530 1535 Ile Ser Asp Ile Asn Pro Tyr Gly Phe Thr Val Ser Trp Met Ala Ser 1540 1545 1550 Glu Asn Ala Phe Asp Ser Phe Leu Val Thr Val Val Asp Ser Gly Lys 1555 1560 1565 Leu Leu Asp Pro Gln Glu Phe Thr Leu Ser Gly Thr Gln Arg Lys Leu 1570 1575 1580 Glu Leu Arg Gly Leu Ile Thr Gly Ile Gly Tyr Glu Val Met Val Ser 1585 1590 1595 1600 Gly Phe Thr Gln Gly His Gln Thr Lys Pro Leu Arg Ala Glu Ile Val 1605 1610 1615 Thr Glu Ala Glu Pro Glu Val Asp Asn Leu Leu Val Ser Asp Ala Thr 1620 1625 1630 Pro Asp Gly Phe Arg Leu Ser Trp Thr Ala Asp Glu Gly Val Phe Asp 1635 1640 1645 Asn Phe Val Leu Lys Ile Arg Asp Thr Lys Lys Gln Ser Glu Pro Leu 1650 1655 1660 Glu Ile Thr Leu Leu Ala Pro Glu Arg Thr Arg Asp Leu Thr Gly Leu 1665 1670 1675 1680 Arg Glu Ala Thr Glu Tyr Glu Ile Glu Leu Tyr Gly Ile Ser Lys Gly 1685 1690 1695 Arg Arg Ser Gln Thr Val Ser Ala Ile Ala Thr Thr Ala Met Gly Ser 1700 1705 1710 Pro Lys Glu Val Ile Phe Ser Asp Ile Thr Glu Asn Ser Ala Thr Val 1715 1720 1725 Ser Trp Arg Ala Pro Thr Ala Gln Val Glu Ser Phe Arg Ile Thr Tyr 1730 1735 1740 Val Pro Ile Thr Gly Gly Thr Pro Ser Met Val Thr Val Asp Gly Thr 1745 1750 1755 1760 Lys Thr Gln Thr Arg Leu Val Lys Leu Ile Pro Gly Val Glu Tyr Leu 1765 1770 1775 Val Ser Ile Ile Ala Met Lys Gly Phe Glu Glu Ser Glu Pro Val Ser 1780 1785 1790 Gly Ser Phe Thr Thr Ala Leu Asp Gly Pro Ser Gly Leu Val Thr Ala 1795 1800 1805 Asn Ile Thr Asp Ser Glu Ala Leu Ala Arg Trp Gln Pro Ala Ile Ala 1810 1815 1820 Thr Val Asp Ser Tyr Val Ile Ser Tyr Thr Gly Glu Lys Val Pro Glu 1825 1830 1835 1840 Ile Thr Arg Thr Val Ser Gly Asn Thr Val Glu Tyr Ala Leu Thr Asp 1845 1850 1855 Leu Glu Pro Ala Thr Glu Tyr Thr Leu Arg Ile Phe Ala Glu Lys Gly 1860 1865 1870 Pro Gln Lys Ser Ser Thr Ile Val Thr Gly Tyr Leu Leu Val Tyr Glu 1875 1880 1885 Ser Val Asp Gly Thr Val Lys Glu Val Ile Val Gly Pro Asp Thr Thr 1890 1895 1900 Ser Tyr Ser Leu Ala Asp Leu Ser Pro Ser Thr His Tyr Thr Ala Lys 1905 1910 1915 1920 Ile Gln Ala Leu Asn Gly Pro Leu Arg Ser Asn Met Ile Gln Thr Ile 1925 1930 1935 Phe Thr Thr Ile Gly Leu Leu Tyr Pro Phe Pro Lys Asp Cys Ser Gln 1940 1945 1950 Ala Met Leu Asn Gly Asp Thr Thr Ser Gly Leu Tyr Thr Ile Tyr Leu 1955 1960 1965 Asn Gly Asp Lys Ala Gln Ala Leu Glu Val Phe Cys Asp Met Thr Ser 1970 1975 1980 Asp Gly Gly Gly Trp Ile Val Phe Leu Arg Arg Lys Asn Gly Arg Glu 1985 1990 1995 2000 Asn Phe Tyr Gln Asn Trp Lys Ala Tyr Ala Ala Gly Phe Gly Asp Arg 2005 2010 2015 Arg Glu Glu Phe Trp Leu Gly Leu Asp Asn Leu Asn Lys Ile Thr Ala 2020 2025 2030 Gln Gly Gln Tyr Glu Leu Arg Val Asp Leu Arg Asp His Gly Glu Thr 2035 2040 2045 Ala Phe Ala Val Tyr Asp Lys Phe Ser Val Gly Asp Ala Lys Thr Arg 2050 2055 2060 Tyr Lys Leu Lys Val Glu Gly Tyr Ser Gly Thr Ala Gly Asp Ser Met 2065 2070 2075 2080 Ala Tyr His Asn Gly Arg Ser Phe Ser Thr Phe Asp Lys Asp Thr Asp 2085 2090 2095 Ser Ala Ile Thr Asn Cys Ala Leu Ser Tyr Lys Gly Ala Phe Trp Tyr 2100 2105 2110 Arg Asn Cys His Arg Val Asn Leu Met Gly Arg Tyr Gly Asp Asn Asn 2115 2120 2125 His Ser Gln Gly Val Asn Trp Phe His Trp Lys Gly His Glu His Ser 2130 2135 2140 Ile Gln Phe Ala Glu Met Lys Leu Arg Pro Ser Asn Phe Arg Asn Leu 2145 2150 2155 2160 Glu Gly Arg Arg Lys Arg Ala 2165 62 306 PRT Homo sapiens misc_feature (1)..(306 ) Xaa = any amino acid, unknown, or other 62 Met His Lys Thr Ala Ser Gln Arg Leu Phe Pro Gly Pro Ser Tyr Gln 1 5 10 15 Asn Ile Lys Ser Ile Met Glu Asp Ser Thr Ile Leu Ser Asp Trp Thr 20 25 30 Asn Ser Asn Lys Gln Lys Met Lys Tyr Asp Phe Ser Cys Glu Leu Tyr 35 40 45 Arg Met Ser Thr Tyr Ser Thr Phe Pro Ala Gly Val Pro Val Ser Glu 50 55 60 Arg Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly Val Asn Asp Lys 65 70 75 80 Val Lys Cys Phe Cys Cys Gly Leu Met Leu Asp Asn Trp Lys Leu Gly 85 90 95 Asp Ser Pro Ile Gln Lys His Lys Gln Leu Tyr Pro Ser Cys Ser Phe 100 105 110 Ile Gln Asn Leu Val Ser Ala Ser Leu Gly Ser Thr Ser Lys Asn Thr 115 120 125 Ser Pro Met Arg Asn Ser Phe Ala His Ser Leu Ser Pro Thr Leu Glu 130 135 140 His Ser Ser Leu Phe Ser Gly Ser Tyr Ser Ser Leu Ser Pro Asn Pro 145 150 155 160 Leu Asn Ser Arg Ala Val Glu Asp Ile Ser Ser Ser Arg Thr Asn Pro 165 170 175 Tyr Ser Tyr Ala Met Ser Thr Glu Glu Ala Arg Phe Leu Thr Tyr His 180 185 190 Met Trp Pro Leu Thr Phe Leu Ser Pro Ser Glu Leu Ala Arg Ala Gly 195 200 205 Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys Phe Ala Cys Gly 210 215 220 Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp Asn Ala Met Ser Glu His 225 230 235 240 Leu Arg His Phe Pro Asn Cys Pro Phe Leu Glu Asn Ser Leu Glu Thr 245 250 255 Leu Arg Phe Ser Ile Ser Asn Leu Ser Met Gln Thr His Ala Ala Arg 260 265 270 Met Arg Thr Phe Met Tyr Trp Pro Ser Ser Val Pro Val Gln Pro Glu 275 280 285 Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Gly Lys Lys Leu Asn Leu 290 295 300 Leu Ile 305 63 314 PRT Homo sapiens misc_feature (1)..(314 ) Xaa = any amino acid, unknown, or other 63 Met Asp Lys Val Gly Lys Met Trp Asn Asn Phe Lys Tyr Arg Cys Gln 1 5 10 15 Asn Leu Phe Gly His Glu Gly Gly Ser Arg Ser Glu Asn Val Asp Met 20 25 30 Asn Ser Asn Arg Cys Leu Ser Val Lys Glu Lys Asn Ile Ser Ile Gly 35 40 45 Asp Ser Thr Pro Gln Gln Gln Ser Ser Pro Leu Arg Glu Asn Ile Ala 50 55 60 Leu Gln Leu Gly Leu Ser Pro Ser Lys Asn Ser Ser Arg Arg Asn Gln 65 70 75 80 Asn Cys Ala Thr Glu Ile Pro Gln Ile Val Glu Ile Ser Ile Glu Lys 85 90 95 Asp Asn Asp Ser Cys Val Thr Pro Gly Thr Arg Leu Ala Arg Arg Asp 100 105 110 Ser Tyr Ser Arg His Ala Pro Trp Gly Gly Lys Lys Lys His Ser Cys 115 120 125 Ser Thr Lys Thr Gln Ser Ser Leu Asp Ala Asp Lys Lys Phe Gly Arg 130 135 140 Thr Arg Ser Gly Leu Gln Arg Arg Glu Arg Arg Tyr Gly Val Ser Ser 145 150 155 160 Val His Asp Met Asp Ser Val Ser Ser Arg Thr Val Gly Ser Arg Ser 165 170 175 Leu Arg Gln Arg Leu Gln Asp Thr Val Gly Leu Cys Phe Pro Met Arg 180 185 190 Thr Tyr Ser Lys Gln Ser Lys Pro Leu Phe Ser Asn Lys Arg Lys Ile 195 200 205 His Leu Ser Glu Leu Met Leu Glu Lys Cys Pro Phe Pro Ala Gly Ser 210 215 220 Asp Leu Ala Gln Lys Trp His Leu Ile Lys Gln His Thr Ala Pro Val 225 230 235 240 Ser Pro His Ser Thr Phe Phe Asp Thr Phe Asp Pro Ser Leu Val Ser 245 250 255 Thr Glu Asp Glu Glu Asp Arg Leu Arg Glu Arg Arg Arg Pro Val Val 260 265 270 Arg Asp Gln Pro Gly Gln His Gly Glu Ile Pro Ser Pro Gln Lys Lys 275 280 285 Tyr Lys Thr Ser Trp Ala Trp Trp Arg Val Pro Pro Val Pro Ala Thr 290 295 300 Arg Glu Ala Glu Val Arg Arg Gln Met Glu 305 310 64 279 PRT Homo sapiens misc_feature (1)..(279 ) Xaa = any amino acid, unknown, or other 64 Met Glu Ile Gly Arg Tyr His Trp Met Tyr Pro Gly Ser Lys Asn His 1 5 10 15 Gln Tyr His Pro Val Pro Thr Leu Gly Asp Arg Ala Ser Pro Leu Ser 20 25 30 Ser Pro Gly Cys Phe Glu Cys Cys Ile Lys Cys Leu Gly Gly Val Pro 35 40 45 Tyr Ala Ser Leu Val Ala Thr Ile Leu Cys Phe Ser Gly Val Ala Leu 50 55 60 Phe Cys Gly Cys Gly His Val Ala Leu Ala Gly Thr Val Ala Ile Leu 65 70 75 80 Glu Gln His Phe Ser Thr Asn Ala Ser Asp His Ala Leu Leu Ser Glu 85 90 95 Val Ile Gln Leu Met Gln Tyr Val Ile Tyr Gly Ile Ala Ser Phe Phe 100 105 110 Phe Leu Tyr Gly Ile Ile Leu Leu Ala Glu Gly Phe Tyr Thr Thr Ser 115 120 125 Ala Val Lys Glu Leu His Gly Glu Phe Lys Thr Thr Ala Cys Gly Arg 130 135 140 Cys Ile Ser Gly Met Phe Val Phe Leu Thr Tyr Val Leu Gly Val Ala 145 150 155 160 Trp Leu Gly Val Phe Gly Phe Ser Ala Val Pro Val Phe Met Phe Tyr 165 170 175 Asn Ile Trp Ser Thr Cys Glu Val Ile Lys Ser Pro Gln Thr Asn Gly 180 185 190 Thr Thr Gly Val Glu Gln Ile Cys Val Asp Ile Arg Gln Tyr Gly Ile 195 200 205 Ile Pro Trp Asn Ala Phe Pro Gly Lys Ile Cys Gly Ser Ala Leu Glu 210 215 220 Asn Ile Cys Asn Thr Asn Glu Phe Tyr Met Ser Tyr His Leu Phe Ile 225 230 235 240 Val Ala Cys Ala Gly Ala Gly Ala Thr Val Ile Ala Leu Leu Ile Tyr 245 250 255 Met Met Ala Thr Thr Tyr Asn Tyr Ala Val Leu Lys Phe Lys Ser Arg 260 265 270 Glu Asp Cys Cys Thr Lys Phe 275 65 207 PRT Homo sapiens misc_feature (1)..(207 ) Xaa = any amino acid, unknown, or other 65 Met Lys Ile Leu Glu Leu Ser Leu Lys Lys Gly Val His Met Leu Gln 1 5 10 15 Cys Leu Cys Gly Arg Ser Leu Arg Ser Ser Asp Thr Pro Arg Glu Pro 20 25 30 Gln Leu Lys Gly Ile Val Thr Arg Leu Phe Ser Gln Gln Gly Tyr Phe 35 40 45 Leu Gln Met His Pro Asp Gly Thr Ile Asp Gly Thr Lys Asp Glu Asn 50 55 60 Ser Asp Tyr Thr Leu Phe Asn Leu Ile Pro Val Gly Leu Arg Val Val 65 70 75 80 Ala Ile Gln Gly Val Lys Ala Ser Leu Tyr Val Ala Met Asn Gly Glu 85 90 95 Gly Tyr Leu Tyr Ser Ser Asp Val Phe Thr Pro Glu Cys Lys Phe Lys 100 105 110 Glu Ser Val Phe Glu Asn Tyr Tyr Val Ile Tyr Ser Ser Thr Leu Tyr 115 120 125 Arg Gln Gln Glu Ser Gly Arg Ala Trp Phe Leu Gly Leu Asn Lys Glu 130 135 140 Gly Gln Ile Met Lys Gly Asn Arg Val Lys Lys Thr Lys Pro Ser Ser 145 150 155 160 His Phe Val Pro Lys Pro Ile Glu Val Cys Met Tyr Arg Glu Pro Ser 165 170 175 Leu His Glu Ile Gly Glu Lys Gln Gly Arg Ser Arg Lys Ser Ser Gly 180 185 190 Thr Pro Thr Met Asn Gly Gly Lys Val Val Asn Gln Asp Ser Thr 195 200 205 66 662 PRT Homo sapiens misc_feature (1)..(662 ) Xaa = any amino acid, unknown, or other 66 Met Asn Leu Gln Pro Ile Phe Trp Ile Gly Leu Ile Ser Ser Val Cys 1 5 10 15 Cys Val Phe Ala Gln Thr Asp Glu Asn Arg Cys Leu Lys Ala Asn Ala 20 25 30 Lys Ser Cys Gly Glu Cys Ile Gln Ala Gly Pro Asn Cys Gly Trp Cys 35 40 45 Thr Asn Ser Thr Phe Leu Gln Glu Gly Met Pro Thr Ser Ala Arg Cys 50 55 60 Asp Asp Leu Glu Ala Leu Lys Lys Lys Gly Cys Pro Pro Asp Asp Ile 65 70 75 80 Glu Asn Pro Arg Gly Ser Lys Asp Ile Lys Lys Asn Lys Asn Val Thr 85 90 95 Asn Arg Ser Lys Gly Thr Ala Glu Lys Leu Lys Pro Glu Asp Ile Thr 100 105 110 Gln Ile Gln Pro Gln Gln Leu Val Leu Arg Leu Arg Ser Gly Glu Pro 115 120 125 Gln Thr Phe Thr Leu Lys Phe Lys Arg Ala Glu Asp Tyr Pro Ile Asp 130 135 140 Leu Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu Glu 145 150 155 160 Asn Val Lys Ser Leu Gly Thr Asp Leu Met Asn Glu Met Arg Arg Ile 165 170 175 Thr Ser Asp Phe Arg Ile Gly Phe Gly Ser Phe Val Glu Lys Thr Val 180 185 190 Met Pro Tyr Ile Ser Thr Thr Pro Ala Lys Leu Arg Asn Pro Cys Thr 195 200 205 Ser Glu Gln Asn Cys Thr Ser Pro Phe Ser Tyr Lys Asn Val Leu Ser 210 215 220 Leu Thr Asn Lys Gly Glu Val Phe Asn Glu Leu Val Gly Lys Gln Arg 225 230 235 240 Ile Ser Gly Asn Leu Asp Ser Pro Glu Gly Gly Phe Asp Ala Ile Met 245 250 255 Gln Val Ala Val Cys Gly Ser Leu Ile Gly Trp Arg Asn Val Thr Arg 260 265 270 Leu Leu Val Phe Ser Thr Asp Ala Gly Phe His Phe Ala Gly Asp Gly 275 280 285 Lys Leu Gly Gly Ile Val Leu Pro Asn Asp Gly Gln Cys His Leu Glu 290 295 300 Asn Asn Met Tyr Thr Met Ser His Tyr Tyr Asp Tyr Pro Ser Ile Ala 305 310 315 320 His Leu Val Gln Lys Leu Ser Glu Asn Asn Ile Gln Thr Ile Phe Ala 325 330 335 Val Thr Glu Glu Phe Gln Pro Val Tyr Lys Glu Leu Lys Asn Leu Ile 340 345 350 Pro Lys Ser Ala Val Gly Thr Leu Ser Ala Asn Ser Ser Asn Val Ile 355 360 365 Gln Leu Ile Ile Asp Ala Tyr Asn Ser Leu Ser Ser Glu Val Ile Leu 370 375 380 Glu Asn Gly Lys Leu Ser Glu Gly Val Thr Ile Ser Tyr Lys Ser Tyr 385 390 395 400 Cys Lys Asn Gly Val Asn Gly Thr Gly Glu Asn Gly Arg Lys Cys Ser 405 410 415 Asn Ile Ser Ile Gly Asp Glu Val Gln Phe Glu Ile Ser Ile Thr Ser 420 425 430 Asn Lys Cys Pro Lys Lys Asp Ser Asp Ser Phe Lys Ile Arg Pro Leu 435 440 445 Gly Phe Thr Glu Glu Val Glu Val Ile Leu Gln Tyr Ile Cys Glu Cys 450 455 460 Glu Cys Gln Ser Glu Gly Ile Pro Glu Ser Pro Lys Cys His Glu Gly 465 470 475 480 Asn Gly Thr Phe Glu Cys Gly Ala Cys Arg Cys Asn Glu Gly Arg Val 485 490 495 Gly Arg His Cys Glu Cys Ser Thr Asp Glu Val Asn Ser Glu Asp Met 500 505 510 Asp Ala Tyr Cys Arg Lys Glu Asn Ser Ser Glu Ile Cys Ser Asn Asn 515 520 525 Gly Glu Cys Val Cys Gly Gln Cys Val Cys Arg Lys Arg Asp Lys Glu 530 535 540 Cys Val Gln Cys Arg Ala Phe Asn Lys Gly Glu Lys Lys Asp Thr Cys 545 550 555 560 Thr Gln Glu Cys Ser Tyr Phe Asn Ile Thr Lys Val Glu Ser Arg Asp 565 570 575 Lys Leu Pro Gln Pro Val Gln Pro Asp Pro Val Ser His Cys Lys Glu 580 585 590 Lys Asp Val Asp Asp Cys Trp Phe Tyr Phe Thr Tyr Ser Val Asn Gly 595 600 605 Asn Asn Glu Val Met Val His Val Val Glu Asn Pro Glu Cys Pro Thr 610 615 620 Gly Pro Asp Ile Ile Pro Ile Val Ala Gly Val Val Ala Gly Ile Val 625 630 635 640 Leu Ile Gly Leu Ala Leu Leu Leu Ile Trp Lys Leu Leu Met Ile Ile 645 650 655 His Asp Arg Arg Trp Phe 660 67 543 PRT Homo sapiens misc_feature (1)..(543 ) Xaa = any amino acid, unknown, or other 67 Met Asn Leu Gln Pro Ile Phe Trp Ile Gly Leu Ile Ser Ser Val Cys 1 5 10 15 Cys Val Phe Ala Gln Thr Asp Glu Asn Arg Cys Leu Lys Ala Asn Ala 20 25 30 Lys Ser Cys Gly Glu Cys Ile Gln Ala Gly Pro Asn Cys Gly Trp Cys 35 40 45 Thr Asn Ser Thr Phe Leu Gln Glu Gly Met Pro Thr Ser Ala Arg Cys 50 55 60 Asp Asp Leu Glu Ala Leu Lys Lys Lys Gly Cys Pro Pro Asp Asp Ile 65 70 75 80 Glu Asn Pro Arg Gly Ser Lys Asp Ile Lys Lys Asn Lys Asn Val Thr 85 90 95 Asn Arg Ser Lys Gly Thr Ala Glu Lys Leu Lys Pro Glu Asp Ile Thr 100 105 110 Gln Ile Gln Pro Gln Gln Leu Val Leu Arg Leu Arg Ser Gly Glu Pro 115 120 125 Gln Thr Phe Thr Leu Lys Phe Lys Arg Ala Glu Asp Tyr Pro Ile Asp 130 135 140 Leu Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu Glu 145 150 155 160 Asn Val Lys Ser Leu Gly Thr Asp Leu Met Asn Glu Ile Ser Ile Thr 165 170 175 Ser Asn Lys Cys Pro Lys Lys Asp Ser Asp Ser Phe Lys Ile Arg Pro 180 185 190 Leu Gly Phe Thr Glu Glu Val Glu Val Ile Leu Gln Tyr Ile Cys Glu 195 200 205 Cys Glu Cys Gln Ser Glu Gly Ile Pro Glu Ser Pro Lys Cys His Glu 210 215 220 Gly Asn Gly Thr Phe Glu Cys Gly Ala Cys Arg Cys Asn Glu Gly Arg 225 230 235 240 Val Gly Arg His Cys Glu Cys Ser Thr Asp Glu Val Asn Ser Glu Asp 245 250 255 Met Asp Ala Tyr Cys Arg Lys Glu Asn Ser Ser Glu Ile Cys Ser Asn 260 265 270 Asn Gly Glu Cys Val Cys Gly Gln Cys Val Cys Arg Lys Arg Asp Asn 275 280 285 Thr Asn Glu Ile Tyr Ser Gly Lys Phe Cys Glu Cys Asp Asn Phe Asn 290 295 300 Cys Asp Arg Ser Asn Gly Leu Ile Cys Gly Gly Asn Gly Val Cys Lys 305 310 315 320 Cys Arg Val Cys Glu Cys Asn Pro Asn Tyr Thr Gly Ser Ala Cys Asp 325 330 335 Cys Ser Leu Asp Thr Ser Thr Cys Glu Ala Ser Asn Gly Gln Ile Cys 340 345 350 Asn Gly Arg Gly Ile Cys Glu Cys Gly Val Cys Lys Cys Thr Asp Pro 355 360 365 Lys Phe Gln Gly Gln Thr Cys Glu Met Cys Gln Thr Cys Leu Gly Val 370 375 380 Cys Ala Glu His Lys Glu Cys Val Gln Cys Arg Ala Phe Asn Lys Gly 385 390 395 400 Glu Lys Lys Asp Thr Cys Thr Gln Glu Cys Ser Tyr Phe Asn Ile Thr 405 410 415 Lys Val Glu Ser Arg Asp Lys Leu Pro Gln Pro Val Gln Pro Asp Pro 420 425 430 Val Ser His Cys Lys Glu Lys Asp Val Asp Asp Cys Trp Phe Tyr Phe 435 440 445 Thr Tyr Ser Val Asn Gly Asn Asn Glu Val Met Val His Val Val Glu 450 455 460 Asn Pro Glu Cys Pro Thr Gly Pro Asp Ile Ile Pro Ile Val Ala Gly 465 470 475 480 Val Val Ala Gly Ile Val Leu Ile Gly Leu Ala Leu Leu Leu Ile Trp 485 490 495 Lys Leu Leu Met Ile Ile His Asp Arg Arg Glu Phe Ala Lys Phe Glu 500 505 510 Lys Glu Lys Met Asn Ala Lys Trp Asp Thr Gly Glu Asn Pro Ile Tyr 515 520 525 Lys Ser Ala Val Thr Thr Val Val Asn Pro Lys Tyr Glu Gly Lys 530 535 540 68 187 PRT Homo sapiens misc_feature (1)..(187 ) Xaa = any amino acid, unknown, or other 68 Met Gln Pro Pro Pro Ser Leu Cys Gly Arg Ala Leu Val Ala Leu Val 1 5 10 15 Leu Ala Cys Gly Leu Ser Arg Ile Trp Gly Glu Glu Arg Gly Phe Pro 20 25 30 Pro Asp Arg Ala Thr Pro Leu Leu Gln Thr Ala Glu Ile Met Thr Pro 35 40 45 Pro Thr Lys Thr Leu Trp Pro Lys Gly Ser Asn Ala Ser Leu Ala Arg 50 55 60 Ser Leu Ala Pro Ala Glu Val Pro Lys Gly Asp Arg Thr Ala Gly Ser 65 70 75 80 Pro Pro Arg Thr Ile Ser Pro Pro Pro Cys Gln Gly Pro Ile Glu Ile 85 90 95 Lys Glu Thr Phe Lys Tyr Ile Asn Thr Val Val Ser Cys Leu Val Phe 100 105 110 Val Leu Gly Ile Ile Gly Asn Ser Thr Leu Leu Arg Ile Ile Tyr Lys 115 120 125 Asn Lys Cys Met Arg Asn Gly Pro Asn Ile Leu Ile Ala Ser Leu Ala 130 135 140 Leu Gly Asp Leu Leu His Ile Val Ile Asp Ile Pro Ile Asn Val Tyr 145 150 155 160 Lys Leu Leu Ala Glu Asp Trp Pro Phe Gly Ala Glu Met Cys Gln Val 165 170 175 Gly Ala Phe Thr His Pro Glu Glu Gly Cys His 180 185 69 127 PRT Homo sapiens misc_feature (1)..(127 ) Xaa = any amino acid, unknown, or other 69 Met Pro Gly Ala Gly Arg Ser Ser Met Ala His Gly Pro Gly Ala Leu 1 5 10 15 Met Leu Lys Cys Val Val Val Gly Asp Gly Ala Val Gly Lys Thr Cys 20 25 30 Leu Leu Met Ser Tyr Ala Asn Asp Ala Phe Pro Glu Glu Tyr Val Pro 35 40 45 Thr Val Phe Asp His Tyr Ala Val Ser Val Thr Val Gly Gly Lys Gln 50 55 60 Tyr Leu Leu Gly Leu Tyr Asp Thr Ala Gly Gln Glu Ile Gly Ala Cys 65 70 75 80 Cys Tyr Val Glu Cys Ser Ala Leu Thr Gln Lys Gly Leu Lys Thr Val 85 90 95 Phe Asp Glu Ala Ile Ile Ala Ile Leu Thr Pro Lys Lys His Thr Val 100 105 110 Lys Lys Arg Ile Gly Ser Arg Cys Ile Asn Cys Cys Leu Ile Thr 115 120 125 70 119 PRT Homo sapiens misc_feature (1)..(119 ) Xaa = any amino acid, unknown, or other 70 Ala Gly Arg Lys Gly Ser His Ser Met Ala Gly Gly Val Val Ser Ser 1 5 10 15 Ala Leu Pro Pro Trp Arg Ala Pro Ser His His Asp Pro Leu Asn Gln 20 25 30 Ala Asp Gly Val Ser Leu Cys Gln Val Glu Gly Thr Ser Ile Lys Phe 35 40 45 His Asp Leu Gln Ile Leu Ser Gly Pro Gly Leu Leu Val Arg Pro Val 50 55 60 Gly Leu Cys Ile Asn Arg Leu Asn Pro Leu Ile Thr Gly Ser Thr Ala 65 70 75 80 Arg Pro Pro Ser Gln Gln Ile Thr Met Pro Ile Pro Glu Ser Ala Ile 85 90 95 Gln Ala His Gly Leu Leu Ser Leu Ser Phe Gln Asn Ala Ser Pro Ala 100 105 110 Ser Cys Phe Leu Val Leu Arg 115 71 148 PRT Homo sapiens misc_feature (1)..(148 ) Xaa = any amino acid, unknown, or other 71 Val Ser Gly Leu Ser Xaa Gly Xaa Ser Ile Ile Pro Thr Phe Pro Glu 1 5 10 15 Ile Leu Ser Cys Ala His Glu Asn Gly Phe Xaa Glu Gly Leu Ser Thr 20 25 30 Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala 35 40 45 Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe 50 55 60 Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Val Ser 65 70 75 80 Asn Gln Ser Phe Ile Cys Ile Phe Leu Ile Phe Val Glu Lys Leu Asp 85 90 95 Leu Glu Asn Leu His Ser Val Leu Leu Ile Val Phe Lys Gly Leu Ala 100 105 110 Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Tyr Gly 115 120 125 Ser Ile Leu Gly Ala Phe Phe Leu Ser Leu Lys Val Ser Gln Cys Lys 130 135 140 Trp Glu Asn Lys 145 72 116 PRT Homo sapiens misc_feature (1)..(116 ) Xaa = any amino acid, unknown, or other 72 Val Ser Gly Leu Ser Xaa Gly Xaa Ser Ile Ile Pro Thr Phe Pro Glu 1 5 10 15 Ile Leu Ser Cys Ala His Glu Asn Gly Phe Xaa Glu Gly Leu Ser Thr 20 25 30 Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala 35 40 45 Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe 50 55 60 Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu 65 70 75 80 Ala Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser 85 90 95 Lys Ser Gln Asn Ile Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu 100 105 110 Pro Asn Glu Thr 115 73 116 PRT Homo sapiens misc_feature (1)..(116 ) Xaa = any amino acid, unknown, or other 73 Val Ser Gly Leu Ser Xaa Gly Xaa Ser Ile Ile Pro Thr Phe Pro Glu 1 5 10 15 Ile Leu Ser Cys Ala His Glu Asn Gly Phe Xaa Glu Gly Leu Ser Thr 20 25 30 Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala 35 40 45 Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe 50 55 60 Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu 65 70 75 80 Ala Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser 85 90 95 Lys Ser Gln Asn Ile Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu 100 105 110 Pro Asn Glu Thr 115 74 117 PRT Homo sapiens misc_feature (1)..(117 ) Xaa = any amino acid, unknown, or other 74 Val Ser Gly Leu Ser Xaa Gly Xaa Ser Ile Ile Pro Thr Phe Pro Glu 1 5 10 15 Ile Leu Ser Cys Ala His Glu Asn Gly Phe Xaa Glu Gly Leu Ser Thr 20 25 30 Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala 35 40 45 Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe 50 55 60 Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu 65 70 75 80 Ala Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Tyr 85 90 95 Gly Ser Ile Leu Gly Ala Phe Phe Leu Ser Leu Lys Val Ser Gln Cys 100 105 110 Lys Trp Glu Asn Lys 115 75 147 PRT Homo sapiens misc_feature (1)..(147 ) Xaa = any amino acid, unknown, or other 75 Val Ser Gly Leu Ser Xaa Gly Xaa Ser Ile Ile Pro Thr Phe Pro Glu 1 5 10 15 Ile Leu Ser Cys Ala His Glu Asn Gly Phe Xaa Glu Gly Leu Ser Thr 20 25 30 Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala 35 40 45 Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe 50 55 60 Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Val Ser 65 70 75 80 Asn Gln Ser Phe Ile Cys Ile Phe Leu Ile Phe Val Glu Lys Leu Asp 85 90 95 Leu Glu Asn Leu His Ser Val Leu Leu Ile Val Phe Lys Gly Leu Ala 100 105 110 Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser Lys 115 120 125 Ser Gln Asn Ile Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu Pro 130 135 140 Asn Glu Thr 145 76 147 PRT Homo sapiens misc_feature (1)..(147 ) Xaa = any amino acid, unknown, or other 76 Val Ser Gly Leu Ser Xaa Gly Xaa Ser Ile Ile Pro Thr Phe Pro Glu 1 5 10 15 Ile Leu Ser Cys Ala His Glu Asn Gly Phe Xaa Glu Gly Leu Ser Thr 20 25 30 Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala 35 40 45 Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe 50 55 60 Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Val Ser 65 70 75 80 Asn Gln Ser Phe Ile Cys Ile Phe Leu Ile Phe Val Glu Lys Leu Asp 85 90 95 Leu Glu Asn Leu His Ser Val Leu Leu Ile Val Phe Lys Gly Leu Ala 100 105 110 Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser Lys 115 120 125 Ser Gln Asn Ile Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu Pro 130 135 140 Asn Glu Thr 145 77 124 PRT Homo sapiens misc_feature (1)..(124 ) Xaa = any amino acid, unknown, or other 77 Glu Lys Glu Glu Val Arg Asn Gln Asn Lys Ser Met Lys Ser Arg Val 1 5 10 15 Arg Glu Lys Leu Leu Leu Arg Phe Leu Gln Ile Leu Leu Ser Ala Cys 20 25 30 Asn Gln Thr Phe Glu Lys Asn Leu Val Leu Lys Gly Cys His Cys Phe 35 40 45 His Pro Leu Xaa Xaa Met Phe Ser Leu Xaa Leu Phe Ser Arg Thr Pro 50 55 60 Thr Ser Glu Gly Ala Ala Ser Glu Arg Asp Cys Glu Ser Ile Tyr Thr 65 70 75 80 Ile Ser Gly Thr Asn Ser Ser Ser Glu Ala Ser His Thr Pro His Leu 85 90 95 Pro Ser Glu Leu Pro Pro Arg Tyr Glu Glu Lys Glu Asn Ala Ala Ala 100 105 110 Thr Phe Leu Pro Leu Ser Ser Glu Pro Ser Pro Pro 115 120 78 466 PRT Homo sapiens misc_feature (1)..(466 ) Xaa = any amino acid, unknown, or other 78 Gly Ala Cys Gly Gly Ser Ser Pro Arg Thr Trp Leu Glu Ala Gly Ser 1 5 10 15 Trp Gly Ala Gly Val His Ala Pro Gly Met Glu Ala Leu Gly Asp Leu 20 25 30 Glu Gly Pro Arg Ala Pro Gly Gly Asp Asp Pro Ala Gly Ser Ala Gly 35 40 45 Glu Thr Pro Gly Trp Leu Ser Arg Glu Gln Val Phe Val Leu Ile Ser 50 55 60 Ala Ala Ser Val Asn Leu Gly Ser Met Met Cys Tyr Ser Ile Leu Gly 65 70 75 80 Pro Phe Phe Pro Lys Glu Ala Glu Lys Lys Gly Ala Ser Asn Thr Ile 85 90 95 Ile Gly Met Ile Phe Gly Cys Phe Ala Leu Phe Glu Leu Leu Ala Ser 100 105 110 Leu Val Phe Gly Asn Tyr Leu Val His Ile Gly Ala Lys Phe Met Phe 115 120 125 Val Ala Gly Met Phe Val Ser Gly Gly Val Thr Ile Leu Phe Gly Val 130 135 140 Leu Asp Arg Val Pro Asp Gly Pro Val Phe Ile Ala Met Cys Phe Leu 145 150 155 160 Val Arg Val Met Asp Ala Val Ser Phe Ala Ala Ala Met Thr Ala Ser 165 170 175 Ser Ser Ile Leu Ala Lys Ala Phe Pro Asn Asn Val Ala Thr Val Leu 180 185 190 Gly Ser Leu Glu Thr Phe Ser Gly Leu Gly Leu Ile Leu Gly Pro Pro 195 200 205 Val Gly Gly Phe Leu Tyr Gln Ser Phe Gly Tyr Glu Val Pro Phe Ile 210 215 220 Val Leu Gly Cys Val Val Leu Leu Met Val Pro Leu Asn Met Tyr Ile 225 230 235 240 Leu Pro Asn Tyr Glu Ser Asp Pro Gly Glu His Ser Phe Trp Lys Leu 245 250 255 Ile Ala Leu Pro Lys Val Gly Leu Ile Ala Phe Val Ile Asn Ser Leu 260 265 270 Ser Ser Cys Phe Gly Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu 275 280 285 Glu Lys Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly 290 295 300 Met Ala Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser 305 310 315 320 Asp Lys Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu 325 330 335 Ile Thr Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His 340 345 350 Ile Lys Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly 355 360 365 Leu Ser Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser 370 375 380 Cys Ala His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu 385 390 395 400 Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly 405 410 415 Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala 420 425 430 Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Val Ser Asn Gln Ser 435 440 445 Phe Ile Cys Ile Phe Leu Ile Phe Val Glu Lys Leu Asp Leu Glu Asn 450 455 460 Leu His 465 79 434 PRT Homo sapiens misc_feature (1)..(434 ) Xaa = any amino acid, unknown, or other 79 Arg Glu Lys Arg Trp Leu Leu Gly Asp Asp Pro Ala Gly Ser Ala Gly 1 5 10 15 Glu Thr Pro Gly Trp Leu Ser Arg Glu Gln Val Phe Val Leu Ile Ser 20 25 30 Ala Ala Ser Val Asn Leu Gly Ser Met Met Cys Tyr Ser Ile Leu Gly 35 40 45 Pro Phe Phe Pro Lys Glu Ala Glu Lys Lys Gly Ala Ser Asn Thr Ile 50 55 60 Ile Gly Met Ile Phe Gly Cys Phe Ala Leu Phe Glu Leu Leu Ala Ser 65 70 75 80 Leu Val Phe Gly Asn Tyr Leu Val His Ile Gly Ala Lys Phe Met Phe 85 90 95 Val Ala Gly Met Phe Val Ser Gly Gly Val Thr Ile Leu Phe Gly Val 100 105 110 Leu Asp Arg Val Pro Asp Gly Pro Val Phe Ile Ala Met Cys Phe Leu 115 120 125 Val Arg Val Met Asp Ala Val Ser Phe Ala Ala Ala Met Thr Ala Ser 130 135 140 Ser Ser Ile Leu Ala Lys Ala Phe Pro Asn Asn Val Ala Thr Val Leu 145 150 155 160 Gly Ser Leu Glu Thr Phe Ser Gly Leu Gly Leu Ile Leu Gly Pro Pro 165 170 175 Val Gly Gly Phe Leu Tyr Gln Ser Phe Gly Tyr Glu Val Pro Phe Ile 180 185 190 Val Leu Gly Cys Val Val Leu Leu Met Val Pro Leu Asn Met Tyr Ile 195 200 205 Leu Pro Asn Tyr Glu Ser Asp Pro Gly Glu His Ser Phe Trp Lys Leu 210 215 220 Ile Ala Leu Pro Lys Val Gly Leu Ile Ala Phe Val Ile Asn Ser Leu 225 230 235 240 Ser Ser Cys Phe Gly Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu 245 250 255 Glu Lys Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly 260 265 270 Met Ala Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser 275 280 285 Asp Lys Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu 290 295 300 Ile Thr Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His 305 310 315 320 Ile Lys Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly 325 330 335 Leu Ser Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser 340 345 350 Cys Ala His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu 355 360 365 Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly 370 375 380 Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala 385 390 395 400 Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Val Ser Asn Gln Ser 405 410 415 Phe Ile Cys Ile Phe Leu Ile Phe Val Glu Lys Leu Asp Leu Glu Asn 420 425 430 Leu His 80 409 PRT Homo sapiens misc_feature (1)..(409) Xaa = any amino acid, unknown, or other 80 Met Met Cys Tyr Ser Ile Leu Gly Pro Phe Phe Pro Lys Glu Ala Glu 1 5 10 15 Lys Lys Gly Ala Ser Asn Thr Ile Ile Gly Met Ile Phe Gly Cys Phe 20 25 30 Ala Leu Phe Glu Leu Leu Ala Ser Leu Val Phe Gly Asn Tyr Leu Val 35 40 45 His Ile Gly Ala Lys Phe Met Phe Val Ala Gly Met Phe Val Ser Gly 50 55 60 Gly Val Thr Ile Leu Phe Gly Val Leu Asp Arg Val Pro Asp Gly Pro 65 70 75 80 Val Phe Ile Ala Met Cys Phe Leu Val Arg Val Met Asp Ala Val Ser 85 90 95 Phe Ala Ala Ala Met Thr Ala Ser Ser Ser Ile Leu Ala Lys Ala Phe 100 105 110 Pro Asn Asn Val Ala Thr Val Leu Gly Ser Leu Glu Thr Phe Ser Gly 115 120 125 Leu Gly Leu Ile Leu Gly Pro Pro Val Gly Gly Phe Leu Tyr Gln Ser 130 135 140 Phe Gly Tyr Glu Val Pro Leu Ile Val Leu Gly Cys Val Val Leu Leu 145 150 155 160 Met Val Pro Leu Asn Met Tyr Ile Leu Pro Asn Tyr Glu Ser Asp Pro 165 170 175 Gly Glu His Ser Phe Trp Lys Leu Ile Ala Leu Pro Lys Val Gly Leu 180 185 190 Ile Ala Phe Val Ile Asn Ser Leu Ser Ser Cys Phe Gly Phe Leu Asp 195 200 205 Pro Thr Leu Ser Leu Phe Val Leu Glu Lys Phe Asn Leu Pro Ala Gly 210 215 220 Tyr Val Gly Leu Val Phe Leu Gly Met Ala Leu Ser Tyr Ala Ile Ser 225 230 235 240 Ser Pro Leu Phe Gly Leu Leu Ser Asp Lys Arg Pro Pro Leu Arg Lys 245 250 255 Trp Leu Leu Val Phe Gly Asn Leu Ile Thr Ala Gly Cys Tyr Met Leu 260 265 270 Leu Gly Pro Val Pro Ile Leu His Ile Lys Ser Gln Leu Trp Leu Leu 275 280 285 Val Leu Ile Leu Val Val Ser Gly Leu Ser Ala Gly Met Ser Ile Ile 290 295 300 Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala His Glu Asn Gly Phe Glu 305 310 315 320 Glu Gly Leu Ser Thr Leu Gly Leu Val Ser Gly Leu Phe Ser Ala Met 325 330 335 Trp Ser Ile Gly Ala Phe Met Gly Pro Thr Leu Gly Gly Phe Leu Tyr 340 345 350 Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala Ile Gln Gly Leu Trp Ala 355 360 365 Leu Ile Ser Gly Leu Ala Met Gly Leu Phe Tyr Leu Leu Glu Tyr Ser 370 375 380 Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile Leu Ser Thr Glu Glu Glu 385 390 395 400 Arg Thr Thr Leu Leu Pro Asn Glu Thr 405 81 466 PRT Homo sapiens misc_feature (1)..(466) Xaa = any amino acid, unknown, or other 81 Gly Ala Cys Gly Gly Ser Ser Pro Arg Thr Trp Leu Glu Ala Gly Ser 1 5 10 15 Trp Gly Ala Gly Val His Ala Pro Gly Met Glu Ala Leu Gly Asp Leu 20 25 30 Glu Gly Pro Arg Ala Pro Gly Gly Asp Asp Pro Ala Gly Ser Ala Gly 35 40 45 Glu Thr Pro Gly Trp Leu Ser Arg Glu Gln Val Phe Val Leu Ile Ser 50 55 60 Ala Ala Ser Val Asn Leu Gly Ser Met Met Cys Tyr Ser Ile Leu Gly 65 70 75 80 Pro Phe Phe Pro Lys Glu Ala Glu Lys Lys Gly Ala Ser Asn Thr Ile 85 90 95 Ile Gly Met Ile Phe Gly Cys Phe Ala Leu Phe Glu Leu Leu Ala Ser 100 105 110 Leu Val Phe Gly Asn Tyr Leu Val His Ile Gly Ala Lys Phe Met Phe 115 120 125 Val Ala Gly Met Phe Val Ser Gly Gly Val Thr Ile Leu Phe Gly Val 130 135 140 Leu Asp Arg Val Pro Asp Gly Pro Val Phe Ile Ala Met Cys Phe Leu 145 150 155 160 Val Arg Val Met Asp Ala Val Ser Phe Ala Ala Ala Met Thr Ala Ser 165 170 175 Ser Ser Ile Leu Ala Lys Ala Phe Pro Asn Asn Val Ala Thr Val Leu 180 185 190 Gly Ser Leu Glu Thr Phe Ser Gly Leu Gly Leu Ile Leu Gly Pro Pro 195 200 205 Val Gly Gly Phe Leu Tyr Gln Ser Phe Gly Tyr Glu Val Pro Phe Ile 210 215 220 Val Leu Gly Cys Val Val Leu Leu Met Val Pro Leu Asn Met Tyr Ile 225 230 235 240 Leu Pro Asn Tyr Glu Ser Asp Pro Gly Glu His Ser Phe Trp Lys Leu 245 250 255 Ile Ala Leu Pro Lys Val Gly Leu Ile Ala Phe Val Ile Asn Ser Leu 260 265 270 Ser Ser Cys Phe Gly Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu 275 280 285 Glu Lys Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly 290 295 300 Met Ala Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser 305 310 315 320 Asp Lys Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu 325 330 335 Ile Thr Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His 340 345 350 Ile Lys Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly 355 360 365 Leu Ser Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser 370 375 380 Cys Ala His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu 385 390 395 400 Val Ser Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly 405 410 415 Pro Thr Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala 420 425 430 Ala Ala Ile Gln Gly Leu Trp Ala Leu Ile Ser Val Ser Asn Gln Ser 435 440 445 Phe Ile Cys Ile Phe Leu Ile Phe Val Glu Lys Leu Asp Leu Glu Asn 450 455 460 Leu His 465 

1. An isolated nucleic acid sequence selected from the group consisting of: an isolated nucleic acid sequence, of an alternative splicing valiant, selected from the group consisting of: (A)(i) the nucleic acid sequence depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 28; (A)(ii) nucleic acid sequences having at least 90% identity with the sequence of (A)(i) with the proviso that each sequence is different than the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing; and (A)(iii) fragments of (A)(i) or (A)(ii) of at least 20 b.p., provided that said fragment contains a sequence which is not present, as a continuous stretch of nucleotides, in the original nucleic acid sequence from which the sequences of (A)(i) have been varied by alternative splicing; an isolated nucleic acid sequence selected from the group consisting of: (B)(i) a nucleic acid sequence depicted in SEQ ID NO: 29 or 30; (B)(ii) nucleic acid sequences having at least 70% identity with the sequence of (B)(i); and (B)(iii) fragments of (B)(i) or (B)(ii) of at least 20 base pairs; an isolated nucleic acid sequence selected from the group consisting of: (C)(i) a nucleic acid sequence depicted in SEQ ID NO: 31 to
 41. (C)(ii) nucleic acid sequences having at least 70% identity with the sequence of (C)(i); and (C)(iii) fragments of (C)(i) or (C)(ii) of at least 20 base pairs.
 2. A nucleic acid sequence according to claim 1 (B)(ii) or claim 1 (C)(ii) wherein the nucleic acid sequences having at least 80% identity with the sequence of claim 1 (B)(i) or claim 1 (C)(i), respectively.
 3. A nucleic acid sequence according to claim 2, wherein the nucleic acid sequences have at least 90% identity.
 4. An isolated nucleic acid sequence complementary to the nucleic acid sequence of claim
 1. 5. An amino acid sequence selected from the group consisting of: (i) an amino acid sequence coded by the isolated nucleic acid sequence of alternative splice variants of claim 1 (A); (ii) homologues of the amino acid sequences of 1(i) in which one or more amino acids has been added, deleted, replaced or chemically modified in the region or adjacent to the region where the amino acid sequences differs from the original amino acid sequence, coded by the original nucleic acid sequence from which the variant has been varied; 2(i) an amino acid sequence coded by the isolated nucleic acid sequence of claim 1(B); 2(ii) fragments of the amino acid sequence of claim 2(i) having at least 10 amino acids; 2(iii) analogs of the amino acid sequences of 2(i) or 2(ii) in which one or more amino acids has been added, deleted, replaced or chemically modified without substantially altering the biological activity of the parent amino acid sequence; 3(i) an amino acid sequence coded by the isolated nucleic acid sequence of claim 1(C); 3(ii) fragments of the amino acid sequence of claim 3(i) having at least 10 amino acids; 3(iii) analogs of the amino acid sequences of claim 3(i) or 3(ii) in which one or more amino acids has been added, deleted, replaced or chemically modified without substantially altering the biological activity of the parent amino acid sequence.
 6. An amino acid sequence according to claim 5, as depicted in any one of SEQ ID NO: 42 to SEQ ID NO:
 69. 7. An amino acid sequence according to claim 5 as depicted in SEQ ID NO:
 70. 8. An amino acid sequence according to claim 5 as depicted in any one of SEQ ID NO: 71 to
 81. 9. An isolated nucleic acid sequence coding for any one of the amino acid sequences of claim
 6. 10. An isolated nucleic acid sequence coding for any one of the amino acid sequences of claim
 7. 11. An isolated nucleic acid sequence coding for any one of the amino acid sequences of claim
 8. 12. A purified antibody which binds specifically to any of the amino acid sequences of claim
 6. 13. A purified antibody which binds specifically to any of the amino acid sequences of claim
 7. 14. A purified antibody which binds specifically to any of the amino acid sequences of claim
 8. 15. An expression vector comprising any one of the nucleic acid sequences of claim 1 and control elements for the expression of the nucleic acid sequence in a suitable host.
 16. An expression vector comprising any one of the nucleic acid sequences of claim 4, and control elements for the expression of the nucleic acid sequences in a suitable host.
 17. A host cell transfected by the expression vector of claim
 15. 18. A host cell transfected by the expression vector of claim
 16. 19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of: (i) the expression vector of claim 15; and (ii) any one of the amino acid sequences of SEQ ID NO: 42 to 81, fragments of these amino acids having at least 10 amino acids and, analogs of said amino acid sequences.
 20. A pharmaceutical composition according to claim 19, for treatment of diseases which can be ameliorated or cured by raising the level of any one of the amino acid sequences depicted in SEQ ID NO: 42 to SEQ ID NO:
 81. 21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of: (i) any one of the nucleic acid sequences of claim 4; (ii) the expression vector of claim 16; and (iii) the purified antibody which specifically bind to any one off SEQ ID NO: 42 to
 81. 22. A pharmaceutical composition according to claim 21, for treatment of diseases which can be ameliorated or cured by decreasing the level of any one of the amino acid sequences depicted in SEQ ID NO: 42 to SEQ ID NO:
 81. 23. A method for detecting a nucleic acid sequence according to claim 1, in a biological sample, comprising the steps of: (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of claim 4; and (b) detecting said hybridization complex; wherein the presence of said hybridization complex correlates with the presence of said nucleic acid sequence in the said biological sample.
 24. A method for determining the level of nucleic acid sequences of claim 1 in a biological sample comprising the steps of: (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of claim 4; and (b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the nucleic acid sequences in the sample.
 25. A method, for determining the level of any one of the nucleic acid sequences of claim 1 in a biological sample comprising the steps of: (i) contacting the sample with probes for amplification of any one of SEQ ID NO: 1 to SEQ ID NO: 41; (ii) proving reagents for amplification; (iii) detecting the presence of amplified products, presence of said products indicating the presence of the nucleic acid in the sample.
 26. A method for determining the ratio between the level of variant of the nucleic acid sequence in a first biological sample and the level of the original sequence from which the variant has been varied by alternative splicing in a second biological sample comprising: (a) determining the level of the variant nucleic acid sequence according to claim 1(A) in the fist biological sample according to the method of claim 24; (b) determining the level of the original sequence in the second biological sample; and (c) comprising the levels obtained in (a) and (b) to give said ratio.
 27. A method according to claim 26, wherein said first and said second biological samples are the same sample.
 28. A method according to any of claim 23, wherein the nucleic acid material of said biological sample are mRNA transcripts.
 29. A method according to claim 28, where the nucleic acid sequence is present in a nucleic acid chip.
 30. A method for detecting any one of the amino acid sequences of depicted in SEQ ID NO: 42 to 69 in a biological sample, comprising the steps of: (a) contacting with said biological sample the antibody of claim 12, thereby forming an antibody-antigen complex; and (b) detecting said antibody-antigen complex wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.
 31. A method for detecting the level of the amino acid sequence of SEQ ID NO: 70 in a biological sample, comprising the steps of: (a) contacting with said biological sample the antibody of claim 13, thereby forming an antibody-antigen complex; and (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.
 32. A method for detecting the amino acid sequences of SEQ ID NO: 71 to 81 in a biological sample comprising the step of: (a) contacting the biological sample with the antibody of claim 14, thereby forming an antibody-antigen complex; and (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.
 33. A method for determining the ratio between the level of any one of the amino acid sequences depicted in SEQ ID NO: 42 to SEQ ID NO: 69 present in a first biological sample and the level of the original amino acid sequences from which they were varied by alternative splicing, present in a second biological sample, the method comprising: (a) determining the level of the amino acid sequences in a first sample by the method of claim 30; (b) determining the level of the original amino acid sequence in the second sample; and (c) comparing the level obtained in (a) and (b) to give said ratio.
 34. A method according to claim 33, wherein said first and said second biological samples are the same sample.
 35. A method for detecting any one of the antibodies of claim 12 in a biological sample comprising the steps of: (a) contacting said biological sample with any one of the amino acid sequences depicted in SEQ ID NO: 42 to 69 thereby forming an antibody-antigen complex; and (b) detecting said antibody-antigen complex wherein the presence of said antibody-antigen complex correlates with the presence of the antibody in said biological sample. 